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Chapter 1
General Introduction
"W e don't know a millionth of one 
percent about anything"
Thomas A. Edison
Chapter 1
Introduction
T he greatest part of the world's biomass is composed of invisible microbes (bacteria, fungi, viruses). This microbial environment partly serves to benefit higher order species, i.e. the visible world. The microbial world is responsible for the recycling of inorganic sources (carbon, phosphates etc.) from 
dead biomass, for symbiotic interaction with higher order species, for maintaining 
balance in complex ecosystems, and is a thriving force in evolution1-4. For higher 
order species, actually thriving in a microbial environment, it means, however, that 
these crucial benefits have some kind of trade-off in the sense of disease. Viruses, 
for example, are obligatory invaders and the host has to evolve counter-measures 
for maintaining its integrity; the innate and adaptive immune systems. Historically 
the focus is on the threats and frequently it is said that microbes and their host 
maintain a "race of arms" for survival5. The other side of the coin is, however, 
that most microbes are innocuous, beneficial, and even shape the host's immune 
system. Deprivation of infections (hygiene) is recently noted as a possible element in 
occurrence of immune mediated diseases like asthma and type 1 diabetes (T1D)6-8. A 
major task of the immune system, whether innate or cognate, is to discriminate self 
from non-self and dangerous from innocent invaders. The immune system itself can 
be subject of derailments in the sense of inflammatory and autoimmune diseases, 
conditions where the host immune system takes part in the disease process. This 
thesis deals with T1D, which is considered to be an autoimmune disease, with 
the immune system and with enteroviruses which are proposed to play a role in 
T1D. In this chapter, a general overview of the immune system will be provided. 
Furthermore, the enteroviruses and their pathogenesis will be introduced. Finally, 
T1D and the putative role of enteroviruses in T1D etiology will be introduced.
The immune system
The immune system can be divided in an innate and adaptive arm; the innate arm is 
responsible for a quick first line of defense against many different pathogens and does 
not require prior exposure to a certain pathogen. Among the cells involved in innate 
immunity are phagocytes, or "eating cells", such as macrophages and neutrophils. These 
cells phagocytose pathogens and subsequently degrade them intracellularly. Natural 
killer cells (NK-cells) do not phagocytose pathogens, but recognize pathogen-infected 
host-cells and release cytotoxic granules that will destroy the pathogen-infected cell.
The adaptive immune response, also known as acquired immune response, 
targets one specific pathogen, and takes some time to develop (4 to 7 days). Once 
this pathogen has been encountered and cleared from the body, memory cells have 
been generated that enable more rapid responses upon future confrontations with this 
particular pathogen. Key players in adaptive immunity are B cells, that produce pathogen- 
specific antibodies, and T cells, that aid in antibody production and kill infected cells. B 
cells become activated upon recognition of a particular antigen (Ag) by its unique B cell 
receptor. The activated B cell can mature to an antibody-producing plasma cell once 
appropriate help by T cells is provided (see below). The produced antibodies (Abs) can 
bind the corresponding pathogen, which is then more easily recognized by phagocytes, 
or triggers the complement system. Furthermore, Abs can neutralize bacterial toxins. For
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T cell-mediated immunity, Ag has to be presented to naïve T cells as a processed peptide 
in the context of a major histocompatibility complex (MHC) molecule by specialized 
antigen-presenting cells (APCs). The most important APC is the dendritic cell (DC, see 
below), but also B cells and macrophages can function as APCs. Naïve CD8+ T cells will 
become activated upon binding of their T cell receptor (TCR) to a matching peptide 
presented in a MHC class I molecule by an APC. For optimal T cell activation, besides 
TCR-stimulation, also adequate co-stimulation and activating cytokines are required9. 
Activated CD8+ T cells will expand and develop into cytotoxic T lymphocytes (CTLs), that 
recognize and kill infected cells (Fig. 1).
Naïve CD4+ T cells are activated upon binding of their TCR to peptides presented 
in MHC II molecules and, with appropriate co-stimulation and cytokine stimulation, will 
subsequently develop into helper T cells (Th) (Fig. 1). Activated Th cells can differentiate 
into different subsets depending on the microenvironment and cytokines, such as 
interleukins (ILs), that are present10, 11. Th1 cells which mainly produce interferon-y (IFN- 
Y), drive cell-mediated CTL responses and activate macrophages. Th2 cells which produce 
IL-4, IL-5 and other cytokines stimulate antibody-mediated responses via stimulation of 
B cells11-13. Recently, Th17 cells, which produce the cytokine IL-17, have been described14, 
15. This subset is thought to be involved in protection from viral, bacterial and fungal 
infections16-20, but may also mediate auto-immune diseases10, 21-23. A special subset of T 
cells is the regulatory T cell (Treg) which can suppress functions of the above-mentioned 
CD4+ and CD8+ effector T cells via cell-cell contact dependent mechanisms. TGF-ß and 
IL-10 contribute to the inhibition of effector T cells24. Tregs are crucial for prevention of 
excessive immune responses that may result in auto-immunity25-28.
Dendritic cells
Dendritic cells (DCs) are APCs with the unique ability to activate naïve T cells, and 
thereby induce adaptive immune responses. They are required to regulate T cell activity 
to boost immune responses when necessary, but also prevent autoimmunity. On the 
other hand, DCs exert influence on innate immunity: for example, NK cell activity can 
be regulated via DCs29-32. Thus DCs are an essential link that bridges innate and adaptive 
immune responses33-35.
DCs can be roughly divided into two distinct populations; the myeloid DCs (mDCs, 
also referred to as conventional DCs) and the plasmacytoid DCs (pDCs) (Fig. 2). Within 
this subdivision, further populations can be discriminated on the basis of expression 
of distinct markers either on the cell surface or intracellularly. These two DC subsets 
can also be functionally separated; mDCs are thought to be the major cells involved in 
activation and differentiation of naïve T cell populations36-38, whereas pDCs can produce 
vast amounts of IFN-a/ß (IFNs) suggesting a major role in viral infections39-41. Cross-talk 
between different DC subsets is thought to be critical for good immune regulation. Due 
to the low frequency in which mDCs and pDCs are detected in human blood, research on 
the function of mDC biology frequently makes use of monocyte-derived DCs (moDCs). 
These can be generated via in vitro differentiation from more common monocytes, using 
IL-4 and granulocyte-macrophage colony-stimulating factor (GM-CSF). moDCs share 
many of the phenotypic and functional characteristics of naturally occurring mDCs, and 
thus function as a good model42.
DCs reside in virtually all tissues of the human body as phagocytic immature 
DCs. Immature DCs (iDCs) capture Ag and subsequently migrate to the lymph nodes
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DCs are present in nearly all tissues of the body and continuously phagocytose antigens from their environ­
ment (1). Depending on the stimuli associated with the antigen encountered, such as PAMPs or DAMPs (2), 
DCs will start maturation and migrate towards the draining lymphoid tissues (3). Here, DCs interact with naïve 
T lymphocytes (Th0) and, depending on the costimulatory signals and cytokines provided by the DC (4), will 
steer proliferation and differentiation of cytotoxic T cells (CTL) and helper T cells (5). Activated effector T cells 
and regulatory T cells (Treg) will subsequently migrate back to the periphery and eliminate the antigen (ef­
fector T cells), or induce tolerance (Treg) (6). Alternatively, Th cells can provide help for B cells, transforming 
them into antibody (Ab)-producing plasma cells (7). The produced Abs can aid in immune responses.
where matching T cells will get instructions. iDCs are very efficient in Ag-capture and use 
several uptake mechanisms such as macropinocytosis, receptor-mediated phagocytosis 
via scavenger receptors (e.g. C-type lectins), or Fcy-receptor-mediated endocytosis of 
antibody-complexes. Pathogen-associated molecules are engulfed, but also apoptotic 
or necrotic cells are phagocytosed42-46. When DCs encounter pathogen-associated 
molecules such as bacterial LPS or double-stranded RNA they start a process called 
maturation, a process that is associated with decreased phagocytic activity, upregulation 
of costimulatory molecules such as CD40, CD80 and CD86, production of proinflammatory 
cytokines, and major changes in morphology and intracellular pathways involved in Ag- 
presentation. Once matured, matDCs are optimally equipped to activate and instruct 
naïve T cells37, 38. Depending on the microenvironment and maturation stimulus, the DCs 
will produce particular cytokines, such as IL-12, IL-4 or TGF-ß, that will control T cell 
differentiation47 (Fig. 1).
Endogenous Ags are processed by the proteasome and subsequently loaded 
onto MHC class I molecules48. In general, exogenous Ags are targeted to MHC class II 
compartments where they are processed into peptides and loaded onto MHC class II 
molecules. The MHC class II-peptide complexes can be recognized by matching CD4+ T 
cells that will develop into distinct types of helper T cells. DCs are rather unique in that 
they can also efficiently present exogenous Ags in the context of MHC class I molecules
12
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to CD8+ T cells, a process called cross-presentation. Cross-presentation enables DCs to 
induce efficient CTL-responses directed against for example tumors or viruses that do 
not infect DCs48.
In addition to the major role that DCs play in induction of immune responses, 
they also play a very important role in maintaining tolerance. DCs play a major role 
in negative selection of autoreactive T and B cells in the thymus49, 50, but it has been 
reported that peripheral DCs may also have the capability to suppress T cell activity51' 
55. These so-called tolerogenic DCs present Ags through specific MHC-TCR complexes, 
but fail to deliver adequate co-stimulatory signals and cytokines required for effective 
T cells stimulation. Such an encounter will result in either T cell apoptosis or anergy, 
or might give rise to immunosuppressive Tregs53, 55-57. Such tolerizing responses occur 
for example upon encountering apoptotic cells in steady-state conditions58. In mouse 
models, tolerogenic DCs have been shown to suppress experimental autoimmune 
diseases59, 60. Moreover, defects in the cross-tolerance via DCs results in accumulation of 
autoreactive T cells and renders mice more prone to autoimmunity61. This implies that 
these tolerogenic responses might play an important role in immune homeostasis and 
autoimmune disease, also in humans.
Pattern recognition receptors
As described above, DCs are crucial initiators of immunity, but are also critical mediators 
of self-tolerance. This raises an intriguing question: How can DCs distinguish between 
pathogens, nonpathogenic microbes and self Ags? Detection of microorganisms is 
mediated by pattern recognition receptors (PRRs) that recognize pathogen-associated 
molecular patterns (PAMPs)62. PAMPs are structures which are unique to pathogens and, 
in general, are not present in healthy tissue (self). Most PAMPs are either ubiquitously 
present on pathogens, such as beta-glucans or flagellins, or are required and produced
Figure 2. Schematic representation of the two major subclasses of DCs.
DCs can be roughly divided into two subpopulations: myeloid DC (mDC, also referred to as conventional DCs) 
and plasmacytoid DC (pDC). Immature mDCs are generally considered to best phagocytose antigens. Mature 
mDCs play a key role in activation and differentiation of T cells. Immature pDCs appear as round cells, that 
transform into cells with a more dendritic cell-like morphology upon maturation. Cross-talk between the vari­
ous DC-subsets is thought to be key for adequate immune regulation.
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during infection, such as dsRNA63-65. Next, it was proposed that DCs, in addition to 
sensing pathogen products, sense danger in the form of altered self, for example factors 
released from damaged cells66, 67. According to this model, immune responses are not 
generated upon microbial invasion itself, but when detectable harm is done to the 
body. The ligands involved in danger-associated PRR-stimulation, the so-called danger- 
associated molecular patterns (DAMPs), are generated or released upon tissue or cell 
damage. DAMPs are proteins/products that are usually sequestered within cells, but are 
released upon damage, such as heat-shock proteins, high-mobility group box 1 (HMGB1) 
or adenosine triphosphate (ATP)68-71. Furthermore DAMPs can be generated or altered 
during cell stress or damage, possibly altering their immunogenic potential72. Upon 
detection of pathogens or damage to the host by PRRs, subsequent signaling cascades 
are initiated by the PRR family members resulting in induction of immune responses.
Several classes of PRRs exist (Fig. 3), of which the best characterized are 
the Toll-like receptors (TLRs). This family of trans-membrane receptors consists of 10 
members that are present on the plasma membrane (TLR1, 2, 4, 5, 6 and 10) or within 
the endosomal compartment (TLR3, 7, 8, 9). Each TLR binds to distinct ligands. Formation 
of hetero-dimers with other TLRs causes further specificity and diversity in the ligands 
that are recognized. TLRs bind to a variety of different ligands, originating from bacteria, 
viruses, and other pathogens. Importantly, PAMPs from virtually all pathogens can be 
recognized, but also DAMPs can bind to these receptors68, 73, 74. Complex signaling occurs 
following binding of a ligand to a PRR, which eventually results in transcription of genes 
encoding for pro-inflammatory cytokines and other inflammatory mediators.
Another important family of PRRs, that is involved in recognition of viruses, is 
the cytoplasmic RIG-I-like helicase (RLH) family. The RLHs retinoic acid-inducible gene I
Toll-like  receptors
Ligan ds: various PAMPs & DAMPs
R IG -like  helicases
Ligan ds: viral RNA
Location: plasma membrane and 
endosomal membrane
Effects:
- DC maturation
- Cytokine production
- T cell activation P a t
Location: cytoplasm 
Effects:
- Type I IFN production 
- Antiviral state induction
tern
Rece
NOD-like receptors
Ligan ds: various PAMPs & DAMPs
Location: cytoplasm
Effects:
-Cytokine production 
- IL-1ß and IL-18 processing
Dtors
C-tvpe lectin receptors
Ligan ds: carbohydrate structures
Location: plasma membrane & 
endosomes
Effects:
- Ag internalization
- Cytokine production
Figure 3. Schematic overview of the four main pattern recognition receptor (PRR) families and their main 
characteristics.
The ligands and location of PRRs are depicted. Furthermore, the most important effects initiated upon trig­
gering of the receptor-families is specified.
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(RIG-I) and melanoma differentiation-associated gene 5 (Mda5) respond to virus infection 
by recognition of distinct RNA structures. Via the adaptor molecule mitochondrial 
antiviral signaling protein (MAVS), they start a signaling cascade that results in activation 
of interferon regulatory factors (IRFs), such as IRF-3 and IRF-7 that initiate type I IFN 
production75, 76. The third family member, laboratory of genetics and physiology 2 (LGP2) 
lacks a signaling domain and is thought to be a negative regulator, although this was 
recently challenged when it was shown that LGP2 can also stimulate Mda5 function75-78.
Two other PRR-families are the C-type lectin receptors (CLRs) and Nod-like 
receptors (NLRs). CLRs are membrane-bound receptors that recognize carbohydrate 
structures, such as mannose, glycoproteins and ß-glucans, and can interact with a variety 
of pathogens. The NLRs are a cytoplasmic family that recognize diverse bacterium- 
related products such as peptidoglycans79. Recent studies have suggested that some 
NLR-family members, such as NALP3, are critical for inflammasome activation by virus- 
associated PAMPs like dsRNA80, 81. New PRRs are still being discovered. These include 
sensors for cytoplasmic DNA, that were proposed to exist for quite some time, but have 
only recently been discovered82, 83.
As mentioned above, DCs play a critical role in maintaining tolerance to self-Ags. 
Immune tolerance results from phagocytosis under conditions where no PRR triggering 
by either PAMPs or DAMPS occurs. Autoimmunity may thus be induced when self-Ags are 
phagocytosed and presented by DCs under conditions of simultaneous PRR triggering47. 
For example, phagocytosis of DNA-containing immune complexes in the presence of 
HMGB1 has been suggested to play a role in systemic lupus erythematosus (SLE)84. Also 
in rheumatoid arthritis (RA), exposure to self-Ags and simultaneous triggering of TLRs is 
thought to be involved in disease development85.
Inhibition of PRRs and immune responses by viruses
RNA viruses are mainly recognized by TLR3, 7 and 8 and the RLHs RIG-I and Mda5. Upon 
encountering a virus, type I IFNs will be produced; a process that can be initiated in 
nearly all nucleated cell types. DCs, and pDCs in particular, can produce exceptionally 
large amounts of IFNs39. These IFNs will stimulate cells to adopt an antiviral state, which 
restricts virus replication. Furthermore, IFNs will also stimulate innate immunity e.g. via 
NK cell stimulation, and adaptive immunity e.g. via influencing DC maturation86-90. To 
establish a productive infection, viruses have evolved to counteract these host defense 
mechanisms. Multiple strategies have been devised and virtually all steps in antiviral 
immunity have been targeted.
Interference with IFN production and IFN function itself is a widely used 
strategy: IFN-transcription can be inhibited by viruses91, 92, or they can produce IFN 
decoy receptors93. In addition, the JAK-STAT signaling cascade, which is activated upon 
triggering of the IFN-a/ß receptor (IFNAR), is targeted by several viruses94. Furthermore, 
the effector molecules (e.g. RNA-dependent protein kinase, PKR; 2'-5'oligoadenylate 
synthetase, OAS; RNaseL), which are induced via JAK-STAT signaling, can be targeted 
once these cells become infected95, 96. In addition, also initiation of IFN-responses via 
PRRs can be inhibited by interfering with the PRR-signaling pathway or prevention of 
binding of viral RNA to PRRs97-99.
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Other strategies that are employed to inhibit immune responses include 
targeting of DC maturation and function100-102. Furthermore, the genetic content of some 
viruses has evolved to encode for their own anti-inflammatory cytokines103, 104.
Enteroviruses
Enteroviruses belong to the family of the Picornaviridae (Fig. 4). Picornaviruses are the 
cause of a number of serious human and animal diseases and major economical damage. 
This large family of small RNA viruses consists of eight genera that include enteroviruses 
(described below), parechoviruses, hepatoviruses, cardioviruses, kobuviruses and 
genera that solely contain animal pathogens, such as the aphthoviruses (including 
foot-and-mouth-disease virus). The enterovirus genus is divided into several species, 
namely human enterovirus-A (HEV-A), HEV-B, HEV-C and HEV-D, rhinoviruses (that cause 
common cold) and bovine and porcine species (Fig. 4). The best-known and mostly 
studied enterovirus is the poliovirus, causative agent of poliomyelitis, which belongs to 
the HEV-C species105. HEV-A species include EV71 which is a major health threat causing 
hand-foot and mouth disease and central nervous system infections in Asia nowadays105, 
106. The enteroviruses most often associated with type 1 diabetes belong to the HEV-B
—  Human enterovirus A Enterovirus 71
p Coxsackie B viruses
■ Human enterovirus B
I Echoviruses
—  Human enterovirus C Polioviruses
—  Human enterovirus D
—  Simian enterovirus A
—  Bovine enterovirus A
—  Porcine enterovirus A
—  Porcine enterovirus B
—  Human rhinovirus A
“ “  Enterovirus “ “ 1 Human rhinovirus B
__ I1 Encephalomyocarditis virusCardiovirus
1__ Theilovirus
i Foot-and-mouth disease virus
Aphthovirus
' Equine rhinitis Avirus
—  Hepatovirus — Hepatitis A virus
Picornaviridae —
I Human parechovirus—  Parechovirus
1 Ljungan virus
—  Erbovirus — Equine rhinitis Bvirus
■ Aichi virus
—  Kobovirus 1
1 Bovine kobuvirus
—  Teschovirus - Porcine teschovirus
Figure 4. Schematic representation of the picornavirus family.
The eight different genera are depicted and their subdivision into species is specified. Some examples of
important human pathogens are given within the enterovirus species.
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species, e.g. coxsackie B viruses (CVB) and echoviruses (EV)105. A more detailed overview 
of their life cycle and pathogenesis will be described below (Fig. 5).
The first requirement for viral infection is entry into cells which is mediated 
by virus-specific receptors. All known serotypes of CVB make use of the coxsackie-and- 
adenovirus receptor (CAR), and for CVB1, -3 and -5 decay accelerating factor (DAF, or 
CD55) can be used as a co-receptor. Different EV serotypes use different receptors, 
including DAF and very late antigen-2 (VLA2). Other cellular molecules that are used 
as enteroviral receptors include integrins and other adhesion molecules107. Upon cell 
entry, the virus releases a single-stranded positive RNA genome in the cytoplasm, that 
is translated via an internal ribosomal entry site (IRES) into one large polyprotein. Virus- 
encoded proteases subsequently cleave this polyprotein to yield the capsid proteins 
and the non-structural replication proteins. The non-structural proteins form replication
RNA
release
VPg
W Æ *
“  cell 
lysis
translation
COOH
proteolytic
processing
K/PÏ1 |2BC|I 2C |3D||3CD|
! i 3A||3AB||3C|
VPg
VPg
VPg
VPg
VPg
VPg
AAA(+) 
— —  AAA(+) 
AAA(+) 
AAA(+)
capsids replication proteins
I (-) RNA 
I synthesis
AAA(+)
AAA(+
(+) RNA 
synthesis
VPg AAA(+)
UUU(
Figure 5. Schematic representation of the picornavirus life cycle.
The virus gains entry into the cell via a virus-specific entry receptor. After this, viral RNA is released into the 
cytoplasm of the cell, where it is translated into a large polyprotein. Processing of the polyprotein by virally 
encoded proteases yields the structural capsid proteins and the non-structural replication proteins. The ge­
nomic RNA is used as a template for the production of complementary negative strand molecules, which, in 
turn can be used for the generation of large numbers of positive stranded RNA molecules. Newly generated 
positive stranded RNA molecules can be encapsidated to produce progeny virus. Alternatively, they can be 
used for additional translation, or they may enter a new round of replication. Progeny viruses are released 
via cell lysis.
complexes and, using the positive RNA strand as a template, will initiate production of 
complementary negative-stranded RNAs. These will subsequently be used to synthesize 
new positive-stranded RNAs. Positive-stranded RNAs can be translated to generate more 
viral proteins, used for amplified replication, or encapsidated to produce new infectious 
virus particles. The newly formed particles accumulate in the cytoplasm and are released 
via cell lysis when the host cell loses its integrity108.
Enterovirus infection leads to massive rearrangement of intracellular 
membranes, resulting in the accumulation of small ER/golgi-derived replication vesicles
17
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in the cytoplasm. Other modifications caused by the non-structural proteins are 
rearrangement of the cytoskeleton, inhibition of transcription and translation of host 
mRNA, and inhibition of ER to golgi transport108, 109. These alterations in the host cell 
serve to shape the best possible environment for viral replication and to suppress the 
host immune response. The virus-induced morphological changes in the infected cells 
are known as cytopathic effects (CPE). Upon infection, apoptotic pathways are switched 
on by the infected host cell, yet the virus suppresses the apoptotic program, at least in 
vitro. Consequently, the cell-death that results after virus infection has hallmarks of both 
apoptosis and necrosis110, 111.
Pathogenesis of Human Enterovirus B
Enterovirus transmission occurs primarily via the fecal-oral route, facilitated by the 
acid-stability of the virus. However, also respiratory transmission may play a role105. 
The majority (up to 80%) of enterovirus infections remains asymptomatic, and most 
of the symptomatic infections are characterized by minor illness with fever, diarrhea, 
vomiting and possibly rashes105, 112. Mild viremia can occur, but virus levels are low and 
transient. Infection with different serotypes is common105. More severe enterovirus 
infections can be accompanied by major viremia and spreading of the virus to secondary 
organs. This can result in myocarditis, pancreatitis, meningitis, encephalitis and other 
complications105. Severe disease is most often observed in neonates, but can also occur 
later in life105, 113. Besides acute forms of disease, HEV-Bs have also been implicated in 
chronic conditions, such as chronic myocarditis, dilated cardiomyopathy105, 114, 115 and 
type 1 diabetes (see below)105.
The efficacy of the immune system is key to the outcome of enteroviral 
infections. Both innate immune responses (e.g. IFN-production and NK cell activation105, 
116) and adaptive immune responses (e.g. antibody production105, 114, 116, 117) are crucial to 
fight enterovirus infections. Prolonged infections might develop in case of a defect in 
one of the above-mentioned antiviral mechanisms. In particular, individuals suffering 
from X-linked agammaglobulinemia may develop severe chronic infections possibly 
with fatal outcome105, 116, 117. Besides host factors, also the virulence of the virus strain 
concerned may play a role105, 118-120. As mentioned above, persistent infections have 
been associated with certain chronic diseases, yet this issue remains controversial105, 
114, 121, 122. when, on the other hand, part of the immune system reacts too aggressive, 
uninfected cells and tissues may also be targeted. The subsequent damage might result 
in chronic inflammation and could result in autoimmune responses. Autoimmunity has 
been suggested to play a role in CVB-induced inflammation, starting with the report 
that uninfected myocytes were also targeted in CVB-induced murine myocarditis105, 
116. Furthermore antibodies reactive to heart tissue have been described in human 
cardiomyopathy105, 116, although this was not confirmed in other studies123. Also in type 1 
diabetes (T1D), a role for enterovirus infections has been proposed (see below).
Type 1 diabetes
Type 1 diabetes (T1D, also known as insulin-dependent diabetes mellitus, IDDM) is a 
chronic, progressive disease that results from the failure of the insulin-producing ß- 
cells in the islets of Langerhans to produce enough insulin. Islets of Langerhans consists 
of insulin-producing ß-cells (~60%), glucagon-producing a-cells (~30%), somatostatin-
18
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producing 5-cells (~10%) and polypeptide-producing PP-cells (>5%)124, 125. T1D treatment 
includes lifelong insulin-injections accompanied by careful monitoring of blood glucose 
levels. T1D can have a long sub-clinical course during which ß-cell damage occurs; 
however, clinical symptoms only arise when over 80% of the total ß-cells mass is impaired 
in insulin production126, 127. Type 1 diabetes is commonly diagnosed in childhood and 
adolescence - hence its former name "juvenile diabetes" -, but it can occur at any age, 
even in the 8th and 9th decades of life128.
T1D can be further classified as immune-mediated (type 1A diabetes) or 
idiopathic (type 1B diabetes). The majority of type 1 diabetes cases (~85-90%) is immune- 
mediated129, 130. In immune-mediated T1D, antibodies against islets constituents such as 
glutamic acid decarboxylase (GAD) 65, insulin, tyrosine phosphatase-like protein (IA-2) 
appear before clinical onset of disease. When Abs against multiple ß-cell associated 
proteins are found, the risk to develop T1D is increased131-134. Infiltration of immune cells 
is frequently observed during immune mediated diabetes, as determined after biopsy 
or at autopsy126, 135, 136. It has been postulated that autoimmune CTL responses may be 
responsible for final ß-cell destruction137, 138.
In idiopathic, or fulminant diabetes, there is no evidence for an autoimmune 
process, and diabetes-associated islets cell antibodies (ICA) are not found128, 139. Patients 
often present with abrupt onset of symptoms. No evidence of insulitis was found in 
the islets after biopsy or at autopsy in Japanese patients140; however, whether this 
finding is universal for patients with idiopathic diabetes is unknown141. Furthermore, 
recent studies reported autoreactive T cell populations and autoantibodies in patients 
with fulminant T1D, thereby questioning whether immune-processes are not involved in 
this type of T1D after all142-144. Due to the controversy between immune-mediated and 
idiopathic diabetes143, the term T1D will be used in the remainder of this thesis to refer 
to both types of diabetes.
Susceptibility to T1D is inherited, and many studies have been performed to 
identify the genetic factors that predispose to T1D. The strongest genetic predisposition 
to T1D is found in the HLA-locus. Especially individuals with HLA-DR3 or DR4 are prone to 
develop T1D145-147. Other susceptibility loci that have been identified include the insulin 
locus, the CTLA4 gene and the PTPN22 gene148-153. New associations are still being found, 
and recently single nucleotide polymorphisms (SNPs) were identified in genes which are 
involved in antiviral immunity154-157.
Studies in monozygotic twins revealed that the concordance rate for the 
development of T1D is only 25-50%, suggesting that T1D development is environmentally 
determined153, 158-160. Further evidence that environmental factors play a role in T1D 
etiology is derived from migration studies; children that migrated from South-Asia - 
where T1D incidence is lowest - to the United Kingdom at young age have similar chance 
to develop T1D as indigenous British. Additional evidence arises from the geographical 
variations in T1D. The lowest incidence (0.6 per 100,000) is found in South-Asia and 
Oceania, whereas Europe has higher T1D incidence, with the highest incidence (40.9 per 
100,000 in 1999) found in Finland134, 160, 161 (Fig. 6). Finally, a substantial rise in incidence 
has been reported over the last decades, which must be due to factors in the environment 
and lifestyle134, 161, 162. Taken together, the epidemiologic and genetic studies indicate that 
environmental factor(s) can initiate disease in a susceptible individual134, 160.
Many different environmental factors have been mentioned as possible causes 
or triggers of T1D. Among these are dietary factors such as cow milk, toxins, and virus
19
Chapter 1
Figure 6. Incidence of type 1 diabetes in children under age 14 years in Europe, 1990-1999.
Shown is a map reflecting the incidence of T1D in different countries in Europe. This map was generated using 
data from the Diamond project group, Incidence and trends of childhood Type 1 diabetes worldwide 1990­
1999, Diabet Med. 2006 Aug;23(8):857-66.
infections134, 163. Virus infections have been associated with T1D for over a century. The 
most extensive evidence for an association with diabetes is found for enteroviruses, 
mainly HEV-B such as CVB and EV. The first associations of HEV-B infections with T1D 
originate from over 4 decades ago (Reference164 and references therein), and were 
strengthened when Yoon and colleagues isolated a CVB4 strain from the pancreas of 
a child with diabetic ketoacidosis165. This virus was capable to induce a diabetes-like 
disease in mice. More cases where enterovirus was isolated from T1D patients have 
been described since166-168, and these strains have been shown to induce diabetes in 
mice166 or productively infect human pancreatic islets in vitro169, 170. Further evidence 
that enteroviruses are involved in T1D arises from serological studies. More diabetes 
patients were found to have anti-enterovirus Abs than a control population and the titers 
of Abs against enteroviruses are higher in T1D patients (reviewed in171). Yet, controversy 
as to whether HEV-B may cause T1D still remains172, 173. The development of reverse- 
transcriptase polymerase chain reaction (RT-PCR) techniques, which are more sensitive 
for detection than serological techniques, further supported the T1D-enterovirus 
association. Analysis of blood or serum from T1D patients and control individuals showed 
that enterovirus RNA is found at onset of disease in 20 to 75% of T1D patients, but not, or 
with much lower frequency, in controls174-181. Enteroviruses have furthermore been found 
in auto-antibody positive (pre-diabetic) persons179, 182, 183 and in patients with established 
T1D174, 175, but importantly, not, or with a much lower frequency, in matched healthy 
controls without predisposition for T1D or in T2D patients174. These studies reinforced
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the conclusions of earlier serological studies suggesting that enterovirus infection is 
associated with the development of type 1 diabetes. However, it should be noted that 
the available data is circumstantial and no direct evidence for a causal relation of HEV-B 
with T1D exists. Although much studies were initially focused on CVB4 and other CVBs, 
also other HEV-B and, albeit rarely, HEV-A species have been have been associated with 
T1D167, 169, 184. Furthermore, Roivainen and colleagues reported that a wide range of HEV- 
B serotypes can infect human pancreatic islets in vitro185, indicating that the capacity of 
HEV-B species is not restricted to CVB4, but that many, if not all, HEV-B species might 
trigger or accelerate T1D development.
Putative mechanisms of HEV-B induced T1D
There are several, not mutually exclusive mechanisms by which enteroviruses may play 
a role in T1D development. (i) These viruses may directly infect and kill ß-cells due to 
lytic activity of the virus. Several independent groups have reported that enterovirus 
RNA and proteins can be detected in the islets of T1D patients136, 186, 187. As mentioned 
above, different serotypes can infect ß-cells in vitro and could thus be involved via 
this mechanism. (ii) Virus-induced inflammation in the pancreas might result in the 
production of cytokines such as TNF-a, IL-1ß and IFN-y, that are toxic to ß-cells either 
alone or in combination188-191. The production of nitric oxide (NO), that occurs during 
inflammation has been mentioned as a cause of ß-cell dysfunction and cell death191-195. 
Not only cells of pancreatic origin may contribute to this bystander effect, also cells of the 
innate immune system such as NK cells and macrophages might be activated and cause 
ß-cell damage195, 196. (iii) Another mechanism that might contribute to the development 
of T1D is activation of the adaptive immune system. Due to both the pro-inflammatory 
microenvironment and the ß-cell damage that have developed upon infection, APCs such 
as DCs encounter self-Ags in an environment where PAMPs and DAMPs are excessively 
present, which could result in DC maturation and priming of (naive) autoreactive T cells. 
It has been reported that development of T1D depends on the balance of autoreactive 
Th1 and Treg cells56, 197 and this balance is greatly influenced by microenvironment and 
maturation status of APCs34, 37, 38. (iv) Autoimmunity might be provoked due to molecular 
mimicry: immune responses directed against the virus may also cross-react with self- 
Ags, such as suggested for the viral protein 2C and GAD65198-200. Although cross-reactivity 
between these proteins has been reported201, 202, its importance in the pathogenesis of 
T1D remains unproven203, 204.
The above-mentioned mechanisms by which HEV-B might contribute to 
the pathogenesis of T1D are not mutually exclusive and could even contribute to the 
development of this autoimmune disease in a synergistic manner. However, more 
research is required to pinpoint the putative mechanisms leading to ß-cell damage and 
establish a potential causal relationship between HEV-B infections and T1D.
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Aim & outline of this thesis
The aim of this thesis was to gain more insight in the possible pathogenic mechanisms 
of HEV-B induced disease. Research focused on DCs, HEV-B and pancreatic cells and the 
interplay between them.
Chapter 2 provides a brief overview of the expression of different PRRs in DC subsets 
under pro-inflammatory and steady-state conditions. Additionally, cross-talk between 
different DC subsets was investigated and a mechanism how pDCs may protect mDCs 
in an environment with high viral burden is postulated. In Chapter 3 we investigated 
the susceptibility of DCs for infection with HEV-B species. This study revealed that CVBs 
are unable to infect DCs or influence their function, whereas EVs productively infect 
DCs resulting in loss-of-function, aberrant response upon subsequent TLR-triggering and 
ultimately, cell death. Chapter 4 reveals that poly I:C matured DCs are protected from 
infection via an IFN-dependent mechanism, whereas DCs matured with other TLR-ligands 
are not protected from infection. Furthermore, we provide evidence that CVB-infected 
cells are efficiently phagocytosed by DCs leading to upregulation of IFNs and ISGs resulting 
in an antiviral state, that also protects DCs from subsequent infection. Chapter 5 focuses 
on the interaction between primary human pancreatic islets and DCs. We showed that 
CVB-infected human islets are phagocytosed by DCs resulting in an upregulation of ISGs. 
Using porcine islets and murine Min6 insuloma cells, we confirmed the importance of 
IFNs for ISG-induction in DCs. We revealed that DC-responses depended on IFNs produced 
by the DCs themselves, but not by the infected cells. Furthermore, RNA within infected, 
phagocytosed pancreatic cells was shown to be of great importance for DC-responses. 
These findings provide important new insights in the possible role of DCs during human 
type 1 diabetes development. Chapter 6 describes the response of primary human islets 
upon infection with HEV-B. We report that antiviral immunity is activated, indicated by 
the induction of ISGs. Furthermore, expression of several cytokines and chemokines was 
induced, and importantly, these could also be detected in the supernatant from infected 
islets. These data suggest that islets, upon infection with HEV-B species, start antiviral 
immune responses and produce a variety of cytokines and chemokines that can attract 
and/or activate cells of both the innate and adaptive immune system that may maintain/ 
aggravate inflammation and might even trigger development of autoimmune processes 
against ß-cells. In Chapter 7 we investigate the presence of enteroviruses in PBMC of 
T1D patients and show that enterovirus RNA can be detected in 4 out of 10 patients, 
but not in any of the controls. Merely complete absence of viral RNA in throat and stool 
samples suggests that it might concern prolonged enterovirus infection. What the role 
of prolonged infection in T1D is remains to be determined, yet one can envisage that 
it results in continuous arousal of the immune system. Finally, Chapter 8 discusses the 
results and significance of the findings described in this thesis.
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Abstract
D endritic cells (DCs) are professional antigen presenting cells that provide a link between innate and adaptive immunity. Multiple DC subsets exist and their activation by microorganisms occurs through binding of conserved pathogen- derived structures to so-called pattern recognition receptors (PRRs). In this study we 
analyzed the expression of PRRs responding to viral RNA in human monocyte-derived 
DCs (moDCs) under steady-state or pro-inflammatory conditions. We found that mRNA 
and protein levels for most PRRs were increased under pro-inflammatory conditions, 
with the most pronounced increases in the RIG-like helicase (RLH)-family. Additionally, 
freshly isolated human plasmacytoid DCs (pDCs) displayed significantly higher levels 
of TLR7, RIG-I, MDA5 and PKR as compared to myeloid DCs and moDCs. Finally, we 
demonstrate for the first time that cross-talk between TLR-matured or virus-stimulated 
pDCs and moDC leads to a type I interferon-dependent antiviral state in moDCs. This 
antiviral state was characterized by enhanced RLH expression and protection against 
picornavirus infection. These findings might represent a novel mechanism by which 
pDCs can preserve the function and viability of myeloid DCs that are attracted to a site 
with ongoing infection, thereby optimizing the antiviral immune response.
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Introduction
Dendritic cells (DCs) are specialized antigen-presenting cells that are crucial players 
in the decision process between tolerance and immunity. They participate in the 
innate immune response, but also orchestrate adaptive immunity via regulation of T 
cell activation and differentiation1, 2. Different DC subsets exist that are specialized in 
regulation of distinct facets of the immune response. For instance, plasmacytoid DCs 
(pDCs) are well equipped to recognize viral structures, resulting in potent type I interferon 
(IFN) production3. Myeloid DCs (mDCs) can recognize structures derived from several 
classes of microorganisms and are key to the induction of Th1 responses via release of IL- 
123-5. For in vitro studies monocyte-derived DCs (moDCs) are often used in stead of mDC. 
Responses of moDCs are similar to mDCs in many aspects3, 6, yet differences exist7, 8.
Recognition of microorganisms occurs via binding of pathogen-associated 
molecular patterns, PAMPs, to so-called pattern-recognition receptors (PRRs), such as 
the cytoplasmic NOD-like receptors and RIG-I-like helicases and the membrane-bound 
C-type lectins and Toll-like receptors9. Triggering of TLRs on DCs by PAMPs, such as 
double-stranded RNA (dsRNA) or lipopolysaccharide (LPS), results in production of pro- 
and anti-inflammatory cytokines and upregulation of MHC and costimulatory molecules 
that collectively determine T cell activation and differentiation10. Despite their crucial 
role in antiviral immunity, TLRs that recognize viral RNA are unable to detect viruses 
in the cytoplasm, due to their endosomal localization. However, the recently identified 
PRR-family called the RIG-I-like helicases (RLHs) appears to be involved in responses to 
cytoplasmic viral RNA. The RLHs retinoic acid-inducible gene I (RIG-I) and melanoma 
differentiation-associated gene 5 (MDA5) respond to different RNA viruses through 
recognition of distinct RNA structures11-14. Activation of RIG-I or MDA5 is of crucial 
importance for the induction of innate antiviral immune responses upon virus infection15. 
The third member of the RLH family, LGP2, lacks a signaling domain and is thought to 
serve as a negative regulator16. Another RNA-sensor that does not belong to the RLH 
family is protein kinase R (PKR), which inhibits translation upon detection of dsRNA in 
the cytoplasm17.
Unlike TLRs, much less is known regarding the function and expression of RLHs. 
The vast majority of studies concerning RLHs have been done in mice or cell lines, with 
little data on expression of these molecules in primary human cells. In this study we 
investigated the expression levels of TLRs and RLHs in human moDCs under steady-state 
or pro-inflammatory conditions. In addition, we determined the expression profiles 
of RNA sensors in different primary human DC subsets which revealed remarkably 
high expression of RLHs in plasmacytoid DCs compared to their myeloid counterpart. 
Differential expression of PRRs likely tailors the response to specific pathogens executed 
by various DC subsets. Cross-talk between DCs subsets might further aid in induction 
of optimal immune responses. We therefore determined the influence of cross-talk 
between pDCs and moDCs, which showed that TLR- or virus-activated pDCs increased 
expression of RLHs in moDCs and induced protection against picornavirus infection.
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Materials & Methods
Culture and stimulation of cells
Monocyte-derived DCs (moDCs) were generated from different donors as described previously18. Immature 
moDCs were harvested on day 6 using cold PBS and incubated with medium (RPMI-1640) alone or stimulated 
with purified LPS (100 ng/ml) + IFNy (400 U/ml) at 37°C for a period of 4, 8 or 24 h. Alternatively, moDCs 
were stimulated using 100 U/ml IFNa2 (Roferon-A®, Roche) or a 1:100 dilution of cell-free supernatant of 
CpG-C or R848 activated-plasmacytoid DCs (pDCs) (collected 24 h after stimulation) or virus-simulated pDC 
(see below). Myeloid and plasmacytoid DCs were isolated using anti-BDCA-1 and anti-BDCA-4-conjugated 
magnetic microbeads, respectively, according to the manufacturer's instructions (Miltenyi Biotec).
RNA isolation
Total RNA was isolated from DC cultures using TRIZOL reagent (Invitrogen Life Technologies) according to 
manufacturer's instructions. RNA integrity was determined by analyzing the ribosomal 28S and 18S bands on 
a 1% agarose gel. The reverse transcription reaction was performed using Moloney murine leukemia virus (M­
MLV) reverse transcriptase (Invitrogen) according to the manufacturers' instructions. To exclude genomic DNA 
contamination we included a '-RT' control for each sample in which the reverse transcriptase was replaced by 
DEPC treated milli-Q after which qPCR on a single-exon gene (SOCS-1) was performed. The cDNA was stored 
at -20°C until further use.
Quantitative PCR
Quantitative PCR (qPCR) analysis of gene expression in DCs was performed using TaqMan® Custom Arrays 
(Applied Biosystems) based on microfluidic card technology. Arrays were run on the ABI PRISM 7900HT 
Sequence Detection System and data were analyzed using SDS 2.2.2 software (Applied Biosystems). 
Alternatively, qPCR data were obtained using SYBR Green (Applied Biosystems) based qPCR according to the 
manufacturers' instructions. Primer sequences are available upon request and were from the Primer Bank 
database19. Reactions were performed on an ABI PRISM 7900 Sequence Detection System (Applied Biosystems). 
Data were analyzed using 7000 System SDS software (Applied Biosystems). Genes with a Ct-value higher than
37 were considered not expressed. ACt values were calculated for all individual genes in all donors, with that 
of porphobilinogen deaminase (PBGD, also known as hydroxymethylbilane synthase (HMBS)) as a reference. 
An Excel macro was used to generate a heatmap, where 1 grayscale encompasses 2 ACt units. White indicates 
highest expression, whereas black corresponds to undetectable expression.
Confocal microscopy
Monocyte-derived DCs (moDC) or plasmacytoid DCs (pDCs) were harvested, washed and allowed to adhere to 
poly-L-lysine coated coverslips in serum free medium for 1 h at 37oC. Cells were fixed with 1% paraformaldehyde 
(PFA) and blocked in PBS with 3% BSA, 10 mM glycine and 2% human serum (blocking buffer, BB). For cell 
surface stainings, moDCs and pDCs were incubated using mouse-anti-human DC-SIGN (Beckman Coulter) or 
mouse-anti human BDCA4 (Miltenyi Biotec GmbH), respectively, or the appropriate isotype control in BB. 
Following incubation and washes, cells were incubated with isotype specific Alexa labeled goat-anti-mouse IgGs 
(Molecular Probes). For intracellular staining, cells were fixed using 1% PFA, permeabilized using 0.1% Triton- 
X100 in PBS and incubated with rabbit polyclonal anti-MDA520 followed by incubation with goat-anti-rabbit IgG 
Alexa 488 (Pharmingen) in BB. Cells were sealed using Mowiol (Merck) and analyzed by confocal laser scanning 
microscopy on a MRC1024 confocal microscope (BioRad, Hercules, CA). Signals were collected sequentially to 
avoid bleed through and were processed with Photoshop 7.0 software (Adobe Systems incorporated). 
Western blot
Equal amounts of protein were separated by 7.5 %  SDS-PAGE, electroblotted onto nitro-cellulose membranes 
(Bio-Rad), followed by probing with the indicated antibodies. Anti-RIG-I and anti-PKR antibodies were purchased 
from ProSci Incorporated and Becton Dickinson Transduction Laboratories, respectively. RIG-I, PKR and MDA5 
antibodies were used in 1:1,000; 1:500 and 1:10,000 dilutions, respectively. After washes, membranes were
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incubated with IRDye anti-mouse or anti-rabbit IgG (1:15,000) (Li-Cor Biosciences). Imaging was done using 
the Odyssey System.
Virus stimulation of pDC and infection of moDC
Echovirus 9 Hill (EV9) and Coxsackievirus B3 Nancy (CVB3) were propagated as described before18. pDCs, 
isolated as described above, were stimulated with CVB3 at a multiplicity of infection (MOI) of 100 in the 
presence or absence of 10% human serum. After 24h supernatants are harvested and used in a 1:10 dilution 
to stimulate moDC cultures. Unstimulated and stimulated moDCs were harvested using cold PBS, washed and 
infected with Echovirus 9 (Hill) at an MOI of 1 in serum free RPMI. After a 60 min incubation at 37oC, cells 
were washed 3 times in an excess volume of PBS after which viral titers were determined at different time 
points post infection (p.i.) as described before18. To exclude CVB3 interference during EV9 replication analysis 
titrations were done in the presence of neutralizing anti-CVB3 antibodies.
Statistical analysis
Differential expression was assessed by means of one-factor ANOVA, and non-parametric pairwise comparison 
of the DC subsets was done using the Tukey's post-hoc test in the R statistics package21. A P value of < 0.05 was 
considered a significant difference.
Results
TLR and RLH profiles in human immature and mature monocyte-derived DCs
Messenger RNA (mRNA) levels of TLRs, RLHs and other PRRs in human moDCs from 
three different donors were determined using custom-designed low density arrays based 
on microfluidic card technology (see materials and methods) and qPCR. In line with 
their function as 'sentinels' of the body, human immature DCs were found to express 
a broad variety of PRRs. Regarding TLRs responding to RNA, i.e. TLR3, TLR7 and TLR8, 
moderate steady-state levels were observed (Fig 1A). In contrast to their RNA-sensing 
TLR-counterparts, significant transcript levels of the RLHs RIG-I, MDA5 and LGP2 were 
detected in all donors, along with high levels of the dsRNA activated anti-viral effector 
molecule PKR. The levels of RIG-I and MDA5 were as much as 25- to 100-fold higher 
compared to expression of TLR3 or TLR7, implying an important role for RLHs in moDC 
biology (Fig 1A). Furthermore, transcripts for essentially all TLRs were detected, as well 
as a broad panel of C-type lectin receptors (CLRs) (Supplementary Figure 1) that can 
bind many pathogens, among which different viruses, and potentially function as entry 
receptors22, 23.
To study potential changes in PRR mRNA levels under pro-inflammatory 
conditions, we stimulated DCs with LPS (100 ng/ml) + IFNy (400 U/ml) for 24 h. Some 
members of the TLR family showed a modest up- or downregulation following exposure 
to LPS/IFNy, and significant donor differences were observed. Also the expression of 
CLRs showed moderate changes (Supplementary Fig. 1). Among the TLRs, the largest 
increases were found in the RNA-sensing TLRs (Fig 1A and Supplementary Fig. 1). TLRs 
involved in the detection of bacteria, such as TLR1, 2 and 4, which expression levels 
were already substantial, showed only a modest increase. Interestingly, differences 
in expression levels were more apparent within the family of cytoplasmic viral RNA 
sensors. Expression of RLHs RIG-I and MDA5 as well as effector molecules like PKR were 
significantly upregulated following stimulation with LPS/IFNy, suggesting that exposure to 
these pro-inflammatory stimuli can affect the responsiveness of DCs to viral pathogens.
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Figure 1. Expression of RNA sensors in human moDCs in steady-state and under pro-inflammatory condi­
tions.
(A) Human moDCs were obtained by culturing freshly isolated blood monocytes from three different donors 
with IL-4 and GM-CSF. Unstimulated moDCs or DCs stimulated with LPS (100 ng/ml) + IFNy (400 U/ml) for 
24h were used. Total RNA of unstimulated, or stimulated cells was isolated and quantitative mRNA expres­
sion levels of the indicated genes were analyzed using low density arrays and conventional qPCR. DCt values 
were calculated with the Ct value for PBGD as a reference. One gray scale color encompasses a 2 DCt range. 
Black corresponds to undetectable mRNAs. (B) Immature moDCs of three different donors were stimulated as 
described for figure 1 and total RNA was isolated 4, 8 or 24 h after stimulation. Quantitative mRNA expression 
levels of the indicated genes were analyzed using conventional qPCR and is displayed relative to unstimulated 
cells (put to 1). PBGD was used as reference gene. One representative example of three independent experi­
ments using different donors is shown. (C) DCs were stimulated as described for (A) and protein levels of RIG­
I, MDA5, PKR and actin were analyzed using western blot 24 h after stimulation. Shown is a representative 
example from two independent experiment using different donors.
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Dynamics of PRR expression upon DC stimulation
Next, we analyzed kinetics of PRR expression following stimulation of DCs, focusing on 
PRRs involved in recognition of viral RNA, i.e. TLR3, TLR7, TLR8, and the cytoplasmic viral 
RNA sensors. Upregulation of TLRs and RLHs peaked approximately 8 h after exposure 
to pro-inflammatory stimuli, and expression of most genes had returned to baseline 
levels after 24 h (Fig. 1B). TLR3 expression showed surprisingly little modulation in time 
compared to the other TLRs and RLHs studied (Fig. 1B, right panel), whereas RIG-I and 
MDA5 mRNA expression increased more than 50-fold (Fig. 1B, left panel). Western blot 
analysis corroborated our PCR results on protein level by showing enhanced expression 
of RIG-I, MDA5 and PKR following 24 h treatment with LPS/IFNy (Fig. 1C). Thus, upon 
exposure to PAMPs and pro-inflammatory stimuli, moDCs rapidly upregulate expression 
of PRRs responding to viral RNA at the mRNA and protein level, which might result in an 
increased capacity to respond to microorganisms.
Expression of RNA sensors in blood myeloid DCs and plasmacytoid DCs, and moDCs
To further study the RLH-family of RNA sensors in human DC subsets, we determined 
their expression profile in moDC, freshly isolated mDCs and plasmacytoid (p)DCs, which 
play a crucial role in antiviral immunity. The expression of TLR3, TLR7 and TLR8 that
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are also involved in viral RNA recognition was analyzed in parallel. Quantitative analysis 
showed that TLR8 levels were approximately 10-fold higher than levels of TLR3 or TLR7 
in moDCs, while differences in expression of these TLRs in freshly isolated mDCs were 
less pronounced (Fig. 2A). In contrast, pDCs were found to express approximately 100­
fold higher levels of TLR7 as compared to TLR8 and as much as 500 times more TLR7 
than TLR3. In addition, highly divergent TLR expression profiles were detected between 
the different DC subsets analyzed. The most pronounced TLR3 expression was found in 
mDCs that showed over 20-fold higher expression compared to moDCs or pDCs. The 
observed differences in expression of TLR7 were even more dramatic: pDCs showed 40- 
and over 200-fold higher TLR7 levels as compared to mDC and moDC (Fig. 2A). Thus far, 
no data is available regarding the expression or function of cytoplasmic RNA sensors in 
human mDCs or pDCs. We found that all DC subsets expressed mRNA of RIG-I, MDA5, 
PKR and LGP2 (Fig. 2B). Of these genes, LGP2 expression was the lowest in all DC-types 
analyzed, which might be related to its proposed function as negative regulator of MDA5 
and RIG-I responses16. For both myeloid DC subsets only a relatively modest difference 
was observed in expression levels of RIG-I and MDA5. In contrast, pDCs expressed 
considerably higher levels of MDA5 compared to RIG-I (Fig. 2B). Furthermore, pDCs 
expressed both RIG-I and PKR at higher levels than moDCs and/or mDCs. The most striking 
difference was observed for expression of MDA5 mRNA, which was expressed in pDCs 
at 10-fold and 20-fold higher levels than in moDCs or mDCs, respectively (Fig. 2B). The 
abundance of MDA5 in pDCs was confirmed at the protein level by confocal microscopy 
(Fig. 2C). The high expression of not only TLR7, but also cytoplasmic RNA sensors and 
antiviral effector molecules in pDCs provides additional evidence for specialization of DC 
subsets and the essential contribution of pDCs to antiviral immunity. This was further 
substantiated by the high constitutive mRNA level of interferon regulatory factor 7 (IRF- 
7), a key transcription factor in the innate immune response against viruses, which was 
significantly higher than in moDCs or mDCs (Fig. 2D)24-26.
Plasmacytoid DC mediated anti-viral immunity in moDCs
Taking into account the crucial role of pDC in antiviral immunity, we next investigated 
whether pDCs could influence antiviral responses in other DC subsets. Therefore, we 
set out to determine whether activation of pDCs could influence RNA-sensor expression 
in DCs of the myeloid lineage by analyzing RLH levels in moDCs that were exposed to 
supernatant of pDCs activated with CpG DNA. No significant direct effect of CpG DNA 
on moDC was observed (data not shown). Strikingly, pDC supernatant diluted as much 
as 100 times triggered a 150- to 300-fold increase in RIG-I, MDA5 and PKR transcript 
levels in moDC. Similar ISG induction in moDCs was found when using recombinant 
human IFNa2 and supernatant from R848-stimulated pDC (Fig. 3A and data not shown), 
suggesting an important role for type I IFNs in this process. Addition of CpG or R848 to 
moDC did not induce ISG-expression (data not shown and Kramer et al.27), excluding 
the possibility that the observed effects are due to direct PRR-stimulation of moDC. The 
importance of type I IFNs was confirmed by the use of blocking anti-IFN-a/ß antibodies, 
which completely prevented the induction of these RNA-sensors following stimulation 
with either pDC supernatant or rIFNa2 (Fig. 3A). The increased mRNA levels of MDA5 in 
moDCs were confirmed at the protein level by confocal analysis (Fig. 3B). Furthermore, 
western blot analysis confirmed increased protein levels of not only MDA5, but also 
RIG-I and PKR upon IFN-stimulation (Fig 3C). Interestingly, MDA5 has been reported
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Figure 2. Human DC subsets express different profiles of viral nucleic acid receptors.
(A) Mean expression (+SD) of TLR3, TLR7 and TLR8 in human moDCs, freshly isolated mDCs and freshly iso­
lated pDCs. RNA was isolated from unstimulated cells and TLR mRNA transcript levels determined using con­
ventional qPCR. Expression levels relative to PBGD. * P<0.05; ** P<0.01. (B) Expression levels of RIG-I, MDA5, 
PKR and LGP2 in resting human DC subsets were determined as described for (A). Shown is mean expression 
+ SD. * P<0.05; ** P<0.01. (C) Confocal laser scanning microscopy analysis of MDA5 expression in human 
moDCs and pDCs. Unstimulated cells were stained using antibodies against DC-SIGN and MDA5 (for moDCs) 
or BDCA2 and MDA5 (for pDCs) followed by incubation with Alexa labeled secondary antibodies. Green indi­
cates MDA5 expression, red indicates DC-SIGN or BDCA2 in moDCs and pDCs, respectively. A representative 
example of three independent experiments using different donors is shown. (D) IRF-7 expression in human 
DC subsets was determined using qPCR as described for (A). Shown is mean expression + SD. * p <0.05; ** p 
<0.01. Mean quantitative gene expression + SD from 6 moDCs, 3 pDCs and 3 mDCs is displayed (for figures 
A, B and D).
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to play a crucial role in the responses to the picornavirus encephalomyocarditisvirus 
(EMCV) in mouse DCs12 and we recently showed that echoviruses, single-stranded RNA 
viruses also belonging to the picornavirus family, can efficiently infect human moDCs18. 
To study whether upregulation of viral sensors, including MDA5, was associated with 
decreased susceptibility for infection, moDCs were exposed to pDC supernatant and 
subsequently infected with the echovirus EV9. EV9 titers rapidly increased in untreated 
moDCs or moDCs exposed to supernatant of unstimulated pDCs, indicating efficient virus 
replication. In contrast, treatment with supernatant of CpG-stimulated pDCs completely 
blocked EV9 replication in human moDCs (Fig. 3D).
To study DC cross-talk under more physiological conditions, pDC were stimulated 
with coxsackievirus B3 (CVB3) in the presence or absence of 10% human serum (HS). As 
we have shown before, CVB3 is not capable of infecting moDC, and has no effect on 
moDC function18. However, pDC activation by CVB3 has been reported in the presence 
of specific antiviral antibodies found in HS28. Stimulation of moDC with supernatant
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of unstimulated pDCs, or CVB3-stimulated pDC without HS had little or no effect on 
expression of RIG-I, MDA5 and PKR mRNA. However, supernatant of pDC exposed to 
CVB3 in the presence of 10% HS caused a profound increase in RNA-sensors in moDC 
(Fig. 4A). The observed effects were highly IFN-a/ß dependent, since mRNA induction in 
the presence of blocking anti-IFN-a/ß antibodies was completely absent (Fig. 4A). pDCs 
produced up to 40 ng/ml IFN-a upon stimulation with CVB3 and human serum (data not 
shown). This is a substantial increase that even exceeds the induction of IFN-a by CpG 
(approx 17 ng/ml, data not shown). To determine if stimulation with virus-activated pDC 
supernatant provided functional protection from infection, moDCs were subsequently 
exposed to EV9. Efficient EV9 replication was observed in moDC that had been treated 
with pDC supernatant from mock-stimulated pDC, as indicated by the increase in virus 
titer. In contrast, moDCs stimulated with supernatant from pDC that were exposed to 
CVB3 in the presence of HS were completely protected from EV9 infection, as shown by 
the dramatic effect on EV9 replication (Fig. 4B). Thus, pDC activation can increase the 
resistance against viral infection in DCs from the myeloid lineage.
Figure 3 TLR-stimulated human pDC induce a state of antiviral resistance in moDCs that inhibits infection 
with EV9.
(A) Human moDCs were exposed to cell free supernatants of pDCs (in a 1:100 dilution in RPMI 1640) that 
had been stimulated with CpG DNA (5^g/ml) for a period of 24 h. Alternatively, moDCs were stimulated using 
100 U/ml IFNa2 (Roferon- A®, Roche). Total RNA was isolated at the indicated time points following stimula­
tion and mRNA transcript levels determined using qPCR with expression of PBGD as a reference. Expression 
is given relative to unstimulated cells (medium). (B) Confocal laser scanning microscopy analysis of MDA5 
expression in human moDCs that were left untreated or exposed to supernatant of pDC activated with CpG 
DNA as described for (A). Cells were stained using antibodies against DC-SIGN and MDA5 followed by incuba­
tion with Alexa labeled secondary antibodies. Green indicates MDA5 expression; red indicates expression of 
DC-SIGN. (C) Human moDCs were stimulated with 200 U/ml IFNa2, or were left untreated. After 24h cells 
were harvested and protein levels of RIG-I, MDA5, PKR and actin were analyzed using western blot. Shown 
is a representative example from two independent experiments using different donors. (D) Human moDCs 
were exposed to cell free supernatants of differently stimulated pDCs for a period of 24 h and subsequently 
harvested, washed and exposed to EV9 at an MOI of 1 in serum free medium for 1 h at 37°C. After washes 
to remove unbound virus, cells were plated out and viral titers were determined at several time points after 
infection. Shown is a representative example of two independent experiments using different donors.
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Figure 4. CVB-stimulated pDC induce a type I IFN-dependent induction of viral RNA sensors in moDC and 
protection from subsequent EV9 infection.
(A) Human moDCs were exposed to cell free supernatants of pDCs (1:10 dilution in RPMI 1640) that were 
either mock or CVB-stimulated in the presence of absence of 10% human serum as indicated. Total RNA was 
isolated following stimulation and mRNA transcript levels were determined using qPCR with expression of 
PBGD as a reference. Expression is given relative to unstimulated cells (medium). (B) moDC were stimulated 
with pDC supernatant as described in (A) for 24h and subsequently harvested, infected with EV9 at an MOI of 
1. EV9 replication was analysed as for Fig 3D. Shown is a representative example of two independent experi­
ments using different donors.
In conclusion, we show that endosomal and cytoplasmic viral RNA sensors 
are widely expressed in moDCs, and this expression is increased upon inflammation. 
Furthermore, under steady-state conditions, these RNA sensors display a differential 
expression pattern in various human DC subsets, with the most substantial expression 
found in pDCs. Finally, cross-talk between virus-activated pDCs and moDCs offers 
protection against viral infection, which underscores the importance of cross-talk between 
DC subsets in optimal induction of immune responses against invading pathogens.
Discussion
DCs act as sentinels of the body and are present in virtually all tissues, where they 
constantly monitor their surroundings for signs of infection. To recognize microorganisms, 
DCs express a vast array of PRRs. Although a large body of information is available 
regarding the expression and function of TLRs in DCs, data on expression and function 
of the different RLH family members in human DCs is virtually absent. We set out 
to determine the quantitative expression levels of TLRs and RLHs in human DCs at 
different experimental conditions, focusing on PRRs involved in recognition of viral RNA. 
Furthermore we compared steady-state expression levels of these sensors in different 
DC subsets, and investigated cross-talk between virus-stimulated pDCs and moDCs.
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Human moDCs were found to express transcripts for all TLR family members, 
and most of the C-type lectins analyzed. The mean expression levels of TLRs responding 
to nucleic acids were considerably lower than those responding to bacterial or fungal 
pathogens. This could represent a mechanism to prevent unwanted responses to host 
nucleic acids that have been associated with autoimmune diseases like systemic lupus 
erythematosus29, 30. On the other hand, expression of PRRs in different cell types can 
be altered under pro- or anti-inflammatory conditions (this study and Homma et al., 
Rosenstiel et al., and Fitzner et al 31-33). Under pro-inflammatory conditions (i.e. LPS/IFNy) 
the expression of TLRs - especially TLR7 and TLR8 - was increased, providing a mechanism 
to efficiently fight infection upon encounter with pathogens. The upregulation of these 
molecules was most pronounced at early time points following stimulation, and had 
declined again after 24h. The rather swift PRR downregulation most likely functions to 
prevent unnecessary high PRR expression levels once infection has been cleared, thereby 
avoiding uncontrolled inflammatory responses.
Myeloid DCs and pDCs have been shown to display distinct TLR profiles that 
enable them to respond to different microbial structures4, 34. We here confirmed these 
data on a quantitative level and showed that expression of TLR7 in pDCs vastly exceeded 
that of TLR3 and TLR8. This is in accordance with the findings that pDCs respond 
strongly to synthetic TLR7, but not TLR8-specific ligands35 and are unresponsive to the 
synthetic dsRNA mimic poly(I:C)4. In contrast, moDCs expressed much higher levels of 
TLR8 compared to TLR3 and TLR7. The highly divergent expression profile of TLR7 and 
TLR8 in human pDCs and myeloid DC subsets likely reflects their ability to induce specific 
responses following recognition of different virus structures.
Virtually no data is currently available regarding RIG-I and MDA5 in human 
DC subsets. A recent mouse study has suggested that RIG-I is crucial for the antiviral 
response of myeloid DCs following exposure to the RNA virus Newcastle disease virus 
(NDV). In contrast, in pDCs RIG-I was shown to be dispensable and the antiviral responses 
against NDV in mice were dependent on the TLR signaling pathway16. Interestingly, our 
finding that RIG-I mRNA levels in human pDCs were significantly higher than the levels 
found in moDCs suggests that in the human setting RIG-I could play a pivotal role in the 
response of pDCs to RNA viruses. Even more pronounced were the expression levels 
of MDA5 in human pDCs that were remarkably higher than those found in moDCs 
or mDCs. MDA5 has recently been shown to mediate type I IFN responses following 
exposure of mouse myeloid DCs to poly(I:C) and the picornavirus EMCV12. Whether the 
prominent expression of MDA5 signifies involvement of this molecule in the response of 
pDCs to picornaviruses remains to be determined. It could be envisioned that the high 
constitutive levels of TLR7, RLHs and PKR in pDCs might not only mediate the robust type 
I IFN production of pDCs in response to viral pathogens but could also protect these cells 
from becoming infected themselves.
The cytoplasmic localization of RIG-I and MDA5 suggests that they play a 
dominant role in case of infection of DCs themselves. However, it could be envisioned 
that viral replication intermediates can come into contact with these molecules upon 
phagocytosis of infected cells, as it has been shown that antigen delivery from the 
endosomal compartment to the cytosol takes places in DCs, for instance to facilitate 
cross-presentation 36-38. However, whether these pathways can efficiently contribute to 
the RIG-I or MDA5 mediated antiviral responses remains to be determined.
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Finally, we revealed a novel effect of cross-talk between pDCs and DCs of 
myeloid origin. It has been described that cross-talk between pDCs and mDCs can 
influence cytokine production, DC maturation and antigen presentation3, 39-41. In this 
study we showed that cross-talk can induce rapid upregulation of RNA sensors in moDCs 
and protection against infection with picornaviruses. This protection depended on type 
I IFNs, cytokines with well-known anti-viral activity that signal through the ubiquitously 
expressed type I IFN receptor. Myeloid DCs are known to respond to IFNa40, 42, 43, but 
pDC derived type I IFNs are known to affect many other cell types when present in their 
vicinity. For example, it has been shown that type I IFNs can influence expression of RLHs 
in keratinocytes and macrophages44-46. Importantly, our study revealed that protection of 
mDC by pDC-derived type I IFNs not only occured upon pDC stimulation using synthetic 
TLR ligands, but also following a more physiological exposure to CVB. The finding that 
pDC mediated protection largely depended on the presence of human serum during virus 
exposure is in line with earlier result by Wang et al. Most likely, virus particles coated with 
anti-viral antibodies are being taken up via an FcR-mediated process, which ultimately 
leads to activation of the pDC through TLRs and possibly other PRRs28. This antibody- 
mediated process depends on the presence of specific anti-viral antibodies induced 
following activation of B-cells. Hence, it is likely to be more efficient upon secondary 
encounter with the same virus, when antibodies are already present and production is 
enhanced. Thus, pDCs could preserve the function and viability of myeloid DCs in case of 
infection with DC-tropic viruses. This will ensure antigen-presentation to both CTL and 
Th-cells, thereby enhancing the antiviral immune response. On the other hand, pDCs 
might mediate unbalanced responses by myeloid DCs or T-cells47, possibly contributing 
to immune-mediated diseases associated with CVB infections, such as cardiomyopathy 
and type 1 diabetes48, 49.
In conclusion, we demonstrate for the first time that human moDCs express 
high mRNA and protein levels of RLHs and PKR, which show a transient increase 
following exposure to pro-inflammatory stimuli. Expression profiling of PRRs involved in 
the antiviral response in different human DC subsets demonstrated that pDCs express 
significantly higher levels of RLHs, PKR and IRF-7 compared to myeloid DCs. The profound 
expression of these antiviral genes in human pDCs is in line with their important function 
in antiviral immunity, and might also explain how these cells survive and function in an 
environment with high virus burden. Finally, cross-talk between virus-stimulated pDCs 
and moDCs enhanced the expression of RIG-I, MDA5 and PKR in moDCs and created 
a state of antiviral resistance that protected these cells against viral infection. Further 
investigation into the novel findings presented here regarding the effect of human DC 
cross-talk on RLH expression and antiviral resistance will contribute significantly to our 
understanding of DC-pathogen interaction.
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Supplementary Figure 1.
Expression o f PRRs in human moDCs in steady-state or under pro-inflam m atory conditions.
Human moDCs were obtained by culturing freshly isolated blood monocytes from  three different donors w ith 
IL-4 and GM-CSF. Unstimulated moDCs or DCs stimulated w ith LPS (100 ng/m l) + IFNy (400 U/ml) for 24h 
were used. Total RNA o f unstimulated, or stimulated cells was isolated and quantitative mRNA expression 
levels o f the indicated genes were analyzed using low density arrays and conventional qPCR. DCt values were 
calculated w ith the Ct value for PBGD as a reference. One gray scale color encompasses a 2 DCt range. Black 
corresponds to  undetectable mRNAs.
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Abstract
Coxsackie B viruses (CVB) and Echoviruses (EV) form a single species; Human enterovirus B (HeV-B), within the genus Enterovirus. Although HeV-B infections are usually mild or asymptomatic, they can cause serious acute illnesses. In 
addition, HeV-B infections have been associated with chronic immune disorders, such 
as type 1 diabetes mellitus and chronic myocarditis/dilated cardiomyopathy. It has 
therefore been suggested that these viruses may trigger an autoimmune process. 
Here, we demonstrate that human dendritic cells (DCs), which play an essential role 
in orchestration of the immune response, are productively infected by EV, but not CVB 
strains, in vitro. Infection does not result in DC activation or the induction of anti-viral 
immune responses. Instead, EV infection rapidly impedes Toll-like receptor mediated 
production of cytokines and upregulation of maturation markers, and ultimately causes 
loss of DC viability. These results describe for the first time the effect of EV on the 
function and viability of human DCs and suggest that infection of DCs in vivo can impede 
regulation of immune responses.
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Introduction
Dendritic cells (DCs) are the most efficient antigen-presenting cells. They are present in 
virtually all organs and tissues throughout the body and are potent initiators of immunity 
via activation of (naïve) T- and B-cells, but also regulate tolerance to self-antigens in 
order to prevent auto-immunity1. Via expression of a broad array of pattern recognition 
receptors, for instance Toll-like Receptors (TLRs) and C-type lectins, DCs can sense the 
presence of a large variety of pathogens, such as bacteria and fungi2, 3. Triggering of 
TLRs results in DC maturation and cytokine production, enabling them to regulate T cell 
activation and differentiation4.
Also in the event of viral infection, DCs play a crucial role in the induction of 
anti-viral immune responses. Besides responding to virus-associated structures, such as 
ssRNA and dsRNA5, 6, DCs can take up virus particles or (apoptotic) virus-infected cells. 
This enables presentation of viral peptides in the context of MHC-II or MHC-I7, 8 and 
the induction of potent anti-viral T cell responses. However, viruses have co-evolved 
with their host to evade the immune system by several mechanisms. Considering the 
central role of DCs in the immune system, it is not surprising that these cells are often 
targeted by viruses. For instance, infection of DCs with cytomegalovirus results in 
defective maturation, hampering the activation of naïve T cells9, 10. In addition, measles 
virus impedes DC derived IL-12 production, while increasing the production of the anti­
inflammatory cytokine IL-1011. This mechanism could possibly explain the observed 
immune suppression as a result of measles virus infection. Thus, although DCs are 
important contributors to anti-viral immunity, virus infection can impair DC function and 
immune responses, potentially leading to persistent infections.
Coxsackie B viruses (CVB) and Echoviruses (EV) are small (20-30 nm), non­
enveloped enteroviruses that are closely related and classified as a single species, 
Human enterovirus B (HeV-B), within the Enterovirus genus of the Picornaviridae family. 
They mainly differ in their capsid-coding region and thus in receptor usage. They are 
acid stable and primarily cause infection of the gastrointestinal tract. Infection usually 
remains limited to the intestine and causes mild disease or remains asymptomatic. 
Incidentally, however, infection spreads via the blood stream to affect specific target 
organs as the brains, pancreas and heart where it can give rise to severe and potentially 
fatal illnesses such as (meningo)encephalitis, pancreatitis and myocarditis12. In addition, 
it has been suggested that CVB and EV play a role in the pathogenesis of chronic immune 
disorders like type 1 diabetes mellitus (T1D)13-15, primary Sjögren's syndrome16 and 
chronic myocarditis/dilated cardiomyopathy17-19. Hence, it has been proposed that HeV- 
B infections may trigger autoimmunity20-22.
To date, no information is available concerning the direct effect of HeV-B 
infections on DCs. We investigated the capacity of several CVB and EV strains to infect 
human DCs and analyzed the potential effects on DC function. We show here that 
the ability of these viruses to infect and replicate in human monocyte-derived DCs is 
restricted to EV strains only. EV infection does not lead to DC activation, but instead 
results in a rapid loss of responsiveness to TLR ligands and induction of cell death.
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Materials & Methods
Virus stocks and purification
Reference strains Echovirus 1 Farouk (EV1 Farouk), EV7 Wallace, EV8 Bryson, EV9 Hill and Coxsackievirus B4 
strain Tilo (CVB4 Tilo) were obtained from the National Institute for Public Health and the Environment (RIVM, 
Bilthoven, The Netherlands). CVB3 Nancy and CVB4 Edwards2 were kindly provided by R. Kandolf (University of 
Tübingen, Germany) and J.W. Yoon (University o f Calgary, Canada), respectively. Production o f virus stocks and 
virus titrations were performed on buffalo green monkey cells. Cells were grown in minimal essential medium 
(MEM) (Gibco) supplemented w ith 10% fetal bovine serum, 100 U/ml penicillin, and 100 m g/m l streptomycin 
at 37°C in a 5% CO2-incubator. A fter infection, cells were incubated until complete cytopathic effect was 
observed. Virus was released by 3  successive cycles o f freezing and thawing and cell debris was removed by 
centrifugation for 5 min at 3000 rpm. For purification, viral particles were pelleted by centrifugation through a 
30% sucrose cushion in a Beckman SW28 ro tor for 6 h at 25,000 rpm. Virus was resuspended in PBS and virus 
titers were determ ined by endpoint titra tion. Serial 10-fold dilutions were tested in 96-well m icro titer plates 
and fifty  percent Tissue Culture Infective Doses (TCID50) were calculated as described before23.
Plasmids
The CVB3 infectious cDNA clone used in this study, p53CB3/T7, has been described previously23. The EV9 Hill 
infectious cDNA clone24 was generously provided by B. Nelsen-Salz (Virology Institute, University o f Cologne, 
Germany).
Isolation of mononuclear cells and generation of monocyte-derived DC
Buffy coats (Sanquin bloodbank Nijmegen) were diluted using PBS containing 0.45% sodium citrate (dilution 
solution). Mononuclear cells were isolated by density gradient centrifugation using Lymphoprep (1.077 g / 
ml; Axis Shield PoC AS) according to  manufacturer's instructions. Cells were washed once in dilution solution 
to  remove Lymphoprep remains and further washed using ice cold dilution solution containing 0.1% BSA 
until clear supernatant was obtained. After counting, cells were resuspended in RPMI 1640 (Invitrogen Life 
Technologies) containing 2% human serum at a density o f 12.5 to15 X 106 cells/m l and plated out in T75 culture 
flasks (Costar) at 37°C for a period o f 1 h. Non-adherent cells were removed by washing thoroughly w ith  PBS 
and the adherent cell fraction was cultured in RPMI 1640 supplemented w ith 100 U/ml antibiotic-antimycotic 
(Invitrogen), 10 mM L-glutamine and 10% FCS. To generate monocyte-derived DC, 300 U/ml IL-4 and 400 U/ml 
GM-CSF (Strahtman) was added to  the culture medium. Medium was refreshed and complete cytokines added 
at day 3. On day 6 , immature DCs were harvested using cold PBS and directly used as described below. To 
obtain mature DCs, cells were stimulated w ith  LPS (100 ng/m l) or R848 (4 ^g /m l) for a period o f 24 h. 
Infection of monocytes and DCs
Monocytes were obtained by incubation o f PBMC in RPMI w ith 2% HS in 96-wells plates for 1 h at 37 °C. 
Nonadherent cells were removed by washing thoroughly w ith  PBS and the adherent cells were infected with 
virus at the indicated MOI in SF medium. After incubation for 60 min at 37oC, cells were washed 3 times with 
PBS and 150 ^ l fu ll medium was added to  the wells. For replication analysis, viruses were released at specific 
times post infection by 3 successive freeze-thaw cycles. Immature and mature DCs were harvested using cold 
PBS, washed and infected at an MOI o f 10 in SF RPMI, unless indicated otherwise. After a 60 min incubation at 
37oC, cells were washed 3 times in an excess volume o f PBS and plated out in 96-wells plates in fu ll medium. 
Titrations were done as described above.
Western blot analysis
At 4 and 8 h post infection, cells were lysed and lysates stored at -20°C. Equal amounts o f protein were 
separated by 12.5% SDS-PAGE, electroblotted onto nitro-cellulose membranes (Bio-Rad), followed by probing 
w ith  rabbit polyclonal antiserum raised against the firs t 60 aa o f CVB3 3A (anti-3A[1-60])25 in a 1:300 dilution. 
Because the 3A proteins o f CVB3 and EV9 are nearly identical (98% identity, 100% similarity), this antibody 
recognizes the 3A protein o f both viruses. After 3 washes, membranes were incubated w ith a 1:1000 dilution
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o f peroxidase-conjugated goat anti-rabbit immunoglobulins (Dako Diagnostika). Analysis was performed using 
the Lumi-Lightplus Western blotting substrate (Roche Molecular Biochemicals) according to the manufacturer's 
instructions.
Immune fluorescence
Immature DC (day 6 ) were harvested using cold PBS and infected w ith  CVB3 or EV9 at an MOI o f 10 in SF 
medium. After a 7 h infection period cells were washed 2 times in PBS, resuspended in SF medium and 50 X 
103 cells were allowed to  adhere to  poly-L-lysine coated coverslips for 1 h at 37oC. Cells were washed, fixed 
w ith  1% paraformaldehyde (PFA) at room tem perature (RT) for 20 min and blocked in PBS w ith  3% BSA, 10 
mM glycine and 2% human serum (blocking buffer, BB) for 60 min at RT. All antibody incubation steps were 
performed in BB. Cells were incubated at RT for 45 min using monoclonal anti-DC-SIGN (PN A07406, Beckman 
Coulter), washed 2 times w ith  PBS, followed by incubation w ith  goat-anti-mouse IgG Alexa 488 (Molecular 
Probes). After fixation w ith 1% PFA and permeabilization using 0.1% Triton-X100 in PBS for 5 min at RT, cells 
were incubated for 45 min w ith rabbit polyclonal anti-3A(1-60), washed 2 times in PBS, followed by incubation 
w ith  goat anti-rabbit IgG Alexa 594 (Molecular Probes). After final washes, cells were sealed using Mowiol 
(Merck) and visualized w ith a fluorescence microscope.
Blocking studies
Before addition o f virus, cells were preincubated at RT fo r 30 min w ith  isotype control (mouse IgG1), anti- 
VLA-2 (BD Pharmingen) or a mixture o f anti-DC-SIGN mAbs AZN-D1 and AZN-D326, 27 (15 ^g/m l). Cells were 
washed w ith  PBS, resuspended in SF RPMI and infected as described above.
Transfection of viral RNA
p53CB3/T7 and pEV9Hill were linearized by digestion w ith SalI and NotI, respectively, and transcribed in vitro 
w ith  T7 RNA polymerase. DCs were harvested, washed w ith PBS and resuspended in phenol-red free Optimem 
(Invitrogen Life Technologies). RNA (20 ^g) was transferred to  a 4-mm cuvette to  which 200 ^ l cell suspension 
containing 3 to  5 X 106 cells was added. Cells and RNA were incubated for 3 min prior to  being pulsed using 
a BioRad GenePulser Xcell (pulse conditions: exponential-wave pulse, 300 V, 150 ^F). After transfection, DCs 
were transferred to  full medium and incubated at 37°C. Virus yields were determ ined at various tim e points 
after transfection as described above.
Flow cytometry
After harvest, cells were washed in ice-cold PBA (PBS containing BSA and azide) and added to  a v-bottom 96- 
wells plate. After incubation for 30 min w ith  PBA containing 2% HS, cells were stained using mouse-anti-human 
monoclonal antibodies against CD40 (mab 89, kind gift o f Dr R. de W aal-Malefyt, DNAX Research Institute, 
Palo Alto, CA), CD80, CD8 6  (both BD Pharmingen) and CD83 (Immunotech) or the appropriate isotype controls 
(Pharmingen) on ice for a period o f 30 min. Cells were washed tw ice in PBA and incubated w ith phycoerythin 
(PE) labeled goat-anti-mouse IgG (Pharmingen) on ice for a period o f 30 min. After washes, cells were fixed in 
2% paraformaldehyde and analyzed by flow  cytom etry on a FACSCalibur apparatus (BD Biosciences). Analysis 
was done using W inMDI 2.8 software.
ELISA
Dendritic cells were stimulated w ith  TLR ligands as described above and 75 X 103 cells/well were plated out 
in trip licate in round-bottom 96-wells plates in full medium. After 6 h or 24 h, plates were centrifuged and 
supernatants harvested and stored at -80°C until cytokine analysis was done. Cytokine concentrations in 
supernatants were determ ined using a TNFa or IL-12p70 specific ELISA (both Pierce-Endogen), respectively 
DAPI staining
Immature DC (day 6 ) were harvested using cold PBS and exposed to  CVB3 or EV9 at an MOI o f 10 in SF medium. 
After a 24 h infection period cells were harvested using trypsin-EDTA, resuspended in SF medium and 50 X 103 
cells were allowed to  adhere to  poly-L-lysine coated coverslips for 1 h at 37oC. Cells were washed once with 
PBS and fixed w ith  1% PFA for 20 min at RT. Following fixation, cells were washed using PBS and incubated at 
RT using DAPI (5 m g/m l) at a 1:15,000 dilution in PBS for 15 min. After final washes, cells were sealed using
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Mowiol (Merck) and visualized using a fluorescence microscope.
Caspase-3/7 activity assay
Caspase activity was measured using the Apo-one® homogeneous caspase-3/7 assay kit (Promega) according 
to  manufacturer's instructions. Briefly, caspase-3/7 reagent was prepared by diluting the caspase-3/7 substrate 
(1:100) w ith  caspase-3/7 buffer. Reagent and cell lysates were added to  white 96-well plates (Porvair Sciences), 
maintaining a 1:1 ratio o f reagent to  lysate. Enhanced lysis o f DCs was achieved by freeze/thawing cells prior 
to  use in assay. Contents were mixed by shaking at 300 rpm on a plate shaker for 2 h at RT. Fluorescence was 
measured at an excitation wavelength o f 485 nm and an emission o f 540 nm.
Statistical analysis
The differences in the mean values o f cytokine production o f infected cells compared to  controls were 
determ ined by two-tailed Student's t  test. A P value o f <0.05 was considered a significant difference.
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Figure 1. Productive infection o f human monocyte-derived DCs by several EV strains.
(A) DCs were infected w ith various CVB- or EV-strains at an MOI o f 10 and viral titers determ ined at several 
tim e points p.i. Representative example o f at least 3 independent experiments using different donors. (B) DCs 
were exposed to  CVB3 or EV9 and lysates made 4 or 8 h p.i. Presence o f virus was shown by Western blot 
using a polyclonal antibody against the non-structural viral protein 3A. Notice the double bands, representing 
3A and its precursor 3AB. Results shown are from  one o f 3 independent experiments w ith  similar results. (C) 
DCs exposed to  CVB3 or EV9 were co-stained using antibodies against the DC marker DC-SIGN and the viral 
protein 3A at 7 h p.i. Presence o f 3A protein in DCs was analyzed using confocal microscopy. Middle panel 
shows individual EV9-infected cell, lower panel shows 3 EV9-infected cells. Representative example o f 2 inde­
pendent experiments. (D) DCs were exposed to  CVB3 or EV9 at different MOIs and the increase in viral tite r 
was determ ined at indicated tim e points.
Results
EV, but not CVB, can productively infect human monocyte-derived DCs
To date, little is known concerning the direct effect of infection with CVB or EV on cells 
of the immune system. We aimed to investigate the capacity of these viruses to infect
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human DCs and the potential consequences of infection for DC function. Therefore, we 
selected a number of representatives from the CVB (CVB3 Nancy, CVB4 Tilo and CVB4 
Edwards 2) and EV group (EV1 Farouk, EV7 Wallace, EV8 Bryson and EV9 Hill) that are 
reported to use several different receptors for cell entry. As shown in figure 1A, all EV 
strains used were capable of infecting DCs, as indicated by a rapid increase in virus titers 
with maximal virus titers already observed after 8 h. Interestingly, DCs did not support 
replication of closely related CVB strains, as no increase in the amount of infectious virus 
was found, even at 48 h post infection (p.i.) (Fig. 1A and data not shown). Thus, a clear 
difference exists in susceptibility of DCs for infection with different HeV-B serotypes. 
CVB3 Nancy and EV9 Hill (further indicated as CVB3 and EV9) were used during the 
remainder of our experiments, unless indicated otherwise. Analysis of viral protein 
synthesis by Western blot using a polyclonal antibody that recognizes the CVB3 and EV9 
3A proteins showed the presence of significant amounts of viral protein in DC cultures 
exposed to EV9, but not CVB3 (Fig. 1B). To exclude that viral replication in cells other 
than DCs accounted for the observed effects, infected cultures were co-stained using 
antibodies against the viral 3A protein and the DC marker DC-SIGN (dendritic cell-specific 
ICAM-3-grabbing nonintegrin)26 at 7 h p.i. Immune fluorescence analysis showed that 
>90% of the EV9-infected cells were positive for both 3A and DC-SIGN. No 3A positive 
cells could be detected in CVB3-exposed cultures (Fig. 1C). This finding confirmed that 
viral replication takes place in DCs.
To investigate whether infection of DCs at a lower multiplicity of infection (MOI) 
would also result in efficient replication, the increase in virus titer after exposure of DCs 
to CVB3 or EV9 at an MOI of 10, 0.1 or 0.001 was determined. Infecting DCs with EV9 at 
an MOI 10,000 X lower than initially used led to a similar increase in virus titer 24 h p.i., 
while no replication was observed for CVB3 at any of the MOIs tested (Fig. 1D). These 
results indicate that EV9 is capable of multiple rounds of infection in DC cultures.
Mature DCs, but not monocytes, are permissive for EV infection
Because we used monocyte-derived DCs throughout our experiments and taking into 
account that monocytes can function as DC precursors both in vitro and in vivo28-30, we 
set out to determine whether these cells are also susceptible to infection. Therefore,
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Figure 2. M ature DCs, bu t no t monocytes, are permissive fo r EV infection.
(A) Monocytes were infected as described for DCs in figure 1 and virus titers determ ined at several tim e points 
p.i. (B) Immature DCs were stimulated w ith  TLR ligands LPS (100 ng/m l) or R848 (4 ^g /m l) for 24 h or left 
untreated (medium) and subsequently exposed to  CVB3 or EV9 at an MOI o f 10, after which viral titers were 
determ ined at several tim e points p.i. Data shown are representative o f at least 3 independent experiments.
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Figure 3. EV infection is no t mediated via DC-SIGN, bu t requires in teraction w ith  a specific cell surface 
receptor.
(A) DCs were preincubated w ith  a combination o f DC-SIGN blocking antibodies (AZN-D1, AZN-D3, 15 ^g /m l) 
or the relevant isotype controls for a period o f 30 min at RT and subsequently infected w ith  EV9 or EV1 at 
an MOI o f 10. Increase in virus tite r was determ ined at several tim e points p.i. Representative example o f 3 
independent experiments. (B) DCs were preincubated w ith  a VLA-2 blocking antibody or isotype control for 
a period o f 30 min at RT and subsequently infected w ith  EV1 at an MOI o f 10. Increase in virus tite r was de­
term ined at several tim e points p.i. Data shown are from one o f tw o  representative experiments w ith  similar 
results. (C) Immature DCs were resuspended in 200 ^l phenol-red free Optimem and electroporated w ith  20 
^g in v itro transcribed RNA encoding the viral genome o f CVB3 or EV9. Viral titers were determ ined at several 
tim e points after transfection. Data shown are representative o f 3 independent experiments.
monocytes were isolated from peripheral blood mononuclear cells (PBMCs) of healthy 
controls and exposed to CVB3 or EV9. No detectable increase in the amount of infectious 
virus was observed, indicating that monocytes are not permissive for infection with 
either of these viruses (Fig. 2A). In concordance with these data, no 3A protein could 
be detected after staining of virus-exposed monocyte cultures with anti-3A antibodies 
(data not shown).
Because of the apparent difference in susceptibility between (immature) DCs 
and monocytes, we investigated whether mature DCs would support viral replication. 
DCs were activated prior to infection by triggering TLR4 or TLR8, involved in recognition 
of bacteria- or virus-associated structures, respectively. Full DC maturation was achieved, 
as determined by flowcytometric analysis of the expression levels of maturation markers 
CD40, CD80, CD83 (data not shown). Infection of both immature and mature DCs with 
EV9 resulted in an approximate 3-log increase in viral titers over a 24-h infection period, 
whereas no titer increase could be observed for CVB3 (Fig. 2B). Thus, DCs are highly 
susceptible to EV infection, irrespective of the DC maturation state.
6
EV infection of DCs is not mediated via DC-SIGN
DC-SIGN is a C-type lectin specifically expressed by DCs, but not monocytes, and 
functions as a pattern recognition receptor for many pathogens. In addition, DC-SIGN 
has been reported to facilitate infection of DCs with several viruses31, 32. Considering the
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difference in susceptibility between monocytes and DCs, we tested whether EV infection 
of DCs could be mediated through DC-SIGN. Therefore, DCs were pre-incubated with 
a combination of DC-SIGN blocking antibodies, which have been previously shown to 
block interaction between DC-SIGN and measles virus31 as well other pathogens33, 34. 
Blocking DC-SIGN did not affect susceptibility of DCs for either EV9 or EV1 (Fig. 3A). Also 
pretreatment of DCs with EGTA, a calcium chelator that inhibits C-type lectin function, did 
not affect infection efficiency (data not shown). These data make it unlikely that DC-SIGN 
is involved in EV entry into DCs. To date, a number of receptors have been identified for 
different HeV-B viruses. However, the receptor for EV9(Hill) is yet unknown. The integrin 
very late antigen-2 (VLA-2) has been recognized as the receptor for EV1 in HeLa cells35. To 
investigate whether infection of DCs is mediated via a specific virus receptor, we tested 
the effect of VLA-2 blockage on EV1 infection. Blocking of VLA-2 completely abrogated 
EV1 infection of DCs, whereas an isotype control antibody had no effect (Fig. 3B). These 
data suggest that EV infection of DCs is mediated via a specific virus receptor.
The difference in susceptibility of DCs for CVB and EV could possibly be due to 
lack of expression of the coxsackievirus and adenovirus receptor (CAR) on DCs. Indeed, 
no CAR (or decay accelerating factor (DAF)) was detected on the cell surface by flow 
cytometry (data not shown), in concordance with earlier findings36. To study whether 
CVB3 is capable of replicating in DCs upon bypassing its receptor, cells were transfected 
with RNA transcribed in vitro from full-length cDNA clones of CVB3 and EV9. Transfection 
resulted in rapid virus production and both CVB3 and EV9 reached similar titers at 8 to
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Figure 4. EV infection does not lead to  DC m aturation or cytokine production.
(A) DCs were exposed to  CVB3 or EV9 at an MOI o f 10 and the expression of maturation markers CD40, CD80, 
CD83 and CD8 6  was determ ined by flow  cytom etry 24 h after infection. Thin black lines indicate isotype con­
tro l. Grey filled histogram represents expression on mock-infected DCs, thick black lines indicate expression 
levels on CVB- or EV9- exposed DCs. (B) DCs were infected w ith  CVB3 or EV9 and levels o f TNFa and IL-12p70 
in supernatants o f infected DC were determ ined by ELISA after a 24 h infection period. To determ ine the 
capacity of DCs fo r cytokine production, cells were stimulated in parallel w ith  TLR ligands LPS (100 ng/ml) 
or R848 (4 |ig /m l). Graphs show mean + SD of trip lica te measurements. Results shown are representative 
example o f 3 independent experiments.
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Figure 5. EV infection impairs responsiveness o f DCs to  TLR ligands.
(A) DCs were exposed to  CVB3 or EV9 and immediately stimulated w ith  TLR ligands LPS (100 ng/m l, data not 
shown) or R848 (4 ^g /m l) after last washing step to  remove unbound virus. Expression levels o f costimulatory 
molecules CD80, CD83 and CD8 6  were determ ined using flow  cytometry. Thin black lines represent isotype 
controls. Grey filled histogram indicate expression on medium stimulated DCs and thick black lines represent 
expression levels on R848-stimulated DCs. (B and C) DCs were exposed to CVB3 or EV9 and immediately 
stimulated w ith  LPS or R848. TNFa or IL-12p70 levels in DC supernatants were determ ined using ELISA after 
a 6 h or 24 h incubation period, respectively. Graphs show mean + SD o f trip licate wells. Representative ex­
amples o f 3 independent experiments. ** , P<0.01 (cytokine production by EV9-infected DCs vs mock-infected 
or CVB3-exposed DCs; two-tailed Students t  test).
10 h after electroporation of viral RNA (Fig. 3C). After this time, only the titer of EV9 
continued to rise because this virus, but not CVB3, is capable of infecting cells that were 
not initially transfected. These results support the idea that the incapability of CVB to 
replicate in DCs is due to the absence of the appropriate receptor.
Human enteroviruses B do not induce DC activation
Next, it was studied whether infection leads to DC activation, as determined by analyzing 
the expression of costimulatory molecules and cytokine production. No upregulation of
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the maturation-associated molecules CD40, CD80, CD83 and CD86 could be observed 
after a 24-h infection period (Fig. 4A). Instead, EV9 infection led to a small decrease in the 
expression of some maturation markers, but this effect was not observed consistently. 
To investigate whether infection of DCs results in the production of pro-inflammatory 
cytokines, the levels of TNFa and IL-12p70 in DC supernatants were determined at 24 h 
p.i. No significant levels (<10 pg/ml) of these cytokines were detected after infection, in 
contrast to the high production observed upon stimulation of DCs with LPS or R848 (Fig. 
4B). Similar results were found for the production of IL1ß, IL-6 and the anti-inflammatory 
cytokine IL-10 (data not shown).
Viral infection is a potent inducer of type I IFNs in many cell types. However, no 
IFNa or IFNß was detected using ELISA and quantitative PCR (qPCR) following infection 
of DCs with CVB3 or EV9, even at early time points after infection (2, 4, or 6 h p.i.) (data 
not shown). Preliminary experiments using a new micro fluidic based qPCR technique, 
to study the expression of a broad array of chemokines and cytokines, revealed that 
infection did not induce significant changes in any of the target genes analyzed (e.g. IL-6, 
IL-8, RANTES (regulated on activation normal T cell expressed and secreted), CCL4, CCL5 
etc) at 7 h p.i. (data not shown). Together, these data indicate that DCs do not become 
activated upon infection with either EV9 or CVB3.
EV infection impairs TLR responses in DCs
To analyze whether infection affects the response of DCs to TLR ligands, cells were 
stimulated with LPS or R848 immediately following infection. Both uninfected and CVB3- 
exposed DCs stimulated with LPS or R848 for 24 h showed an increased expression of
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Figure 6 . EV9 infection results in rapid cell death in DC cultures.
(A) DCs were exposed to CVB3 or EV9 at an MOI o f 10 and the percentage o f dead cells in DC cultures was 
determ ined at several tim e points p.i. using a Trypan Blue exclusion assay. Graphs show mean +/- SD o f 5 
independent experiments. (B) DC morphology 24 h after exposure to CVB3 or EV9, as analyzed using light 
microscopy. (C) DCs were exposed to CVB3 or EV9 at an MOI o f 10 and nuclear staining was performed using 
DAPI 24 h post exposure. (D) DCs were exposed to CVB3 or EV9 and lysates made at several tim e points p.i. 
Caspase-3/7 activity was measured in DC lysates. Graphs show mean +/- SD o f trip licate measurements. One 
representative example o f 3 independent experiments is shown.
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CD80, CD83 and CD86 (Fig. 5A). In contrast, infection with EV9 prior to TLR stimulation 
consistently resulted in a profound reduction of DC maturation. In addition to phenotypic 
maturation of DCs, TLR ligation leads to the release of cytokines like TNFa and IL-12p70. 
High levels of these pro-inflammatory cytokines were detected following stimulation 
with LPS or R848 in supernatants of uninfected and CVB3-exposed DCs. In contrast, 
EV9-infected DCs produced significantly lower levels of TNFa and this deficiency 
became apparent as soon as 6 h after stimulation (Fig. 5B). The modest decrease in 
TNFa production after activation of CVB3-exposed DCs was not observed consistently. 
IL-12p70 levels were undetectable during these early time points, since it is secreted 
at a later phase after activation. However, analysis of supernatants at 24 h p.i. showed 
that the production of this cytokine is also dramatically impaired (Fig. 5C). Analysis of 
cytokine mRNA levels in TLR-activated infected cells revealed that EV9 infection hinders 
transcription of TNFa and IL-12p70 at very early time points after infection (data not 
shown). These findings indicate that infection can rapidly shut-down TLR responses in 
DCs.
Effect of HeV-B on DC viability
HeV-B virus release from infected cells is generally thought to be mediated via cell lysis. 
The kinetics of lytic activity was studied in relation to the observed functional impairment 
of DCs after infection. Therefore, DCs were exposed to CVB3 or EV9 and the percentage 
of dead cells determined by a Trypan Blue (TB) exclusion assay at different time points 
p.i. While at 8 h p.i. no significant difference could be observed in cell viability in the 
different cultures, hardly any viable cells could be detected 24 h after EV9 infection. 
Survival in mock-infected or CVB3-exposed cultures was comparable (Fig. 6A). These 
findings were confirmed by light microscopic analysis, revealing obvious signs of cell 
death in EV9-infected DC cultures (Fig. 6B).
Enteroviruses are known to trigger a complex type of cell death that shows 
characteristics of both necrosis and apoptosis. Staining of the nuclei of EV9-infected DCs 
at 24 h p.i. with DAPI revealed predominantly crescent-shaped nuclei with condensed 
chromatin (Fig. 6C), a feature that is typical for enterovirus-infected cells37. Only few 
cells with fragmented nuclei were typically observed. No changes in nuclear phenotype 
were observed in CVB3-exposed cells. Analysis of the activity of effector caspases-3 and 
-7 in infected DCs showed little caspase activity up to 8 h p.i., but a steep increase was 
observed at later time points in EV9-infected, but not CVB3- exposed cells (Fig. 6D). 
Thus, EV9 infection of DCs triggers rapid cell death that shows signs of both necrosis and 
apoptosis.
Discussion
In this study, we showed that EV, but not CVB strains, are highly efficient in productively 
infecting both immature and mature DCs in vitro. Remarkably, the infection did not 
result in activation of DCs. Instead, EV impaired the response of DCs to TLR ligands, 
since both maturation and cytokine secretion following stimulation with LPS or R848 
were significantly decreased in EV-infected DCs. The clear difference between CVB and 
EV regarding outcome of infection is most likely related to absence of the appropriate 
receptor for CVB on the DC surface, since bypassing the receptor by electroporation of
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CVB RNA resulted in highly efficient replication in DCs. Finally, infection with EV led to 
rapid killing of DCs within 24 h after infection.
HeV-B belong to the most common viral causes of intestinal infections in life. 
Although infection usually remains limited to the intestinal tract, the virus can cause 
serious illnesses by spreading to target organs12. In addition, HeV-B infections have 
been associated with chronic immune disorders14, 17-19, but direct proof is lacking and a 
pathogenic mechanism has not yet been elucidated. Explanations are sought either in 
viral persistence in target organs19, 38, 39, blood40-42 or in viral triggering of an autoimmune 
process21, 43, theories that are not mutually exclusive. So far, particularly CVB are thought 
to be involved. However, evidence is growing that other serotypes, like EV, can also play 
a role15, 44, 45. Our study shows that DCs, which are critically involved in orchestration of 
the immune response, can become directly affected by EV in vitro, raising the possibility 
that EV may modulate immune responses in vivo.
In contrast to monocyte-derived DCs and macrophages, monocytes themselves 
are refractory to HeV-B infection in vitro46, 47. In line with this, poliovirus, another 
member of the genus Enterovirus, has recently been shown to replicate in monocyte- 
derived macrophages but not in monocytes48. Thus, within the myeloid lineage, there 
is a profound difference in susceptibility for infection. Interestingly, it has been shown 
that also the maturation stage of DCs can determine susceptibility for and outcome of 
infection with for instance cytomegalovirus49, 50. However, we found that both immature 
and mature DCs were equally supportive of EV replication, whereas neither of them could 
be productively infected by CVB. Also the type of TLR triggered to induce maturation 
(e.g. TLRs involved in recognition of bacterial vs viral structures) could possibly affect 
outcome of infection. Therefore, we determined susceptibility of DCs which had been 
activated with LPS (TLR4) or R848 (TLR7/8). Both ways of DC activation allowed for 
similar replication efficiency of EV in DCs. These findings indicate that DCs are highly 
permissive for infection with EV, independent of DC maturation stage or nature of the 
maturation stimulus. Also poliovirus has recently been shown to productively infect both 
immature and mature DCs, although it should be noted that in their study the DCs were 
not activated using TLR ligands48.
The difference in susceptibility between monocytes and DCs, led us to 
investigate whether infection was mediated by DC-SIGN, a DC-specific C-type lectin 
that was discovered in our lab and is crucially involved in recognition and uptake of 
many different pathogens51. It has recently been described that DC-SIGN can serve as a 
receptor for measles virus52 and human herpesvirus 832, thereby facilitating infection of 
DCs. Blocking of DC-SIGN did not alter the susceptibility of DCs for EV infection. However, 
infection with EV1 could be prevented by blocking VLA-2, the EV1 receptor. These data 
suggest that EV infection most likely takes place through interaction with a specific cell 
surface receptor rather than DC-SIGN. In concordance with this idea, no CAR or DAF 
expression was found on DCs, which explains the incapability of the CVB strains tested to 
infect DCs. CVB3 was capable of efficient replication upon transfection of viral RNA. The 
latter finding suggests that DCs, when infected via alternative routes, may also become 
functionally affected by CVB. Such alternative routes can be antibody-mediated uptake 
via Fc-receptors, or phagocytosis of infected, dying cells. Indeed, it has recently been 
described that the susceptibility of PBMC and monocytes to CVB4 can be enhanced 
via an antibody-dependent mechanism46, 53. This mechanism might provide a possible 
explanation for the observed presence of CVB in PBMCs of some T1D patients at onset of
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the disease54. Whether such alternative routes mediate infection of DCs by CVB requires 
further investigation.
Although several viruses induce DC activation upon infection55, 56 and exposure 
of monocytes or PBMC to HeV-B results in the production of cytokines57-59, infection of 
DCs with CVB or EV did not result in DC activation. This unresponsiveness is striking 
since DCs play a central role in the defense against viruses and other microorganisms. 
However, enteroviruses are known to deploy several strategies to curtail anti-viral host 
cell responses. This is achieved by for instance the action of viral proteases that cleave 
transcription factors and translation initiation factors, thereby shutting off cellular 
gene expression60, 61. In addition, the 3A protein has been shown to inhibit ER-to-Golgi 
transport23, 62 thereby interfering with cytokine secretion and antigen presentation63, 64. 
These mechanisms might underlie the absent upregulation of co-stimulatory molecules 
and lack of synthesis of cytokines like type I IFNs, TNFa and IL-12 in infected DCs. In 
addition, the virus affected the response of DCs to TLR ligands. This might be mediated 
via above mentioned effects of infection on gene expression or protein transport or 
altered TLR expression levels or localization. Furthermore, decreased cell viability 
following infection might also contribute to inhibited TLR responses. However, we found 
that also early responses, such as TNFa production, were dramatically impaired, already 
before signs of cell death became apparent. This finding demonstrates that the EV not 
only suppresses DC activation as a direct result of infection but also limits TLR-mediated 
immune responses. Previous studies have yielded similar results upon infection of DCs 
with other viruses9, 65. Our findings add EV to the growing list of pathogens that can 
interfere with DC function.
In summary, our data demonstrate for the first time that DCs can become 
productively infected with EV, but not with CVB strains. Infection does not result in 
DC activation or the induction of anti-viral immune responses, but instead impairs 
the response to TLR ligands and induces cell death. This might represent an important 
evasion strategy, as targeting DCs would interfere with stimulation of T cells specific for 
EV or other pathogens. Consequently, failure in clearing virus-infected cells could result 
in persistent infection and possibly contribute to HeV-B associated diseases, such as T1D 
and chronic myocarditis.
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Abstract
D endritic cells (DCs) play a central role in instructing antiviral immune responses. DCs, however, can become targeted by different viruses themselves. We recently demonstrated that human DCs can be productively infected with echoviruses 
(EV), but not coxsackieviruses (CVB), both of which are RNA viruses belonging to the 
Enterovirus genus of the Picornavirus family. We now show that phagocytosis of CVB- 
infected, type I IFN deficient cells induces an antiviral state in human DCs. Uptake of 
infected cells increased the expression of the cytoplasmic RNA helicases RIG-I and MDA5 
as well as other interferon stimulated genes and protected DCs against subsequent 
infection with EV9. These effects depended on recognition of viral RNA and could be 
mimicked by exposure to the synthetic dsRNA analogue poly(I:C), but not other TLR- 
ligands. Blocking endosomal acidification abrogated protection, suggesting a role for 
TLRs in the acquisition of an antiviral state in DCs. In conclusion, recognition of viral 
RNA rapidly induces an antiviral state in human DCs. This might provide a mechanism by 
which DCs protect themselves against viruses when attracted to an environment with 
ongoing infection.
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Introduction
Dendritic cells (DCs) are crucial for the induction of antiviral immunity via instruction of 
both the innate and adaptive immune system1-3. The hallmark of antiviral responses is 
production of type I IFNs. Although classically plasmacytoid DCs were thought to be the 
major producers of type I IFNs4, 5, it has been shown that conventional DCs can produce 
similarly high type I IFN levels upon viral infection6. In fact, all nucleated cells are capable 
of type I IFN production, resulting in the establishment of an antiviral state in neighboring 
cells via upregulation of so-called interferon stimulated genes (ISGs).
DCs express a vast array of pattern recognition receptors (PRRs), such as Toll­
like receptors (TLRs) that enable them to recognize viral pathogen-associated molecular 
patterns (PAMPs) like dsRNA7 and ssRNA8-10. TLRs responding to viral nucleic acids are 
localized within the endosomal compartment11, 12 and are triggered upon endocytosis 
of viral particles or virus-infected cells, but presumably do not sense cytoplasmic virus 
replication upon infection of the DC itself. Instead, recent studies have identified two 
structurally related RNA helicases, retinoic acid inducible gene I (RIG-I)13 and melanoma 
differentiation associated gene 5 (MDA5)14, both ISGs, as critical mediators in the 
response to infection with different RNA viruses in mice15-17. Triggering of MDA5 or RIG-I 
causes recruitment of the shared adaptor protein IFN-ß promoter stimulator 1 (IPS-1), 
also known as mitochondrial antiviral signaling protein (MAVS), virus-induced signaling 
adaptor (VISA), and CARD adaptor inducing IFN-ß (Cardif)18-21, leading to induction of 
type I IFNs. RIG-I deficient cells display greatly diminished type I IFN responses to various 
RNA viruses and in vitro transcribed dsRNA17, 22. Interestingly, MDA5 deficient cells are 
selectively unresponsive to certain picornaviruses, such as encephalomyocarditis virus 
(EMCV) and Theiler's encephalomyelitis virus as well as the synthetic dsRNA analogue 
poly(I:C)15, 17. This specificity might be related to the presence or absence of 5' triphosphate 
groups, which was recently reported to be a critical structure for RIG-I activation23, 24. The 
essential contribution of these RNA helicases to antiviral immunity becomes evident in 
RIG-I or MDA5 KO mice that readily succumb upon infection with Japanese encephalitus 
virus or EMCV, respectively15, 17.
To date, most data regarding RIG-I and MDA5 are derived from mouse studies, 
while still little is known regarding the role of these viral sensors in human cells. We 
recently showed that infection of human monocyte-derived DCs with EV, but not CVB, 
results in rapid inhibition of TLR-mediated responses and massive cell death25. As it is 
difficult to reconcile these in vitro effects with the generally mild clinical outcome of 
EV infections, we set out to investigate the conditions that could potentially alter DC 
susceptibility. In the present work, we demonstrate that phagocytosis of virus-infected 
cells results in enhanced expression of RIG-I, MDA5 and other ISGs and protects DCs 
against EV infection. These effects require intact endosomal acification and depend on 
the presence of RNA in infected cells. Thus, DCs engage a state of antiviral resistance 
following recognition of viral RNA.
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Materials & Methods
Virus stocks and purification
Reference strains Echovirus 1 Farouk (EV1 Farouk), EV7 Wallace, EV8 Bryson, EV9 Hill and EV11 Gregory were 
obtained from  the National Institute for Public Health and the Environment (RIVM, Bilthoven, The Netherlands), 
CVB3 Nancy was kindly provided by R. Kandolf (University o f Tübingen, Germany). Production o f virus stocks 
and virus titrations were performed on buffalo green monkey cells as described previously 25. Serial 10-fold 
dilutions were tested in 96-well m icro titer plates and fifty  percent Tissue Culture Infective Doses (T C ^ J  were 
calculated as described before26.
Plasmids
The EV9 Hill infectious cDNA clone27 was generously provided by B. Nelsen-Salz (Virology Institute, University 
o f Cologne, Germany).
Stimulation of monocyte-derived DCs
Monocyte-derived DCs were generated as described previously25. Mature DCs were obtained by stimulating 
cells w ith  poly(I:C) (20 ^g/m l), LPS (100 ng/m l), R848 (4 ^g/m l), PAM3Cys-SKKKK (PAM, 2 ^g /m l) for a period 
o f 24 h, unless indicated otherwise. To block the actions o f type I IFN, cells were stimulated in presence or 
absence o f neutralizing anti-human type I IFN antibodies (1:100, Iivari, Kaaleppi or bovine serum, courtesy of 
I. Julkunen, National Public Health Institute, Helsinki, Finland)28. To block endosomal acidification, DCs were 
cultured w ith  chloroquine (CQ, 10 ^M ) starting 1 h prior to  poly(I:C) stimulation. For infection, immature or 
mature DCs were harvested using cold PBS, washed and infected at an MOI o f 1 w ith  indicated viruses in SF 
RPMI. After 60 min incubation at 37oC, cells were washed 3 times in an excess volume o f PBS after which viral 
titers were determ ined at different tim e points post infection (p.i.) as described above.
Western blot
Equal amounts o f protein were separated by 12.5% SDS-PAGE, electroblotted onto nitro-cellulose membranes 
(Bio-Rad), followed by probing w ith  the indicated antibodies. Anti-RIG-I and anti-PKR antibodies were purchased 
from  ProSci Incorporated and Becton Dickinson Transduction Laboratories, respectively. Production o f rabbit 
polyclonal anti-MDA5 was described previously29. RIG-I, PKR and MDA5 antibodies were used in 1:1,000; 1:500 
and 1:10,000 dilutions, respectively. After washes, membranes were incubated w ith IRDye anti-mouse or anti­
rabbit IgG (1:15,000) (Li-Cor Biosciences). Imaging was done using the Odyssey System. Western blot analysis 
o f viral protein 3A was done as described before25.
Transfection of viral RNA
pEV9Hill was linearized by digestion w ith  NotI and transcribed in v itro w ith T7 RNA polymerase (Promega). DCs 
were harvested, washed w ith  PBS and resuspended in phenol-red free Optimem (Invitrogen Life Technologies). 
RNA electroporation was performed as described before 25.
RNA isolation
Total RNA was isolated from  DC cultures using TRIZOL reagent (Invitrogen Life Technologies) according to 
manufacturer's instructions, w ith m inor modifications. RNA integrity was determ ined by analyzing the 
ribosomal 28S and 18S bands on a 1% agarose gel. The reverse transcription reaction was performed using 
Moloney murine leukemia virus (MMLV) reverse transcriptase (Invitrogen) according to  the manufacturer's 
instructions. For each sample a "-RT" control was included in which the reverse transcriptase was replaced by 
DEPC treated milli-Q. The cDNA was stored at -20°C until fu rthe r use.
Quantitative PCR
Quantitative analysis o f gene expression in DCs was done using SYBR Green based qPCR. The qPCR reactions 
were performed in a 25 ^ l volume containing: 12.5 ^ l SYBR Green mix (Applied Biosystems), 1.5 ^l fo rw ard / 
reverse primer (300 nM endconcentration), 4.5 ^l m illi-Q  and 5 ^l cDNA dilution. Reactions were performed on 
an ABI 7900HT Sequence Detection System (Applied Biosystems). Analysis was done using sequence detection 
system software (SDS, version 2.0, Applied Biosystems). Primer sequences are available upon request and were
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designed using the freely accessible Primer Bank program30.
Uptake of Vero cells
Vero cells were labeled using PKH26 (Sigma-Aldrich) according to  manufacturers instructions and infected 
w ith  CVB3 at an MOI o f 10. Cells were harvested and washed 6 -8  h p.i. and resuspended in fresh medium at a 
density o f 5 X 106 cells/mL prior to  placing them at -20°C until fu rther use. Vero cell preparations were added 
to  DC cultures at a ratio o f 1:1 (in some experiments DCs had been pretreated w ith CQ as described above). 
Alternatively, Vero cell preparations were exposed to  a m ixture o f RNAse A (Roche) and RNAse V-I (Ambion) or 
an equal volume o f PBS for a period o f 15 min at 37°C prior to  addition to  DCs. Uptake o f Vero cells by DCs was 
analyzed using flowcytom etry and confocal microscopy.
Confocal microscopy
DCs were harvested, washed and allowed to adhere to  poly-L-lysine coated coverslips in serum free medium 
for 1 h at 37oC. Cells were fixed w ith  1% paraformaldehyde (PFA) and blocked in PBS w ith  3% BSA, 10 mM 
glycine and 2% human serum (blocking buffer, BB). For cell surface stainings, cells were incubated using 
mouse-anti-human DC-SIGN (Beckman Coulter) or mouse-anti human HLA-DR/DP (ascites) in BB, washed 
and incubated w ith  isotype specific Alexa labeled goat-anti-mouse IgGs (Alexa 568/Alexa 647, Molecular 
Probes). For intracellular staining, cells were fixed using 1% PFA, permeabilized using 0.1% Triton-X100 in 
PBS and incubated w ith rabbit polyclonal anti-MDA5 followed by incubation w ith  goat anti-rabbit IgG Alexa 
488 (Molecular Probes) in BB. After final washes, cells were sealed using Mowiol (Merck) and analyzed using 
confocal microscopy (Biorad MRC 1024).
Statistical analysis
Statistical analysis was performed using Student's t  test (2-tailed distribution). A P-value < 0.05 was 
considered a significant difference.
Results
Poly(I:C) induces resistance against viral infection in human DCs
We previously reported that human DCs display a striking difference in susceptibility to 
infection with distinct enteroviruses, a genus of the picornavirus family. While DCs are 
productively infected with EV, they are resistant to infection with the closely related CVB25. 
Here, we investigated the effect of stimulation with different TLR ligands on susceptibility 
for EV infection. Untreated DCs and DCs stimulated with LPS (TLR4), PAM3Cys (TLR1/2) 
or R848 (TLR7 or TLR8) were all highly susceptible to EV9 infection, leading to significant 
increases in virus titers and viral proteins (Fig. 1A). In contrast, stimulation with the 
synthetic viral dsRNA analogue poly(I:C) dramatically reduced EV9 replication (Fig. 1A), 
in a concentration dependent manner (data not shown). Time course analysis showed 
that resistance to EV9 infection was accrued within 6 h after poly(I:C) exposure (Fig. 1B). 
Additionally, infection of DCs with EV1, EV7, EV8 and EV11 could also be inhibited by 
poly(I:C) treatment, showing that the protective effect applied to a broad range of EV 
strains (Fig. 1C). Poly(I:C) stimulated DCs also displayed reduced virus replication upon 
delivery of in vitro transcribed EV9 RNA directly into the DC cytoplasm, suggesting the 
induction of an active antiviral state, rather than simple downregulation of the (as yet 
unidentified) EV9 receptor on the cell surface (Fig. 1D).
To evaluate the effects of TLR triggering on expression of genes that are crucially 
involved in the innate antiviral response, we determined mRNA levels of the viral sensors 
RIG-I and MDA5 and the effector molecule PKR. Stimulation with PAM, R848 or lipoteichoic 
acid (LTA) did not affect ISG expression and only a modest increase was observed in 
some experiments using LPS. However, stimulation with poly(I:C) consistently induced a
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Figure 1. Poly(I:C) s tim ula tion protects human DCs against EV infection and increases expression o f RIG-I, 
MDA5 and PKR.
(A) DCs were left untreated or stimulated w ith poly(I:C) (20 ^g /m l), LPS (100 ng/m l), R848 (4 ^g /m l) or PAM- 
3Cys-SKKKK (PAM, 2 ^g /m l) for 24 h and infected w ith EV9 at an MOI o f 1, after which viral titers were de­
term ined at several tim e points p.i. Insert shows the expression o f viral protein 3A and its precursor 3AB in 
unstimulated DCs (left lane) or poly(I:C) stimulated DCs (right lane) (B) DC were stimulated w ith poly(I:C) (20 
^g /m l) at different tim e points prior to  infection w ith  EV9 at an MOI o f 1. Increase in viral titers was deter­
mined 24 h p.i. (C) DCs were left untreated or stimulated w ith  poly(I:C) (20 ^g /m l) for a period o f 24 h and 
subsequently infected w ith  EV1, EV7, EV8 , EV9 or EV11 at an MOI o f 1. Shown is the increase in viral titers 24 
h p.i. (D) DCs were stimulated w ith poly(I:C) (20 ^g /m l) for 24 h and subsequently electroporated using 20 
^g in v itro transcribed RNA from  the full-length cDNA clone o f EV9. Increase in viral titers was determ ined at 
several tim e points after electroporation. (E) DCs were stimulated using LPS, R848, PAM or poly(I:C) as de­
scribed for (A) and mRNA levels o f RIG-I, MDA5 and PKR were determ ined using qPCR at several tim e points 
after stimulation. (F) Protein expression o f RIG-I, MDA5 and PKR was analyzed by western b lot 24 h after 
stimulation o f DCs as described in (A). (G) DCs were left untreated or stimulated w ith  poly(I:C) (20 ^g/m l) 
for 24 h after which DCs were harvested, stained using DC-SIGN and MDA5-specific antibodies and analyzed 
using confocal microscopy as described in materials and methods. (H) DCs were stimulated w ith poly(I:C) (20 
^g /m l) in the presence or absence o f type I IFN neutralizing antibodies (Iivari, Kaaleppi and bovine anti-IFNa, 
see materials and methods). After 8 h, mRNA expression levels o f RIG-I, MDA5 and PKR were determ ined 
using qPCR. Shown is mean expression + SD o f 3 independent experiments using different donors (*, P<0.05; 
* * , P<0.01). (I) DCs were stimulated w ith poly(I:C) (20 ^g /m l) in the presence or absence o f type I IFN neutral-
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izing antibodies fo r 24 h, washed and subsequently infected w ith EV9 at an MOI o f 1 after which virus titers 
were determ ined at several tim e points p.i. Data shown is representative of >5 (A, E), 3 (C, D, F, G, H, I)) or 2
(B) independent experiments
strong upregulation of RIG-I, MDA5 and PKR (Fig. 1E and data not shown). Western blot 
(WB) analysis corroborated our findings by qPCR and demonstrated elevated protein 
levels following exposure to poly(I:C) (Fig. 1F). Confocal analysis showed an increased 
expression of endogenous MDA5 in the cytoplasm of poly(I:C) stimulated human DCs 
(Fig. 1G). Furthermore, neutralizing antibodies against type I IFN inhibited the effect of 
poly(I:C) on both expression of ISGs (Fig. 1H) and viral infection (Fig. 1I) implying that 
poly(I:C) exerts its effect at least in part via autocrine type I IFN stimulation.
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Figure 2. Phagocytosis o f virus-infected cells increases the expression o f RIG-I, MDA5 and PKR.
(A) PKH26 labeled Vero cell preparations (mock-or CVB3-infected) were added to  CFSE labeled DC cultures in 
a ratio of 1:1. A fter 24 h, the number o f CFSE+PKH26+ DCs was analyzed using flowcytometry. (B) Presence of 
PKH26+ Vero cell material w ith in  DCs after a 24 h coculture as analyzed using confocal microscopy. DCs were 
stained using anti-MHCII (C) DCs were cocultured w ith mock- or CVB3-infected Vero cell preparations and the 
mRNA expression of PKR and IRF7 was determ ined using qPCR at different tim e points after start of cocul­
ture. (D) DCs were cocultured w ith  Vero cell preparations as described in (A) and protein expression of RIG-I, 
MDA5 and PKR was determ ined using western blot 24 h after start of coculture. (E) DCs were cocultured w ith 
Vero cell preparations as described in (A) and 24 h later cells were stained w ith  MHC-II and MDA5-specific 
antibodies and analyzed using confocal microscopy. Data shown are representative o f > 6  (A), 4 (B) or 3 (C-E) 
independent experiments using different donors.
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Collectively, these data indicate that exposure to synthetic dsRNA causes 
upregulation of both viral sensors and effector molecules and protects DCs against EV 
infection.
Phagocytosis of infected cells by DCs leads to upregulation of ISGs
To study the DC-virus interaction in a more physiological model, we explored whether 
phagocytosis of CVB3-infected cells by DCs would induce similar effects as stimulation 
with poly(I:C). CVB3 was used because this virus, if released from infected (dying) cells, 
does not cause infection of DCs 25 nor upregulation of RIG-I, MDA5 or PKR (data not 
shown). Since secretion of type I IFNs by infected cells could influence susceptibility 
for infection and ISG expression in DCs, all experiments were performed with Vero 
cells, which carry a genetic defect in type I IFNs synthesis 31 32. CVB3-infected, but not 
uninfected Vero cells, were efficiently taken up by DCs (data not shown), likely reflecting 
the effect of infection on Vero cell viability. For the remainder of our experiments we used 
freeze-thawed cell preparations that were taken up with equal efficiency, irrespective 
of the infection status of the cells (Fig. 2A). This enabled us to analyze the effect of 
uptake of uninfected or virus-infected cells on ISG expression and susceptibility in DCs. 
Confocal analysis confirmed the flowcytometry data by showing the presence of PKH26+ 
compartments within DCs (Fig. 2B). As the primers for human RIG-I and MDA5 cross- 
react with their Vero cell (Cercopithecus aethiops, African green monkey) homologues, 
we focused on mRNA expression of the ISGs IRF7 and PKR. Although uptake of mock- 
infected Vero cells had no effect, phagocytosis of CVB3-infected cells caused a rapid and 
profound upregulation of IRF7 and PKR in DCs (Fig. 2C). Western blot analysis showed 
that uptake of CVB-infected, but not of mock-infected Vero cells, resulted in increased 
protein levels of RIG-I, MDA5 and PKR (Fig. 2D). No ISG protein expression was detected 
in CVB3-infected Vero cell preparations as such (data not shown). Confocal analysis 
further confirmed increased MDA5 levels in DCs that had taken up CVB3-infected Vero 
cells as compared to mock-infected cells (Fig. 2E). Thus, phagocytosis of CVB3-infected 
cells by DCs leads to rapid upregulation of molecules involved in the innate antiviral 
response and can occur independently of type I IFN released by infected cells.
Phagocytosis of CVB-infected cells protects DCs against EV infection
To determine whether upregulation of ISGs following uptake of infected cell preparations 
by DCs resulted in functional protection, DCs were subsequently infected with EV9. 
Vero cell preparations themselves did not support replication of EV9 (data not shown). 
Phagocytosis of infected preparations resulted in a markedly decreased EV replication in 
DC cultures, while uptake of uninfected cells had no effect (Fig. 3A). Western blot analysis 
showed notably lower levels of the viral protein 3A and its precursor 3AB in DCs that had 
taken up CVB-infected Vero cells, which confirmed inhibited EV growth (Fig. 3A).
We next assessed whether phagocytosis of these preparations could protect 
DCs against EV9-induced cell death. As shown in figure 3B, EV9 caused massive cell 
death in both untreated DCs and DCs that had taken up uninfected cell preparations. In 
contrast, uptake of CVB3-infected cell preparations strongly enhanced cell survival. Also 
exposure to poly(I:C) decreased cell death following EV infection. Taken together, these 
data indicate that phagocytosis of virus-infected cells can effectively protect human DCs 
against the lethal effects of EV infection.
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Figure 3. Phagocytosis o f infected cells protects DCs against EV infection.
(A) DCs were left untreated or cultured w ith mock or CVB-infected Vero cell preparations for a period o f 24 h 
after which DCs were harvested, washed and subsequently infected w ith EV9 at an MOI o f 1. Viral titers were 
determ ined at different tim e points p.i. Insert shows the expression o f viral protein 3A and its precursor 3AB 
follow ing uptake o f mock-infected (left lane) or CVB3-infected (right lane) Vero cells, 8 h after infection o f DCs 
w ith EV9. (B) DCs were treated as described in (A) and the percentage o f dead cells was determ ined using 
a trypan blue exclusion assay 48 h p.i. Graph shows mean + SD o f 4 quadruplicates per condition (* * * ,  P < 
0.001). Data shown are representative o f at least 3 independent experiments using different donors.
ISG upregulation in DCs following phagocytosis of infected cells requires intact 
endosomal acidification and is mediated via recognition of viral RNA
Infected, dying cells taken up by DCs are localized to so-called phagosomes, which 
subsequently "mature" via fusion with the endosomal/lysosomal compartments, 
resulting in a progressive decrease in pH33. Interestingly, intracellular TLRs are also 
recruited to these compartments, enabling interaction with potentially released PAMPs, 
like dsRNA, which occurs in a pH dependent fashion34. To determine if endosomal 
acidification is required for the induction of viral resistance following uptake of infected 
cell preparations, we pretreated DCs with chloroquine (CQ), a chemical that blocks 
acidification of these compartments. Pretreatment of DCs with CQ markedly decreased 
mRNA expression of IRF7 and PKR (Fig. 4A) as well as RIG-I, MDA5 and PKR protein 
levels (Fig. 4B). Importantly, the CQ mediated reduction in ISG levels was accompanied 
by reduced protection against EV infection (Fig. 4C). These effects were not related to 
impaired phagocytosis, since CQ had no effect on uptake of Vero cell preparations (data 
not shown). CQ also reduced the poly(I:C) mediated increase in ISG expression (Fig. 4D) 
and completely abrogated the inhibitory effect of poly(I:C) on infection (Fig. 4E).
We next investigated the potential contribution of viral RNA present in the 
infected Vero cell preparations to both upregulation of ISGs and the induction of 
a resistant state. To this aim, CVB3-infected and uninfected cell preparations were 
incubated with a mixture of RNAses prior to addition to DCs. RNAse treatment did not 
affect uptake of preparations by DCs (data not shown). Degradation of RNA resulted in 
a strongly reduced upregulation of IRF7 and PKR mRNA levels (Fig. 4F) and RIG-I, MDA5 
and PKR protein expression in DCs (Fig. 4G). Furthermore, RNAse treatment abrogated 
the protective effect on EV infection of DCs (Fig. 4H), demonstrating the essential role of 
recognition of viral RNA in the induction of an antiviral state.
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Figure 4. Induction o f an antivira l state requires intact endosomal acidification and is mediated via recogni­
tion  o f vira l RNA.
(A) DC were left untreated or preincubated w ith  CQ (10 ^M ) for 1 h prior to  addition o f Vero cell preparations. 
After an 8 h coculture, cells were harvested and mRNA expression o f IRF7 and PKR was analyzed using qPCR.
(B) DCs were stimulated as in (A) and protein expression o f RIG-I, MDA5 and PKR was determ ined using WB 16 
h after coculture (C) DCs were stimulated as in (A) and infected w ith EV9 at an MOI o f 1 16 h after coculture. 
Viral titers were determ ined at several tim e points p.i. (D) DC were left untreated or preincubated w ith  CQ 
(10 ^M ) prior to  addition o f poly(I:C) (20 ^g/m l). After 8 h stimulation, the expression o f RIG-I, MDA5 and 
PKR and IRF 7 was analyzed using qPCR. Shown is mean expression + SD o f 3 independent experiments using 
different donors (** , P<0.01). (E) DCs were treated as described in (A) and after 8 h stimulation, cells were 
harvested, washed extensively and infected w ith  EV9 at an MOI o f 1, after which viral titers were determ ined 
at several timepoints p.i. (F) Vero cell preparations were left untreated or exposed to  a mixture o f RNAseA
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and RNAseV-I prior to  addition to  DC cultures as described in materials and methods. Expression o f PKR and 
IRF7 in DCs was analyzed using qPCR 8 h after addition o f Vero cell preparations. (G) DCs were cocultured 
w ith  Vero cell preparations as described in (D) and protein expression o f RIG-I, MDA5 and PKR was analyzed 
by WB 16 h after start o f coculture. (H) DCs were treated as described in (D) and 16 h after start o f coculture, 
cells were harvested, washed and infected w ith EV9 at an MOI o f 1. Data are representative o f 3 independent 
experiments using different donors.
Discussion
Phagocytosis of infected cells represents one of the defense mechanisms against viral 
infection and is executed by different immune cells. Here we report that uptake of CVB3- 
infected cells by human DCs resulted in rapid increase in both mRNA and protein levels 
of viral sensors including the RNA helicases RIG-I and MDA5 and effector molecules like 
PKR. Upregulation of these ISGs required intact endosomal acidification, was dependent 
on the presence of viral RNA and could be mimicked by exposure to the synthetic dsRNA 
analogue poly(I:C). Moreover, DCs that had taken up CVB-infected cells were protected 
against lethal infection with EV.
Recent mouse studies have highlighted the role of various RIG-like helicases in 
recognition of viral RNA15' 17, 22. These findings have challenged our view of the relative 
importance of TLRs and non-TLRs in anti-viral immunity. For instance, recognition of 
the synthetic dsRNA mimetic poly(I:C) was classically thought to be mediated via TLR3 
7, while more recent data implicate MDA5 to be a crucial component for type I IFN 
production upon poly(I:C) stimulation or viral infection in mice15, 17. Very limited data 
is available regarding these novel RNA sensors in the human setting, but one study 
shows that poly(I:C) responses in human cell lines are RIG-I dependent35, suggesting the 
existence of species-specific or cell-type specific differences, analogues to the species- 
specific difference in recognition of ssRNAs by TLR7 and TLR89.
We previously demonstrated the dramatic consequences of EV infection on the 
function and viability of human DCs25. We presently document that distinct TLR ligands 
displayed a remarkably different effect on the induction of viral resistance in DCs. While 
poly(I:C) rapidly increased the level of different ISGs, including RIG-I and MDA5, and 
protected DCs against infection, other ligands such as PAM, LTA and R848 did not. LPS 
caused a modest increase in ISG expression. This might imply that ISG upregulation is 
mediated in a TRIF dependent fashion, as both poly(I:C) and LPS have been reported to 
signal via this adaptor protein36.
To study the effects of viral RNA recognition under conditions that more closely 
resemble the physiological situation, we used a model system in which DCs acquired 
virus-infected cells via phagocytosis. Uptake of CVB3-infected cells resulted in ISG 
upregulation and protection against EV, both of which could be blocked by CQ. As CQ is 
known to increase endosomal pH and it has been shown that the interaction between 
poly(I:C)/TLR334 and CpG/TLR937 is pH dependent, this would suggest a role for TLR3 
in our experiments. Alternatively, CQ could hamper transport of viral structures, such 
as dsRNA, to the cytoplasm where recognition by other PPRs like RIG-I or MDA5 could 
take place. However, a recent study has shown that CQ treatment of human DCs rather 
increases export of soluble antigen from early endosomes into the cytosol thereby 
promoting antigen cross-presentation38. Identification of the exact routing of viral PAMPs 
following uptake by DCs can possibly aid in dissecting the relative contribution of TLRs 
and RNA helicases to different facets of the antiviral immune response.
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It has been shown that, besides viral nucleic acids, viral proteins can also alter the 
activation status of DCs39, 40, which could affect DC susceptibility following phagocytosis 
of infected cells. Our experiments identified RNA within infected Vero cell preparations 
to be the crucial component for both ISG upregulation and resistance against infection. 
Since uptake of non-infected cells had no effect, we favor a role for viral RNA in these 
processes. However, we can not exclude that infection leads to modification of host RNA 
structures that could be subsequently recognized by different RNA sensors. The use of 
Vero cells in our experiments showed that phagocytosis of infected cells by DCs can 
induce protection independently of type I IFN released by infected cells. Thus, recognition 
of RNA could preserve the ability of DCs to engage an antiviral state, even when type I 
IFN responses in the infected cells are blocked as a consequence of viral immune evasion 
strategies.
In conclusion, recognition of viral RNA rapidly induces an antiviral state in 
human DCs. This might reveal a mechanism by which DCs protect themselves against 
viruses when attracted to an environment with ongoing infection, thereby facilitating 
adequate instruction of virus-specific T cells to clear viral infection.
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Abstract
T
ype 1 diabetes is a chronic endocrine disorder, in which enteroviruses, such as 
coxsackie B viruses and echoviruses, are possible environmental factors that 
can trigger or accelerate disease. The development or acceleration of type 1 
diabetes depends on the balance between autoreactive effector T cells and regulatory T 
cells. This balance is particularly influenced by dendritic cells (DCs).
Objective. To investigate the interaction between enterovirus-infected human pancreatic 
islets and human DCs.
Research Design and Methods. In vitro phagocytosis of human or porcine primary islets 
or Min6 mouse insuloma cells by DCs was investigated by flow cytometry and confocal 
analysis. Subsequent innate DC responses were monitored by qPCR and western blotting 
of interferon-stimulated genes (ISGs).
Results. We show that both mock- and coxsackievirus B3 (CVB3)-infected human and 
porcine pancreatic islets were efficiently phagocytosed by human monocyte-derived DCs. 
Phagocytosis of CVB3-infected, but not mock-infected human and porcine islets resulted 
in induction of ISGs in DCs, including the RIG-I-like helicases (RLHs) RIG-I and Mda5. 
Studies with murine Min6 insuloma cells, which were also efficiently phagocytosed, 
revealed that increased ISG-expression in DCs upon encountering CVB-infected cells 
resulted in an antiviral state that protected DCs from subsequent enterovirus infection. 
The observed innate antiviral responses depended on RNA within the phagocytosed 
cells, required endosomal acidification and were type I interferon (IFN)-dependent. 
Conclusions. Human DCs can phagocytose enterovirus-infected pancreatic cells and 
subsequently induce innate antiviral responses, such as induction of RLHs. These 
responses may have important consequences for immune homeostasis in vivo and may 
play a role in the etiology of type 1 diabetes.
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Introduction
Type 1 diabetes mellitus, or insulin-dependent diabetes, is a chronic endocrine disorder 
characterized by the progressive loss of insulin-producing ß-cells. In the majority of cases, 
type 1 diabetes is associated with an autoimmune reaction against ß-cell constituents. 
Genetic predisposition is a major risk factor for the acquisition of type 1 diabetes but the 
pair-wise concordance between monozygotic twins is limited (< 40%), which indicates 
that other, environmental, factors are involved1. Also other observations (a gradual rise 
of the incidence and a 10-fold difference in occurrence of type 1 diabetes in different 
parts of Europe) point to a significant contribution of the environment1.
Enteroviruses of the Human Enterovirus B (HEV-B) species of the Picornaviridae, 
such as coxsackievirus B (CVB) and echovirus (EV), have since long been associated 
with type 1 diabetes2-4. These small, non-enveloped single-stranded RNA viruses are 
widespread. Infection usually remains limited to the gastrointestinal tract and causes 
mild disease or even remains asymptomatic. However, during severe infections it can 
spread to secondary target organs such as the pancreas, brain and heart5. CVB has been 
implicated in type 1 diabetes on the basis of (i) isolation of virus from patients with acute 
diabetes, (ii) detection of viral RNA in blood at onset (iii) epidemiological surveys, and 
(iv) prospective studies (reviewed in6, 7).
Importantly, several recent studies reported detection of HEV-B in the pancreatic 
islets of type 1 diabetes patients at autopsy, providing evidence that these viruses are 
able to infect beta cells in vivo8-10. Inflammation in pancreatic islets is common in type 
1 diabetes patients, and several immune cells can be detected in the islets of type 1 
diabetes patients. Among these are phagocytes, as well as different subsets of T cells, 
such as effector CD4+ and CD8+ T cells and in some cases regulatory T cells (Treg)8, 11 12. The 
development or acceleration of type 1 diabetes might depend on the balance between 
autoreactive effector T cells and Treg13; a balance which is predominantly decided by 
dendritic cells (DCs).
The importance of antigen-presenting cells (APCs, such as macrophages and 
DCs) in type 1 diabetes development has been shown in vivo in mouse studies, where 
phagocytosis of CVB-infected islet cells was crucial for development of auto-immune type 
1 diabetes. Resident APCs were shown to engulf CVB-infected ß-cells, and subsequently 
stimulated antigen-specific T cell proliferation and induced diabetes upon adoptive 
transfer14. Furthermore, mouse studies have revealed that influx of macrophages and 
DCs precedes that of effector T cells in the islets and aberrantly express pro-inflammatory 
cytokines15. In human pancreatic islets DCs are present in low numbers under steady- 
state conditions; however, as ß-cell destruction ensues leading to diabetes there is an 
increase in DC-infiltrate16, 17, strengthening the hypothesis that these cells likely play an 
important role in the progression of human type 1 diabetes. To our knowledge, no studies 
have been performed that examine the interaction between CVB-infected human islets 
and human DCs.
DCs are the professional APCs of the immune system and play a decisive role in 
initiating immune responses and maintaining self tolerance. They do not only participate 
in innate immunity, but also initiate and control adaptive immunity18. DCs continuously 
sample their microenvironment; they phagocytose pathogens or pathogen-associated 
products such as immune complexes, yet also apoptotic cells are taken up19. This results 
in the induction of immunity against invading pathogens and tolerance to self-antigens,
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respectively20. Induction of an immune response occurs when DCs detect pathogen- 
associated "danger signals" or pathogen-associated molecular patterns (PAMPs), 
through specialized receptors, known as pattern recognition receptors (PRRs). These 
PRRs include several receptors that sense the presence of viral RNA, such as Toll-like 
receptors (TLR) 3, 7 and 8 and the RIG-I-like helicases (RLHs), retinoic acid-inducible gene 
I (RIG-I) and melanoma differentiation-associated gene 5 (Mda5)21, 22. Polymorphisms 
and mutations in PRR family members have been associated with disease, including 
autoimmune diseases such as type 1 diabetes23-25. The interaction between PRRs and 
PAMPs facilitates DC maturation, after which the DCs migrate to draining lymph nodes 
where they present antigen to T lymphocytes18. During viral infection, triggering of these 
receptors induces type I interferons (IFNs). The IFNs are crucial for a first innate line of 
defense against invading viruses, yet they also influence adaptive immunity by affecting 
DC cytokine production and maturation26 and autoimmunity27.
In this study, we set out to investigate the interaction between human DCs 
and CVB-infected islets and the immunological consequences that follow. For this, we 
used monocyte-derived DCs from healthy blood donors and CVB-infected pancreatic 
islet preparations or CVB-infected Min6 cells, a murine insuloma cell line. We show that 
both human islets and Min6 cells are phagocytosed by human DCs. CVB-infected cells, 
but not mock-infected cells, induced DC activation as indicated by the expression of 
interferon-stimulated genes (ISGs) resulting in protection of the DCs from subsequent 
enteroviral infection. These innate DC responses depended on the recognition of RNA 
in the CVB-infected cells and additionally required IFNs produced by the DC itself, but 
did not depend on soluble factors secreted by the infected cells. These virus-induced 
alterations in DCs may have important consequences for immune homeostasis in vivo 
and may play a role in the etiology of type 1 diabetes.
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Research Design and Methods
Virus stocks and purification
Reference strain Echovirus 9 Hill (EV9) was obtained from  the National Institute for Public Health and the 
Environment (RIVM, Bilthoven, The Netherlands). CVB3 Nancy (CVB3) was kindly provided by R. Kandolf 
(University o f Tübingen, Germany). Production o f virus stocks and virus titrations were performed on buffalo 
green monkey cells as described previously. Serial 10-fold dilutions were tested in 96-well m icro titer plates and 
50% Tissue Culture Infective Doses (TCID50) were calculated as described before28.
Islet and Min6 cell culture
Human and porcine pancreatic islets were isolated in Pittsburgh as described before29. Human islets were 
obtained from  deceased anonymous donors procured by CORE (Center for Organ recovery and Education, 
Pittsburgh), and islets were isolated using a modification o f the semi-automated method described by Ricordi29
Islets batches used in this study were obtained from  4 adult human pancreas and 3 porcine donors, cultured 
for a minimum o f 3 to 6 days in CMRL-1066 medium containing 10% fetal calf serum, 2 mM L-glutamine, 100U/ 
ml penicilin, 0.1mg/m l streptomycin (Complete CMRL), at 37°C in an atmosphere o f 5% CO2. Islet viability was 
estimated by dual fluorescence viability dyes (Calcein-AM and Propidium Iodide, Invitrogen, Eugene, OR) and 
was higher than 80% in all batches. Glucose stimulated insulin release was carried out by dynamic perifusion31. 
After culture for 3 to  6 days the islets were sent to  Nijmegen as free-floating islets and cultured in Complete 
CMRL in ultra low attachment culture plates (Corning) at 37°C in 5% CO2. Islets were cultured in Nijmegen for 
maximum 2 days before start o f the experiments,
M in6 cells32 were a kind gift from  Dr. Merja Roivainen and Dr. Per Bendix Jeppesen, and were cultured in 
DMEM (Gibco) supplemented w ith  15% FCS, ciproxin, 50^M  ß-mercaptoethanol at 37°C in 5% CO2. Medium 
was refreshed every other day.
Infection of islets and Min6 cells
Islets and M in 6 cells were infected in a small volume o f CMRL-1066 or DMEM, respectively, at indicated 
m ultip lic ity o f infection (MOI) for 1 h at 37°C. Subsequently, cells were washed and viral titers were determined 
at different tim e points as described above. In some experiments supernatant from infected cultures was 
harvested at indicated tim e post infection (p.i.) and cleared from  cell debris by centrifugation before stimulation 
o f other cells.
Stimulation of monocyte-derived DCs
Monocyte-derived DCs were generated as described previously28. Mature DCs were obtained by stimulating 
cells w ith  poly(I:C) (20 ^g/m l). Stimulation o f DCs w ith  supernatant from  M in 6 cells or from  DC/Min6 co­
cultures was performed using a 1:2 dilution o f supernatant. To block the actions o f type I interferons (IFNs), 
cells were stimulated in presence or absence o f neutralizing anti-human IFN antibodies (1:75, Iivari, Kaaleppi 
or bovine serum, courtesy o f Dr Julkunen, National Public Health Institute, Helsinki, Finland)33. For infection, 
stimulated or unstimulated DCs were harvested using cold PBS and infected in RPMI. After 60 min incubation 
at 37oC, cells were washed and viral titers were determ ined as described above.
Uptake of human pancreatic islets and Min6 cells
Human and porcine pancreatic islets or M in6 cells were labeled using PKH26 (Sigma-Aldrich) according to 
manufacturers instructions and infected w ith  CVB3 at an MOI o f 10. DCs were labeled using CFSE (Invitrogen) 
according to  manufacturer's instructions. PKH-labeled cells were added to  CFSE-labeled DC cultures at a ratio 
o f 1:1. Alternatively, labeled, infected M in6 cells were incubated for 48h and subsequently harvested and 
resuspended in fresh medium at a density o f 5^106 cells/mL prior to  placing them at -20°C until fu rthe r use. 
Freeze-thawed cell preparations were subsequently used in DC co-cultures at a 1:1 ratio and resulted in similar 
inductions o f ISGs and innate responses compared to  co-culture w ith  viable cells (Supplementary figure 1 
and34). These cell preparations were also used for RNase-treatment prior to  DC stimulation. For tha t purpose
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M in 6 cell preparations were exposed to  a mixture o f RNaseA, RNase VI and RNaseI (all Ambion) or an equal 
volume o f PBS for a period o f 30 min at 37°C prior to addition to  DCs. Uptake o f islets or M in6 cells by DCs was 
analyzed using flow  cytom etry and confocal microscopy. In some experiments phagocytosis was inhibited using 
cytochalasin D (CytD) (2,5^g/m l), or endosomal acidification was inhibited using chloroquine (CQ) (10^M). DCs 
were pretreated fo r 30 min w ith  CytD or CQ, and subsequently stimuli were added. Both treatments had no 
effect on cell viability as assessed by trypan blue exclusion 8 h after stimulation.
Confocal microscopy
Staining and visualization o f DCs has been described before34. Human islets were adhered onto fibronectin- 
coated coverslips for 2h at 37°C in islet medium and subsequently fixed in 2% PFA. Cells were blocked in PBS 
containing 100 mM glycine and 2% goat serum, permeabilized using TX-100 and stained w ith  mouse anti-VP1 
(Dakocytomation) and rabbit anti-3A35 followed by incubation w ith  goat anti-mouse IgG alexa 488 and goat 
anti-rabbit IgG alexa 594. Cells were analyzed using a Leica DMR microscope.
RNA isolation, quantitative PCR (qPCR), western blot and flow cytometry 
These techniques have been described before34 
Statistical analysis
Statistical analysis was performed using Student's t  test (2-tailed distribution). A P-value < 0.05 was considered 
a significant difference.
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Results
Human dendritic cells phagocytose human pancreatic islets and induce innate immune 
responses.
Human pancreatic islets were found to be susceptible to infection by CVB3 as indicated 
by the profound increase in virus titer, cytopathic effects and immunofluorescence 
staining against viral proteins 3A and VP1 (Fig. 1A-C). The latter revealed that only a 
small number of cells were infected. Infected cells mainly resided at the outer layers of 
the islets, where cells might be more accessible for the virus (Fig. 1C). Previously it was 
shown that such a productive infection results in impaired islet function36.
To investigate whether human DCs can phagocytose human pancreatic islets, 
PKH-labeled human islets were mock- or CVB3-infected for 48 hours and subsequently co­
cultured with CFSE-labeled DCs. CVB3 has no direct effect on human DCs and is incapable 
of infecting DCs28. Mock- and CVB3-infected islets were taken up with equal efficiency, 
as indicated by the number of DCs that became PKH-positive (Fig. 1D). Confocal analysis 
confirmed uptake of human pancreatic islets material by DCs. The DC plasma membrane 
was stained with CD86 specific antibodies (green), and PKH-positive islet cells (red) were 
observed within the DCs (Fig. 1E).
To examine whether and how DCs respond to virus-infected human islets we 
studied activation of innate immune response pathways by measuring levels of ISGs, 
such as RIG-I, Mda5, PKR and IRF-7 following phagocytosis of infected cells. qPCR 
revealed induction of ISGs after engulfment of CVB3-infected islets; moreover, increased 
expression was observed for all ISGs tested (Fig. 1F). Importantly, stimulation of DCs with 
mock-infected human islets alone did not induce any ISGs (Fig. 1F). Furthermore, also 
stimulation with CVB3 alone did not induce ISGs28, suggesting that the induction depends 
on the presence of virus or viral products within phagocytosed cells. CVB3 was not able 
to replicate in DCs upon entry via phagocytosis, as determined by endpoint titration at 
several times after start of co-cultures (data not shown). In some experiments, freeze- 
thawed mock- or CVB-infected cells were used. This had no effect on either phagocytosis 
or ISG-induction (see below).
At this stage we were unable to discriminate whether the ISGs were upregulated 
in DCs or in the islets themselves. Therefore, we performed experiments using porcine 
islets, which have been shown a useful model for studies on the interaction of CVBs with 
ß-cells37. To discriminate between ISGs in porcine islets and human DCs, primers were 
used that specifically recognize human, but not porcine ISG sequences. Infection and 
uptake of porcine islets by DC was similar as described above for the human islets (data 
not shown). Phagocytosis of CVB-infected porcine islets resulted in a profound increase 
in human ISGs (Fig. 1G). Thus, using porcine islets we confirmed induction of ISGs in 
human DCs upon uptake of CVB3-infected human islets, and, additionally revealed that 
ISG-expression is increased in the human DC-population.
Phagocytosis of CVB3-infected Min6 cells by human DCs results in an antiviral state 
that protects DCs from subsequent enterovirus infection.
To further investigate the underlying mechanism of DC responses upon uptake of islets, 
we selected the murine Min6 cell line as a model for pancreatic ß-cells. Min6 cells retain 
the physiological characteristics of normal ß-cells, and respond to glucose within the 
physiological range32. These islet-like cells grow in patches (Fig. 2B, left panel) and were
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Figure 1. CVB replicates in human and porcine pancreatic islets, and DC can phagocytose islets, resulting 
in induction o f ISGs.
(A and B) Human islets cells were infected w ith  CVB3 at an MOI o f 10 and (A) at indicated tim e points replica­
tion was analysed and (B) at 48h p.i. images were taken. (C) Human islets were infected w ith CVB3 at an MOI 
o f 10. A fter 24 h incubation, islets were adhered onto fibronectin coated coverslips and stained using 3A (red) 
and VP1 (green) specific antibodies. Hoechst stain is included to  visualize cell nuclei (D) Human islets were 
PKH-labeled and infected w ith CVB3 at an MOI o f 10 and cultured for 48h before addition to CFSE-labeled DC. 
Uptake of islets either mock-infected (M) or CVB-infected (CVB) was analyzed by flow  cytom etry 24h after 
co-culture. (E) Human islets were PKH-labeled and infected as in (D) and co-cultured w ith unlabeled DC for 
24h. Subsequently, DCs were harvested, stained using CD8 6 -specific antibodies (green), and analyzed using 
confocal microscopy. (F) Human islets were infected w ith  CVB3 at an MOI of 10 for 48 h prior to  addition 
to DCs. Expression o f RIG-I, Mda5 and PKR mRNA in DCs was analyzed using qPCR. (G) Porcine islets were 
prepared and co-cultured as in (F) and at indicated times ISG-induction was analyzed. In some experiments 
(F, G) freeze-thawed preparations of islets were used, but these yielded similar results compared to using vi­
able cells. Experiments are representative of 2, 3 or more than 3 independent experiments. Med = medium, 
unstimulated DCs; Islet/M  = mock-infected human islets; Islet/CVB = CVB-infected human islets; porc Islet/M  
= mock-infected porcine islets; porc Islet/CVB = CVB-infected porcine islets.
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Figure 2. M in 6  cells are a good model fo r prim ary pancreatic cells, are phagocytosed by DCs and induce 
innate antiviral immune responses.
(A and B) M in6 cells were infected w ith CVB3 at an MOI o f 10 and (A) at indicated tim e points replication was 
analyzed and (B) at 48h p.i. images were taken. (C) M in6 cells were PKH-labeled and infected w ith CVB3 at 
an MOI of 10. A fter 24h incubation cells were harvested and added to  CFSE-labeled DCs at a 1:1 ratio. 24h 
after co-culture cells were harvested and uptake was determ ined using flow  cytometry. (D) M in6 cells were 
prepared as in (C) and co-cultured w ith  unlabeled DCs for 24h, after which DCs were harvested, stained as for 
1E and analyzed using confocal microscopy. (E and F) M in 6 cells were prepared as in (C), and after 48h incuba­
tion, cells were harvested and added to  DCs at a 1:1 ratio, or DCs were stimulated w ith  20|ag/ml poly I:C or left 
untreated. At (E) 5h after addition, or (F) 5h and 8 h after addition, mRNA induction o f ISGs was determ ined 
as described. (G) Protein expression o f RIG-I, Mda5, and PKR was analyzed by western blot 24h after stimula­
tion o f DCs as described fo r panel (E). (H) DCs were stimulated as in (E) and after 24h co-culture cells were 
harvested and infected w ith EV9 at an MOI of 1. At indicated times p.i. EV9 replication was analysed. Poly I:C 
was used as a positive control (34). In some experiments freeze-thawed cell populations were used but these 
yielded similar results compared to using viable cells (Supplementary figure 1). Data shown are representa­
tive (A-D, G, H) or averages (E, F) o f at least 3 independent experiments. Med = medium, unstimulated cells; 
M 6 /M  = mock-infected M in 6 cells; M 6 /CVB = CVB-infected M in 6 cells. * = p < 0.05; n.s. = not significant.
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confirmed to express several ß-cell associated mRNAs (e.g. GAD65, IGRP, IA2, insulin, 
data not shown). Analogous to human and porcine islets, Min6 cells were susceptible to 
infection with CVB3 as shown by the increase in virus titer (Fig. 2A). Cytopathic effects 
were observed in nearly 100% of the cells (Fig. 2B), suggesting that the majority of cells 
were infected. Uptake of mock- and CVB3-infected Min6 cells by DCs was very efficient 
(up to 75%) as shown by flow cytometry and confocal analysis (Fig. 2C and 2D).
Upon engulfment of CVB-infected Min6 cells, IFN-ß and ISGs were strongly 
induced in DCs (Fig. 2 E and F), reaching a greater than 100-fold increase compared to 
unstimulated DCs in the case of RIG-I, while Mda5 and PKR showed increases of up to 
20- and 10-fold, respectively (Fig. 2F). The induction of ISGs following uptake of infected 
Min6 cells was confirmed at the protein level by western blotting (Fig. 2G). No ISG signal 
was observed in mock- or CVB3-infected Min6 cells alone (data not shown), excluding 
that the observed protein induction in DC/Min6 co-cultures is due to detection of Min6 
cell proteins. In some experiments, freeze-thawed mock- or CVB-infected cells were 
used. This had no effect on either phagocytosis or ISG-induction (Supplementary Fig 1).
IFNs and ISGs induce an antiviral state that restricts virus replication38. To 
determine whether upregulation of ISGs following uptake of CVB3-infected Min6 cells 
protects DCs from subsequent infection, DCs that had taken up Min6 cells were infected 
with EV9, an enterovirus strain that does replicate in DCs28, but not in Min6 cells (data 
not shown). Uptake of mock-infected cells had no influence on replication of EV9 in DCs. 
In contrast, phagocytosis of CVB-infected Min6 cells strongly protected the DCs from EV9 
replication (Fig. 2H).
Innate responses in DC that phagocytosed CVB3-infected Min6 cells depend on 
autocrine IFN-a/ß signaling.
ISGs can be upregulated through both IFN-dependent and IFN-independent pathways39, 
40. To investigate whether secreted cytokines like IFN-a/ß were involved in ISG induction, 
we stimulated fresh DCs with cell-free supernatant from DC/Min6 co-cultures. An 
increase in ISGs was observed upon stimulation of DCs with supernatant from co-cultures 
of DCs plus CVB-infected Min6 cells, but not of DCs plus mock-infected Min6 cells (Fig. 
3A). Moreover, the induction of ISGs after uptake of CVB-infected cells was markedly 
reduced in the presence of neutralizing IFN-a/ß antibodies, at both the mRNA level 
(Fig. 3B) and protein level (Fig. 3C compare lanes 6 and 7), implying that ISG induction 
strongly depends on IFNs.
To determine whether IFNs produced by DCs or the infected Min6 cells were 
responsible for ISG upregulation, supernatants from infected Min6 cultures were added 
to DCs, after which ISG-induction was monitored. Although recombinant murine IFNa 
induced ISG expression in DCs, supernatant of either mock- or CVB-infected Min6 cells 
did not (Fig. 3D). Thus cytokines potentially produced by infected Min6 cells are not 
responsible for ISG expression in DCs.
Collectively, these data imply that DCs induce an innate immune response upon 
uptake of CVB3-infected Min6 cells and that this induction depends on IFN-induction by 
DCs themselves.
Induction of ISGs in DCs following uptake of CVB3-infected Min6 cells require endosomal 
acidification and recognition of viral RNA.
Both PRRs located on the cell surface and those with intracellular localization may
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Figure 3. Type I IFNs produced by DC themselves are required fo r ISG induction.
(A) DCs were stimulated w ith cleared supernatants from  stimulated DC and DC/Min6 co-cultures (harvested 
24h after co-cultured started and used at a 1:2 dilution) and 8 h after stimulation mRNA induction o f RIG-I, 
Mda5, and PKR were determ ined using qPCR. (B) M in6 cells were infected w ith CVB3 at an MOI o f 10 and 
after 48h incubation cells were harvested and added to  DCs at a 1:1 ratio. Stimulations were performed in 
the absence or presence o f neutralizing antibodies (Iivari, Kaaleppi, and bovine anti-IFN-a/ß; see Materials 
and Methods). After 8 h, mRNA expression levels o f RIG-I, Mda5, and PKR were determ ined using qPCR. (C) 
DC were treated as in (B) and after 24h protein expression o f RIG-I, Mda5, and PKR was analyzed by western 
blotting. (D) DCs were stimulated w ith  100U/ml mIFNaA or cleared supernatants from  M in 6 cells (harvested 
48h p.i. and used at a 1:2 dilution) and after 8 h ISG mRNA induction was determ ined. Data shown are rep­
resentative o f 2 (C), or average o f 3 (A, B, D) independent experiments. Sup = supernatant; Med = medium, 
unstimulated cells; IC = poly I:C; M 6/M  = mock-infected M in 6 cells; M 6/CVB = CVB-infected M in6 cells; w /o 
Ab or w  Ab = w ithou t or w ith neutralizing anti IFN-a/ß antibodies, respectively; mIFNa = murine recombinant 
IFN-a. * = p < 0.05; n.s. = not significant.
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Figure 4. Induction o f innate immune responses in DC after M in 6 /CVB uptake requires (viral) RNA w ith in  
M in 6 cells.
(A) DCs were pretreated w ith Cytochalasin D for 30 minutes prior to  stimulation w ith TLR ligands or M in6 
cells. After 8 h, mRNA expression levels o f RIG-I, Mda5, and PKR were determ ined using qPCR. (B) DCs were 
pretreated w ith chloroquine for 30 minutes, stimulated as in (A) and mRNA expression was determ ined as in 
(A). (C) M in6 cell preparations were exposed to  a m ixture o f RNase A, RNase VI and RNase I prior to  addition 
to  DC cultures as described. Expression o f RIG-I, Mda5 and PKR in DCs was analyzed using qPCR 5h after ad­
dition o f M in6 cell preparations. (D) DCs were co-cultured w ith  M in6 cell preparations as described for panel 
A, and protein expression o f RIG-I, Mda5, and PKR was analyzed by western blotting 24h after the start o f 
co-culture. Data are representative o f 2 (D) or average o f 2 (A, B, C) independent experiments. In these ex­
periments freeze-thawed cell populations were used. Med = medium, unstimulated cells; IC = poly I:C; M 6/M  
= mock-infected M in6 cells; M 6/CVB = CVB-infected M in6 cells; w /o  RNase or w  RNase = w ithou t or w ith 
RNase-treatment o f M in6 cell preparations prior to  co-culture. * = p < 0.05; n.s. = not significant.
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mediate the observed responses in DCs. To investigate whether phagocytosis of cells 
is required for the induction of ISGs, or whether extracellular exposure to infected cells 
might initiate ISG reponses in DCs (e.g. via TLRs on the plasma membrane), phagocytosis 
was inhibited using Cytochalasin D (CytD). DCs pretreated with CytD and subsequently 
stimulated with CVB3-infected Min6 cells did not show any induction of ISGs, indicating 
that phagocytosis is required for ISG-induction. Similar decreases in ISG induction were 
observed when using CVB-infected primary porcine islets (data not shown). Poly I:C- 
induced ISGs were also reduced upon CytD-treatment, as has been reported before41. 
Importantly, LPS induced responses were not abrogated in the presence of CytD, proving 
that CytD has no adverse effects on DC viability or ISG-induction (Fig 4A)42.
Phagocytosed cells are localized to so-called phagosomes, which subsequently 
"mature" via fusion with the endosomal/lysosomal compartments, followed by 
progressive decrease in pH20, 43. Intracellular TLRs (TLR3, 7, 8, 9) are also recruited to 
these compartments, enabling interaction with potentially released PAMPs, like dsRNA, 
which occurs in a pH-dependent fashion44. Alternatively, phagocytosed material might be 
translocated into the cytoplasm, where for example the RLHs (RIG-I, Mda5) can interact 
with viral RNA. To determine if endosomal acidification is required for the induction of 
ISGs following uptake of infected cell preparations, we pretreated DCs with chloroquine 
(CQ), a chemical that blocks acidification of these compartments. Pretreatment of DCs 
with CQ markedly decreased CVB-infected Min6-induced mRNA expression of RIG-I, Mda5 
and PKR (Fig 4B), suggesting that endosomal acidification is critical for DC reponses upon 
phagocytosis of infected cells. Similar decreases in ISG induction were observed when 
using CVB-infected primary porcine islets (data not shown). FACS analysis showed that 
phagocytosis of Min6 cells was not inhibited due to CQ treatment (data not shown). Poly 
I:C induction, known to require endosomal acidification, was also decreased41, 44. LPS- 
induced responses do not require endosomal acidification41, 44. As expected, LPS-induced 
ISG and IL-6 expression was not decreased, indicating that viability and intracellular 
signaling to induce cytokines was unaltered upon CQ-treatment (Fig 4B and data not 
shown).
Using RNases, we investigated the contribution of (viral) RNA in our CVB-infected 
cells to DC responses. For this, freeze-thawed Min6 cell preparations were used, as 
viable cells with an intact plasma membrane will make degradation of intracellular RNA 
impossible. RNase-treatment of freeze-thawed Min6 cell preparations prior to addition 
to DCs reduced upregulation of RIG-I, Mda5 and PKR at both mRNA and protein level 
(Fig. 4C and Fig. 4D compare lane 4 and lane 6), demonstrating the important role of viral 
RNA present in infected cells for the induction of innate immunity. Together, our data 
show that phagocytosis of CVB-infected cells is required, and that subsequent signaling 
requires endosomal acidification and depends on the presence of viral RNA.
Discussion
DCs play a critical role in inducing immunity and preventing auto-immunity. Although 
diabetes pathogenesis and the possible role of APCs such as DCs therein has been 
investigated in mice14, 15, to our knowledge, no studies have been performed that 
examined the interaction between islets and DCs in humans. Here, we show for the 
first time that CVB-infected human islets are efficiently phagocytosed by human DCs 
resulting in a rapid RNA- and IFN-dependent innate antiviral response by the DCs.
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The response of DCs was further characterized with use of porcine islets and 
murine Min6 cells. Mock-infected cells did not induce innate responses, even though, 
surprisingly, their phagocytosis was as efficient. The reason for equal uptake of mock- 
and CVB-infected cells is unknown; islets/ß-cells may display enhanced molecular signals 
that mediate phagocytosis ("eat-me signals", such as phosphatidyl serines (PS))45, possibly 
caused by ER-stress inherent to massive insulin production 46. Preliminary data revealed 
that PS are higher expressed on the outer cell surface of steady-state insulin-producing 
Min6 cells when compared to other steady-state cell lines that are not efficiently 
phagocytosed (e.g. HeLa, L929, BGM, Vero) (data not shown). Whether PS or other "eat- 
me signals" are present on isolated primary human pancreatic islets, and facilitate their 
engulfment requires further investigation. Nevertheless, equal uptake of mock- and 
CVB-infected cells enabled us to make a good comparison of DC-responses, because 
only the infection status of islets or Min6 cells or islets differed. Phagocytosis of CVB- 
infected islets and Min6 cells invariably resulted in an increase in ISGs. Importantly, this 
IFN-dependent ISG-increase was sufficient to completely protect DCs from subsequent 
EV9 infection. This reveals a mechanism by which DCs may protect themselves when 
attracted to an environment with ongoing infection, ensuring their functional integrity.
Viral RNA is known to be an important inducer of antiviral immunity by triggering 
PRRs from the TLR and RLH family. Here we show that induction of innate responses 
in DCs requires endosomal acidification and is largely dependent on the presence of 
RNA within the infected cells. Some residual ISG induction is still observed after RNase 
treatment. Possibly, part of the RNA might be shielded within intact virus particles, and 
therefore be inaccessible for RNases. This residual viral RNA may have triggered ISG 
induction, when recognized in endosomes and/or lysosomes following phagocytosis. 
Although we favor the idea that viral RNA present in CVB-infected cells triggers antiviral 
immunity, we can not exclude that viral proteins or modified host proteins contribute to 
the observed antiviral responses.
Interestingly, engulfment of CVB-infected cells resulted in the development 
of type 1 diabetes in a susceptible mouse model14. In that study, resident APCs in the 
pancreas were shown to engulf CVB-infected ß-cells, and these APCs were capable 
to subsequently stimulate antigen-specific T cell proliferation and trigger diabetes, 
demonstrating that the (infectious) microenvironment may drive innate, as well as 
adaptive and autoimmune responses in vivo. We studied human DC maturation in 
vitro and our preliminary data on the induction of costimulatory molecules showed 
no consistent upregulation, even though ISG-induction was consistently observed. In 
some donors upregulation of CD80 and CD86 and production of TNF-a and IL-12 were 
observed in DCs upon uptake of CVB3-infected Min6 cells; however, in the majority of 
DC-donors no increases were observed. The reason for these inconsistent outcomes is 
unknown and requires further investigation.
Obviously, during phagocytosis of infected cells by DCs in vivo, other cell 
populations are present that can interact with DCs. These cells, including macrophages, 
plasmacytoid DCs and NK cells, and the cytokines they produce, can greatly influence 
the microenvironment and DC responses. For instance, IFNs can, besides their function 
in innate immunity, also influence adaptive immunity. The amount of IFNs, timing 
of encountering IFNs, but also possible synergy with other PRR-stimuli can greatly 
influence DC maturation47, 48. Moreover, other pancreas-constituents, such as duct cells 
may influence DC function. For example, duct cells produce TNF-a upon CVB3 infection
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(G. Vreugdenhil, F. van Kuppeveld J. Galama and D. Pipeleers, unpublished observation), 
and duct cell-derived TNF-a has been shown to influence DC maturation49. Further in 
depth investigation of adaptive immune responses in DCs from healthy controls upon 
encountering CVB-infected islets and the interplay with other cell types and cytokines 
would be extremely valuable.
Most human infections with enteroviruses are efficiently controlled due to 
adequate antiviral immune responses. Prolonged or successive enterovirus infections 
have been suggested to play a role in the development of type 1 diabetes50, 51, raising the 
possibility that individuals susceptible for type 1 diabetes may have impaired anti-viral 
defense. The genetic background of susceptible individuals greatly influences disease 
development. For example, polymorphisms in Mda5, the RNA sensor that recognizes 
picornavirus RNA52, have been associated with type 1 diabetes development25,53. 
Alterations in Mda5 function may affect adequate sensing of viral infections, and thus 
hamper antiviral immunity. CVB-infection in a genetically susceptible individual might 
therefore progress to chronic inflammation in the pancreas. In this pro-inflammatory 
environment, where self-antigens and viral antigens are encountered by DCs, 
autoimmunity might develop or accelerate, ultimately resulting in type 1 diabetes.
In conclusion, we show that CVB-infected human islets, porcine islets and 
Min6 cells are phagocytosed by human DCs and that this results in an RNA- and IFN- 
dependent antiviral state in DCs. These events may alter programming of DCs and thus 
influence the development of Treg and/or effector T cell populations. These novel findings 
provide important new insights in the possible role of DCs during human type 1 diabetes 
development.
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Supplementary Figure 1. Uptake o f and response to  live M in 6 cells and freeze-thawed M in 6 cell lysate by 
DCs is comparable.
(A) M in6 cells were PKH-labeled and infected w ith  CVB3 at an MOI o f 10 and cultured for 48h before addi­
tion to  CFSE-labeled DC in a 1:1 ratio. Alternatively, labeled, infected M in 6 cells were harvested 48h p.i. and 
stored at -20°C. Subsequently, these freeze-thawed cell lysates were added to  CFSE-labeled DCs in a 1:1 
ratio. Uptake o f islets either mock-infected (M in6/M ) or CVB-infected (M in 6/CVB) M in 6 was analyzed by flow  
cytom etry 24h after co-culture. (B) Live, infected M in 6 cells or infected M in 6 cell lysates were added to  DCs as 
in (A). Expression o f RIG-I, Mda5 and PKR mRNA in DCs was analyzed using qPCR at 5 and 8 h after coculture.
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Chapter 6
Abstract
E
nteroviruses, such as coxsackie B viruses (CVB) and echoviruses (EV), have 
been implicated as environmental factors that may trigger or accelerate type 
1 diabetes, but the underlying mechanism remains elusive. The aim of this 
study was to gain insight into the antiviral responses that are generated by primary 
human pancreatic islets upon enterovirus infection. Upon CVB-infection, transcription 
of interferons and interferon-stimulated genes was induced, and also mRNA of several 
different cytokines and chemokines was upregulated. Analysis of secreted cytokines 
and chemokines revealed that a variety of pro-inflammatory cytokines is produced, 
such as interleukin (IL) 8, IL-6 and tumor necrosis factor-a (TNF-a). Also chemotactic 
proteins such as interferon-inducible protein 10 (IP-10) were produced. UV-inactivated 
CVB did not induce any responses, suggesting that replicating virus is a prerequisite for 
antiviral responses. The double-stranded RNA (dsRNA) analog poly I:C induced a partially 
overlapping cytokine response, implying that dsRNA generated during CVB infection may 
be the trigger that initiates antiviral responses. These data provide insight in antiviral 
responses of human islets, and may shed light on the underlying mechanisms of virus- 
induced type 1 diabetes.
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Introduction
Type 1 diabetes is an endocrine disorder in which the pancreatic beta cells in the islets 
of Langerhans are gradually destroyed. The aetiology of the disease is not completely 
understood; however, it is known that both genetic and environmental factors play a role1. 
Inflammation is observed in the islets of type 1 diabetes patients and may mediate ß-cell 
dysfunction and cell death, thereby contributing to diabetes development (reviewed by 
Eizirik et al.2). In addition, autoimmune responses against ß-cell constituents are found 
in the majority of type 1 diabetes cases, and this may further add to type 1 diabetes 
development.
Enterovirus infections, especially with human enterovirus B species (HEV-B, 
such as coxsackie B viruses (CVB) and echoviruses (EV)), are implicated as environmental 
factors that may trigger or accelerate type 1 diabetes3, 4. Enteroviruses are small non­
enveloped single-stranded RNA viruses with a lytic life cycle. Infections are common 
and usually mild; however, during severe infections virus can spread to secondary target 
organs such as the pancreas, brain and heart5, 6. Recently, we have shown that HEV- 
Bs interact with dendritic cells (DCs) and influence DC function7, 8. Several studies have 
reported HEV-B detection in the pancreatic islets of type 1 diabetes patients at autopsy, 
providing evidence that these viruses are able to infect beta cells in vivo9-11. Consistently, 
human pancreatic islets can be infected with several different species of enteroviruses 
in vitro12.
Upon infection, type I interferons (IFNs) are produced as a first line of antiviral 
defense. They bind to the IFN receptors in a paracrine and autocrine fashion and thereby 
induce a signaling cascade which results in the production of several IFN-stimulated 
genes (ISGs). Among these are transcription factors such as interferon regulatory 
factor 7 (IRF-7), which mediate induction of antiviral proteins. Furthermore, effector 
proteins, such as 2'-5'oligoadenylate synthethase 1 (OAS1) and RNA-dependent protein 
kinase (PKR), which are involved in degradation of viral RNA and translation inhibition, 
respectively. In addition, also RNA sensors, such as melanoma differentiation-associated 
gene 5 (Mda5) and retinoic acid-inducible gene I (RIG-I), that recognize viral RNA and 
subsequently induce antiviral responses are induced. Besides IFNs, also other cytokines 
may be induced.
Cytokines can have harmful effects on ß-cell viability13, 14, and furthermore 
trigger and maintain inflammation and infiltration of immune cells into pancreatic islets. 
Tumor necrosis factor a (TNF-a) and interleukin 1ß (IL-1ß) are pro-inflammatory cytokines 
which are detected in the islets of type 1 diabetes patients at autopsy15. Furthermore, 
also interferon-a (IFN-a) and interferon-inducible protein 10 (IP-10) can be found in 
islets of type 1 diabetes patients, but not in islets from controls16, 17. These inflammatory 
mediators may be involved in the etiology of type 1 diabetes.
Little is known about cytokine production and secretion upon enterovirus 
infection in islets. In this study, we show that a broad array of cytokines is produced and 
secreted upon CVB3 infection. We further showed that virus replication is required for 
cytokine production and investigated what triggers may mediate cytokine production.
95
Chapter 6
Research Design and Methods
Virus stocks and purification
CVB3 Nancy (CVB) and CVB4 Edwards2 were kindly provided by R. Kandolf (University o f Tübingen, Germany) 
and J.W. Yoon (University o f Calgary, Canada), respectively. Production o f virus stocks and virus titrations were 
performed on buffalo green monkey cells as described previously7. Serial 10-fold dilutions were tested in 96- 
well m icro titer plates and fifty  percent Tissue Culture Infective Doses (TCID50) were calculated as described 
before18.
Human islet culture
Human pancreatic islets were isolated in Pittsburg as described before19. Human islets were obtained from 
deceased anonymous donors procured by CORE (Center for Organ recovery and Education, Pittsburgh), 
and islets were isolated using a modification o f the semiautomated method described by Ricordi19, 20. Islets 
batches used in this study were obtained from  8 adult pancreas donors, cultured for a minimum o f 3 to  6 
days in CMRL-1066 medium containing 10% fetal calf serum, 2 mM L-glutamine, 100U/ml penicilin, 0.1mg/ml 
streptomycin (Complete CMRL), at 37°C in an atmosphere o f 5% CO2. Islet viability was estimated by dual 
fluorescence viability dyes (Calcein-AM and Propidium Iodide, Invitrogen, Eugene, OR) and was higher than 
80% in all batches.Glucose stimulated insulin release was carried out by dynamic perifusion21. After culture for 
3 to  6 days the islets were sent to  Nijmegen as free-floating islets and cultured in Complete CMRL in ultra low 
attachment culture plates (Corning) at 37°C in 5% CO2. Islets were cultured in Nijmegen for maximum 2 days 
before start o f the experiments,
Infection of human pancreatic islets
Human pancreatic islets were infected in a small volume o f Complete CMRL, at indicated m ultip lic ity of 
infection (MOI) for 1 h at 37°C. Subsequently, cells were washed 3 times in PBS and cultured in Complete 
CMRL. For replication analysis, viral titers were determ ined at different tim e points post infection (p.i.) as 
described above. At indicated times p.i. cells and supernatant were harvested for RNA isolations and cytokine 
detection, respectively.
RNA isolation
Total RNA was isolated from  islets using TRIZOL reagent (Invitrogen Life Technologies) according to 
manufacturer's instructions, w ith m inor modifications. The reverse transcription reaction was performed using 
Moloney murine leukemia virus (MMLV) reverse transcriptase (Invitrogen) according to  the manufacturer's 
instructions. For each sample a "-RT" control was included in which the reverse transcriptase was replaced by 
DEPC treated water. The cDNA was stored at -20°C until fu rthe r use.
Quantitative PCR
Quantitative analysis o f gene expression in islets was done using SYBR Green based qPCR. The qPCR reactions 
were performed in a 20 ^l volume containing: 10 ^ l SYBR Green mix (Roche), 1.5 ^l forward/reverse primer 
(300 nM endconcentration), 2 |il m illi-Q  and 5 |il cDNA dilution. Reactions were performed on a LightCycler 480 
(Roche). Analysis was done using LightCycler 480 Software (LC480 SW Version 1.5, Roche). Primer sequences 
are available upon request and were designed using the freely accessible Primer Bank program22.
Cytokine detection
Supernatant o f islet cultures were harvested at indicated times p.i., and stored at -20°C. Prior to  cytokine- 
measurements, supernatants were filtered using Microcon Centrifugal filte r devices w ith a cut-off value of 
100 KDa (M illipore) according to  manufacturer's instructions, in order to  remove infectious virus, but retain 
the cytokines and chemokines (which have a maximum size o f approx 30 KDa). Microcons were washed with 
200^l Complete CMRL once, before applying the supernatants. Cytokine levels were measured and analysed 
using the Bio-Plex system and a 27-plex luminex kit (Bio-Rad Laboratories) and data analysis was performed 
w ith  Bio-Plex Manager software (Bio-Rad Laboratories). Luminex 27-plex included the fo llow ing cytokines and 
chemokines: IL-1ß, IL-1Ra, IL-2, IL-4, IL-5, IL-6 , IL-7, IL-8 , IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, eotaxin, bFGF,
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G-CSF, GM-CSF, IFN-y, IP-10, MCP-1, MIP-1a, MIP-1ß, GG-BDGF, RANTES, TNFa and VEGF.
Statistical analysis
Statistical analysis was performed using a paired Student's t  test (two-tailed distribution) on 10log transformed 
luminex data sets. A p-value >0.05 was considered a significant difference.
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Figure 1. mRNA induction o f various antivira l genes, cytokines and chemokines in human pancreatic islets 
upon CVB3 infection.
(A) Human islets were infected w ith  an MOI o f 10 and at indicated times p.i. virus titers were determ ined 
by endpoint titra tion. (B) Human islets were infected w ith  CVB3 or UV-inactivated CVB3 at an MOI o f 10, or 
were mock infected and at indicated times mRNA induction o f IFN-ß, RIG-I, MDA5, IRF7, OAS1 and PKR was 
determ ined using qPCR. (C) mRNA induction o f IL-6 , IL-8 , IL-1ß, IFN-y, IL-18, IP-10, RANTES, MIP-1ß, MCP-1 
and IL-15 was determ ined by qPCR in islets infected as in B.
Results
mRNA expression in human pancreatic islets upon enterovirus infection
To study the islet responses upon enterovirus infection, we infected islets with CVB3 and 
determined expression of IFN-ß and ISGs. Replication of CVB3 in primary human islets 
was very efficient, as indicated by the rapid increase of virus titer over time (Fig. 1A) 
and the induction of cytopathic effects (CPE, data not shown). Quantitative PCR (qPCR) 
revealed that IFN-ß was induced 24h p.i. and further increased over time. All ISGs tested 
were induced, at varying levels. The highest induction was observed for OAS1; up to 
100-fold increase at 48 h p.i., whereas other ISGs showed increases of 20- to 40-fold 
at 48 h p.i. (Fig. 1B). Although ISGs were induced upon infection in all experiments, the 
magnitude of the responses varied greatly between individual donors (e.g. range 8 -  99 
times increase of OAS1 in 5 donors at 48 h p.i.).
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To further study innate immune responses, we examined expression of a 
selection of cytokines and chemokines that might be induced upon infection. We found 
that mRNA expression of several genes was induced. Interferon-inducible protein 10 
(IP-10) induction was most pronounced in all donors, up to 1000-fold increases were 
observed compared to mock-infected islets. Also RANTES (Regulated upon Activation 
Normal T-cell Expressed and Secreted) expression was strongly induced, whereas other 
genes were induced at lower levels (MIP-1ß, MCP-1, IL-1ß, IL-6, IL-8), or were hardly 
induced at all (IFN-y, IL-15, IL-18) (Fig. 1C).
To study whether replicating virus is required for antiviral responses, UV- 
inactivated CVB3 was used to infect islets in parallel. UV-inactivated virus did not replicate 
and no CPE was induced (data not shown). None of the ISGs, cytokines or chemokines 
tested showed any mRNA increase with inactivated virus; indicating that replication is a 
requirement for antiviral gene induction (Fig. 1B &1C).
Several cytokines and chemokines are produced upon infection with CVB3.
The amount of gene transcription does not necessarily relate to the amount of 
synthesized, or bioactive protein. Several cellular mechanisms are operating which 
regulate translation of mRNAs. Additionally, for some cytokines, such as IL-1ß, a post- 
translational modification/processing is required to yield bioactive protein. Moreover, in 
the case of enterovirus infection, viral proteases are able to suppress cellular translation. 
These proteases are known to cleave cellular factors and may thus also cleave the 
produced cytokines and chemokines. Therefore, we set out to investigate the amount 
of secreted cytokines and chemokines in supernatant of mock- or CVB3-infected islet 
cultures. Because very limited information is available regarding cytokine and chemokine 
production by enterovirus-infected islets, we chose to investigate a broad range of 
cytokines and chemokines using a luminex 27-plex bead-assay (Biorad). We determined 
cytokine expression in mock- or CVB-infected islets at 48 h p.i. in four different 
experiments using islets from different donors. Various cytokines and chemokines were 
detected in the supernatant of human islets. Mock-infected islets produced relatively 
high basal levels (more than 1ng/ml) of IL-6, IL-8, MCP-1, VEGF and some IL-10 (Fig. 2 and 
supplementary table 1). Upon CVB3-infection pro-inflammatory cytokines (e.g. IL-1ß, IL- 
6, TNF-a) were induced. IL-6 production was most pronounced (>10 ng/ml in all donors) 
and TNF-a production reached approximately 1 ng/ml for all donors. IL-1ß production 
was increased, yet cytokine levels remained low (below 100 pg/ml for all donors). IFN-y, 
a Th1 cytokine which also has antiviral properties, was induced, whereas production of 
the Th1-inducer IL-12 was not increased upon infection. Of the Th2-associated cytokines, 
IL-4 was increased upon infection, yet the concentration remained low (below 200 pg/ 
ml for all donors). IL-5 and IL-13 were not induced upon infection at all. Also the anti­
inflammatory IL-10 was not induced. Several of the chemokines tested were increased 
(IP-10, RANTES, IL-8, MIP-1a, eotaxin). IP-10 showed the most pronounced induction of 
all cytokines and chemokines tested; 20 to 100-fold increases were observed, depending 
on the donor. This confirmed our qPCR data, which also showed highest increases for 
IP-10. IL-8 showed a substantial increase and was produced at highest levels (up to 200 
ng/ml). Notably, MCP-1, that was already produced in mock-infected islets, did not show 
obvious increases in all donors. Several growth factors were included in the analysis and 
a striking increase was observed for G-CSF. Other growth factors such as PDGF and GM- 
CSF were not significantly increased and VEGF even showed a minor decrease.
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Figure 2. Human islets produce various cytokines and chemokines upon CVB3 infection.
Human islets were mock or CVB3-infected w ith  an MOI o f 10 and at 48h p.i. supernatant was harvested and 
analyte-levels were determ ined as described. Data shown are from  4 different experiments using different 
donors. All values are in pg/m l. ns, not significant; *, p-value >0.05; * * , p-value >0.01.
In short, many pro-inflammatory cytokines and chemokines were induced upon 
CVB-infection of human pancreatic islets, as well as Thl-associated IFN-y, whereas no or 
little Th2 and anti-inflammatory cytokines were induced.
Kinetics of cytokine induction follow replication kinetics.
To further study the kinetics of virus-induced cytokines and chemokines production, 
a more detailed analysis of cytokines and chemokines produced at several times p.i. 
was performed. This revealed that most CVB-induced cytokines were hardly induced 
at 8h p.i., but were increased at 24h p.i. and further increased 48h and 72h p.i. (Fig. 
3). This increased cytokine production follows the increases in virus titer, although 
cytokine production further increases up to 72 h p.i., whereas virus replication reaches 
a maximum at 48h p.i. Comparison of cytokine secretion with mRNA induction kinetics
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Figure 3. Cytokine production in CVB3, CVB4 E2, and UV-inactivated CVB-infected islets.
Human islets were infected w ith CVB3, UV-inactivated CVB3 or CVB4 E2 w ith  an MOI o f 10, or were mock- 
infected. At indicated times p.i. supernatant was harvested and analyte-levels were determ ined as described. 
Shown are IL-6 , IL-8 , IP-10, RANTES, MCP-1 IL-15 and G-CSF. Values in pg/ml.
in the corresponding donor, revealed that the continuous increase in cytokines and 
chemokines is found at both mRNA and protein level for most genes/proteins (data not 
shown) with the exception of IP-10. mRNA levels of IP-10 were already at maximum 
levels around 24h p.i. and showed a decrease afterwards (Fig. 1C).
CVB3 and CVB4 induce the same cytokine pattern upon infection of pancreatic islets.
HEV-Bs are the viruses which are most often associated with T1D and include six 
different CVBs and several echoviruses. Among the CVBs is the CVB4 Edwards 2 (CVB4 
E2) strain that was isolated from the pancreas of a type 1 diabetes patient and is 
therefore considered to be more "diabetogenic" compared to other CVBs23. To asses 
whether different responses were generated upon infection with a different serotype, 
we compared CVB3-induced responses to CVB4 E2-induced responses.
Similar cytokine patterns were induced by both CVB3 and CVB4 E2, although 
the magnitude of the induction and the kinetics were somewhat different between the 
two. CVB4 E2-induced responses were a little reduced compared to CVB3, and induced 
rather later for some cytokines (Fig. 3). The observed differences might be due to minor 
variation in amount of virus or replication kinetics. UV-inactivated virus did not induce
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cytokines and chemokines at any of the time points tested (Fig. 3), corroborating our 
qPCR data and providing further proof that viral replication is a prerequisite for induction 
of antiviral responses in human pancreatic islets. When using UV-inactivated virus, it 
is unknown whether virus entry and RNA release occur. Using the compound AG7404, 
we further dissected whether virus entry or replication is a prerequisite for cytokine 
induction. AG7404 was recently discovered to inhibit enterovirus replication, but does 
not inhibit virus entry, RNA release, or translation. AG7404 completely abolished CVB3 
replication in islets (data not shown). No CVB3-induced cytokine production was observed 
in islets in the presence of AG7404 (data not shown). This further confirms that virus 
replication is required for cytokine induction, and indicates that viral RNA release and 
translation are not sufficient to induce cytokines and chemokines in pancreatic islets.
CVB-induced cytokines may be induced by dsRNA and IFNs
The enterovirus genome is a single-stranded RNA strand of positive polarity. During 
replication, viral replication proteins are involved in the replication of viral RNA. 
Replication starts with synthesis of a negative strand, giving rise to the double-stranded 
(ds) RNA intermediate. Negative strands are subsequently used as a template for the 
production of new positive strands, again giving rise to dsRNA intermediates. dsRNA is
Time (h p.i.)
Figure 4. Cytokine induction by po ly I:C and recom binant human IFN-a2.
Human islets were stimulated w ith  poly I:C (100^g/m l), or recombinant human IFNa2 (150 U/m l) and at 
indicated times cytokines were determ ined as for Fig 3. Shown are IL-6 , IL-8 , IP-10, RANTES, MCP-1 IL-15 and 
G-CSF. Values in pg/ml.
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a known ligand for several pattern recognition receptors (e.g. Toll-like receptor 3, TLR3; 
Mda5), and induces the production of type I IFNs. We set out to investigate the response 
of islets to dsRNA and IFN-a. Therefore, we determined responses induced by poly I:C, a 
dsRNA analog, or by recombinant human IFNa2.
Addition of poly I:C (100^g/ml) to the culture medium gave rise to increased 
IL-6, IL-8, IP-10 and RANTES production in islets, similar to viral infection. In contrast, no 
G-CSF was produced after poly I:C stimulation. IL-15 and MCP-1, that were only slightly 
induced upon infection, were markedly increased after poly I:C stimulation (Fig. 4). This 
suggests that the receptors and downstream signaling pathways involved in detection of 
viral infection and poly I:C may largely overlap, yet some differences exist.
Stimulation of islets with recombinant IFN-a2 (150U/ml) caused increased IP- 
10 production, yet had no effect on any of the other cytokines and chemokines tested 
(Fig 4 and data not shown). The concentration used induced several ISGs, as assessed 
by qPCR (data not shown), indicating that this concentration is sufficient to induce an 
antiviral state. IP-10 induction is known to be IFN-dependent24. We examined whether 
other pro-inflammatory cytokines and chemokines indeed did not rely on IFN-feedback 
for their induction using neutralizing anti-IFN-a/ß antibodies (Abs). Cytokines and 
chemokines such as IL-6, IL-8, G-CSF, IFN-y and others were still induced upon infection 
in the presence of neutralizing anti-IFN Abs, suggesting that these did not depend on 
IFNs for their induction (data not shown). These data indicate that IFN-a feedback may 
mostly contribute to the major IP-10 increases that are observed upon CVB-infection.
Discussion
Enterovirus infections are considered to be environmental factors in type 1 diabetes 
etiology, yet the underlying mechanisms that result in ß-cell destruction remain elusive. 
Here we report that upon CVB-infection, a broad anti-viral response is generated in 
primary human islets, which encompasses the production of a variety of IFNs, ISGs, 
cytokines and chemokines. Our study shows that these cytokines and chemokines are 
not only expressed at the mRNA level, but are also translated and secreted.
Human pancreatic islets produced several cytokines under steady-state culture 
conditions. Among these were IL-6, IL-8 and MCP-1. Previous studies have shown that 
these cytokines are produced by human pancreatic islets ex vivo, and this may be partially 
due to stress generated during the isolation procedure19. Besides these three, IL-10 and 
VEGF were also produced. The anti-inflammatory cytokine IL-10 might be produced in 
order to reduce inflammation caused by isolation. During islet isolation endothelium may 
be damaged and disrupted, possibly leading to VEGF induction in order to revascularize 
the islets.
Upon CVB-infection, expression of a variety of cytokines and chemokines was 
induced or increased. Highest production was found for IP-10, corroborating earlier 
findings25. IP-10 is known for its chemotactic effects on lymphocytes, monocytes and 
NK-cells26, 27, but has also been reported to inhibit angiogenesis and colony formation27' 
29. Expression is reported to rely on IFN-y30, 31; however, we show that recombinant IFNa2 
highly induces production of IP-10, in agreement with other reports24. Interestingly, 
several independent groups have shown that IP-10 serum-levels are increased in type 
1 diabetes patients and individuals at risk to develop the disease32-34, and recently, IP-10 
was detected in islets of type 1 diabetes patients with fulminant diabetes16. This implies
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an important role for IP-10 in disease-development. Mouse studies corroborate this, 
ß-cells secrete IP-10 in response to inflammation, and this subsequently mediates the 
chemoattraction of T cells35. Furthermore, neutralization of IP-10 was shown to decrease 
diabetes in mice36, 37.
Besides IP-10, several other pro-inflammatory cytokines and chemokines were 
produced upon infection, such as IL-8, IL-6, TNF-a, RANTES, MIP-1ß and others. These 
can have adverse effects on islet function, and may induce ER-stress and ß-cell death 
(reviewed by Eizirik et al.2). Furthermore, T lymphocytes, monocytes, NK cells and other 
immune cells may be attracted to the site of infection, and activation of these cells may 
be triggered. The generated T cell responses will probably be Th1, as IFN-y is induced, 
whereas secretion of Th2-associated cytokines (e.g. IL-4, IL-5, IL-13) is much lower, and 
hardly increased upon CVB infection. IL-17-producing Th17 cells have been reported to 
contribute to several autoimmune diseases38-40. Although some IL-17 was detected in 
islet preparations, it was not increased upon infection.
Several growth factors were included, of which only G-CSF was increased upon 
infection. G-CSF is a colony stimulating factor that particularly induces granulocyte 
proliferation and differentiation in the bone marrow. It also stimulates survival, 
proliferation and function of granulocytes, especially neutrophils, in the blood41. What 
the role of G-CSF in type 1 diabetes etiology is remains to be determined.
The use of UV-inactivated CVB and AG7404 revealed that replicating virus 
was a prerequisite for induction of antiviral responses and cytokine production. The 
observation that the dsRNA analog poly I:C induced several cytokines and chemokines 
that were also induced upon CVB-infection suggests that viral dsRNA may be a trigger 
to induce antiviral responses. Recombinant IFN-a2 only induced production of IP-10, 
but just one concentration was tested. Perhaps higher levels of IFN-a2 will induce 
other cytokines and chemokines as well. Furthermore, other IFN-a subtypes may also 
contribute to these inductions. However, preliminary experiments using neutralizing 
anti-IFN Abs suggest that the majority of virus-induced cytokines and chemokines do 
not rely on IFNs for their induction.
Islets consist of several types of endocrine cells, endothelium and resident 
immune cells such as macrophages and DCs42. All these cell types could contribute to 
the cytokines and chemokines that are induced. Duct cells, for example, can produce 
TNF-a43, and pancreatic endothelium produces pro-inflammatory cytokines like IL-6 and 
IL-8 upon CVB-infection44. To identify the cell type that is responsible for the production 
of cytokines and chemokines, further investigation is required. However, that also the ß- 
cells themselves may play a role is demonstrated by the study of Tanaka and colleagues16. 
They detected IP-10 in all subtypes of islet cells, including a-cells and ß-cells, in the islets 
of three deceased type 1 diabetes patients that were found positive for enterovirus 
capsid protein. Furthermore, IFN-a can be found in human ß-cells of diabetes patients, 
indicating that ß-cells themselves participate in cytokine production17.
Our findings suggest that a full-blown immune-response is ongoing in infected 
islets. Feedback-mechanisms should restrict further inflammation when the infection 
resolves. However, these feedback mechanisms may be differently regulated in different 
individuals, and unrestrained inflammation may result in type 1 diabetes2. Perhaps 
inflammation is not correctly cut down once infection is resolved in individuals at risk 
for type 1 diabetes. In addition, in susceptible individuals aberrant adaptive immune
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responses against ß-cells may be generated, potentiated by inflammation in the islets. 
These autoimmune responses may further contribute to type 1 diabetes.
As mentioned above, IP-10 serum levels are increased in type 1 diabetes 
patients, and this has also been reported for IFN-a, MIP-1a, MIP-1ß and TNF-a45-47. Thus, 
sustained production of inflammatory mediators seems to occur in individuals with type 
1 diabetes. These inflammatory mediators may be produced by PBMC in the blood, but 
also cytokines originating from elsewhere in the body, such as inflamed pancreatic islets, 
may contribute to increased serum levels. The underlying mechanism for sustained 
cytokine production is unknown, but could relate to delayed or ineffective clearance of 
virus infection, or the genetic makeup of these individuals. Polymorphisms present in 
the population can predispose for disease, and some single nucleotide polymorphisms 
(SNPs) that are associated with type 1 diabetes are found in inflammatory mediators 
such as RANTES, TNF-a and others48-50. Furthermore, SNPs in Mda5, which is the viral 
sensor for enteroviruses, have been associated with type 1 diabetes51, 52. Additionally, 
an association was found for SNPs in OAS1, an important effector protein in antiviral 
defense, with type 1 diabetes53, 54. Thus individuals may be more prone to aberrant 
antiviral responses depending on their genetic makeup.
In conclusion, we report that a broad antiviral response is generated by human 
pancreatic islets upon CVB-infection. This response is characterized by the induction 
of IFNs and ISGs and further encompasses the secretion of several pro-inflammatory 
cytokines, chemokines and growth factors. Virus replication is a prerequisite for these 
responses and the observation that the dsRNA analog poly I:C yields a largely similar 
cytokine pattern implies that viral dsRNA may trigger these responses. These data 
provide new insight in the antiviral responses of human pancreatic islets and provide 
a mechanism by which enteroviruses may induce type 1 diabetes in susceptible 
individuals.
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Cytokine production in enterovirus-infected human islets
Cytokine Donor 1 
Mock CVB3
Donor 2 
Mock CVB3
Donor 3 
Mock CVB3
Donor 4 
Mock CVB3 p-value
IL-1ß 10 45 15 19 17 85 <7 51 0,039
I L-1Ra 226 1334 531 712 712 2820 187 1308 0,036
IL-2 50 178 97 138 10 2 459 50 174 0,023
IL-4 23 83 43 56 51 158 23 80 0,027
IL-5 20 29 49 20 59 46 20 20 0,521
IL-6 2626 18036 5727 11855 6930 311861 3664 16547 0,056
IL-7 241 233 395 184 451 457 74 103 0,658
IL-8 17465 74661 28338 75891 40453 237003 44953 151638 0,004
IL-9 370 420 486 346 582 689 245 409 0,552
IL-10 2304 1866 3716 1462 5007 3869 686 688 0,183
IL-12p70 870 665 1285 527 1727 1459 235 235 0,186
IL-13 190 164 377 142 320 322 78 78 0,320
IL-15 547 759 381 2 1 1 596 894 391 1017 0,455
IL-17 335 550 335 398 378 1034 <90 611 0,099
eotaxin 397 996 597 550 690 1207 279 657 0,091
bFGF 232 362 266 189 298 403 76 232 0,293
G-CSF 85 1433 116 614 177 4606 306 2314 0,007
GM-CSF 172 535 357 340 389 959 104 458 0,077
IFN-y 703 3235 1378 2131 1851 6931 625 2929 0,019
IP-10 662 62792 557 11522 779 20004 2528 118975 0,002
MCP-1 19452 >21877 15181 1 10 2 2 25841 36617 25241 48042 0,403
MIP-1a 298 968 381 429 434 1258 260 1072 0,045
MIP-1ß# 541 1605 479 775 621 1788 743 2613 0 ,0 10
PDGF 140 218 347 163 403 471 28 177 0,491
RANTES 2 10 1209 325 510 416 1214 2 10 995 0,025
TNF-a 262 1126 490 698 522 2513 198 1107 0,026
VEGF 9923 6712 19247 5132 30399 20461 2277 1979 0,119
Supplementary Table 1. Cytokine and chemokine production by human pancreatic islets upon CVB3 
infection.
Human islets were mock or CVB3-infected with an MOI of 10 and at 48h p.i. supernatant was harvested and 
analyte-levels were determined by 27-plex as described. Data shown are from 4 different experiments using 
different donors.
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Abstract
P revious studies have shown that enteroviral RNA can be detected in blood at onset of type 1 diabetes (T1D). The infection may play a role in triggering of T1D and genetic host factors might contribute to this process. We investigated (i) 
whether enterovirus is present at onset of T1D in peripheral blood mononuclear cells 
(PBMC), plasma, throat or stool and (ii) whether enteroviral presence is linked with HLA- 
DR type and/or polymorphisms in melanoma differentiation-associated gene 5 (MDA5) 
and 2'-5' oligoadenylate synthetase 1 (OAS1), factors of anti-viral immunity. For this, 
PBMC, plasma, throat and stool samples from 10 T1D patients and 20 unrelated controls 
were tested for presence of enteroviruses (RT-PCR), for HLA-DR type and polymorphisms 
in MDA5 and OAS1. Enterovirus RNA was detected in PBMC of 4/10 T1D patients, but 
none of 20 controls. Plasma was positive in 2/10 T1D patients and none of 20 controls, 
suggesting that enteroviruses found at onset of T1D are mainly present in PBMC. All 
throat samples from positive T1D patients were virus-negative and only 1 fecal sample 
was positive. The negative results for all throat- and most stool samples argues against 
acute infection. Enterovirus presence linked with HLA-DR4 but not with polymorphisms 
in MDA5 or OAS1.
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Background
Coxsackie B viruses (CVB) and echoviruses, both belonging to the human enterovirus 
B (HEV-B) species, have for decades been indicated as environmental factors in type 
1 diabetes (T1D) which is generally regarded an autoimmune disease (reviewed in1, 
2). Support for their role in T1D is deduced from: (i) prospective cohort studies which 
showed that enterovirus infections coincide with onset of autoimmunity and with clinical 
onset of T1D1; (ii) detection of enterovirus RNA in blood of T1D patients (see below) 
and (iii) detection of enterovirus in islets of individuals with established T1D3-5. Thus, 
enteroviruses may be involved in T1D along various routes: indirectly, through triggering 
of autoimmunity, or more directly, through infection of islets and destruction of ß cells. 
It should be noted, however, that these two processes do not necessarily exclude each 
other; they may even be interrelated.
Enterovirus RNA has been found in blood by RT-PCR at onset of disease in 20 
to 75% of T1D patients6-13. Enterovirus has furthermore been found in auto-antibody 
positive (pre-diabetic) persons11, 14, 15 and in patients with established T1D7, 13, but not, 
or with a much lower frequency, in matched healthy controls without predisposition for 
T1D or in T2D patients13. So far, none of the studies that detected viral RNA in blood of 
T1D patients investigated the stage of infection: whether a positive RT-PCR was due to 
early infection with virus excreted in the throat, or convalescence with virus detectable 
in stool only, which can last for up to 3 months16. Another possibility is that virus remains 
detectable beyond convalescence (stool negative). Taken together, the difference with 
unrelated healthy people suggests that T1D patients and those at risk for the disease are 
more susceptible for enteroviruses or are unable to clear the infection, both conditions 
which might be involved in T1D.
Besides environmental factors, a strong genetic predisposition is involved. 
HLA-DR3 and DR4 are major risk factors, whereas DR2 is negatively associated with 
the disease17-21. Also other genetic factors have been associated with T1D and new 
associations are still being found, including two recently identified single nucleotide 
polymorphisms (SNPs) that are involved in antiviral immunity22-25. These factors, 
melanoma differentiation-associated gene 5 (MDA5) and 2'-5'oligoadenylate synthetase 
1 (OAS1), play an important role in the innate defence against RNA viruses by sensing or 
degrading (entero)viral RNA, respectively. These SNP's may thus provide a link between 
(entero)viruses and T1D.
In this study we investigated (i) whether blood mononuclear cells contain enteroviral 
RNA, (ii) what is the stage of infection and (iii) whether infection is linked with particular 
risk alleles for HLA-DR and/or with SNPs in MDA5 and OAS1.
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Patients and methods
Patients and control group
Patients and controls were included at the Paediatric Clinics of the Erasmus University Medical Centre 
Rotterdam and the Canisius-Wilhelmina Hospital Nijmegen. Ten T1D patients (5 males, 5 females) were 
included and samples were collected within a month of diagnosis. Mean age of the patient group was 9.7 years 
(range 5-14 years). For comparison, a group of 20 hospitalized children (9 males, 10 females, 1 of whom the 
gender is unknown) of the same age range, with non-endocrine disorders was included. Their mean age was 
12.5 (range 6-17 years). Samples from T1D patients were obtained between November 2003 and November 
2004, and from healthy controls in June 2004. Informed consent was given by the parents, based on a study 
protocol which was approved by the local Ethical Committees of the respective hospitals.
Laboratory samples
The following samples were collected: (1) 5 ml of citrate blood for isolation of plasma and PBMC, (2) 5 ml 
of clotted blood for serum, (3) throat swab in virus transport medium and (4) a fecal sample. PBMC were 
isolated as instructed by the manufacturer (Becton and Dickinson, Erembodegem, Belgium). After processing, 
all samples were quickly frozen and stored at -800 C until use.
Virus detection
RNA was isolated from 200 l^ plasma, an equivalent of 2 -105 PBMCs (isolated PBMCs dissolved in PBS), and 
stool sample homogenate. For the in-house nested RT-PCR, RNA extraction was done using the MagNaPure 
LC Isolation station (Roche Applied Science, Mannheim, Germany). Amplification was performed in a nested 
PCR reaction as described previously26. Real-time PCR was performed as described previously27. Real-time 
NASBA (NucliSens EasyQ) was performed according to manufacturer's instructions (BioMérieux, Boxtel, The 
Netherlands). Amplification techniques were regularly tested by Quality Control for Molecular Diagnostics 
(QCMD) standards. An enterovirus-specific internal homologous control RNA was included in each sample 
during the extraction to monitor the NucliSens EasyQ and PCR procedures at the individual sample level. This 
excludes false negatives due to possible inhibitory factors in input samples, which could be present especially in 
stool samples. Sensitivity of the methods is at least 0.002 to 0.01 TCID50 for in-house nested RT-PCR and real­
time PCR, depending on the enterovirus strain tested. NASBA is similar, or somewhat less sensitive compared 
to the PCRs, depending on the enterovirus strain.
Interferon-a detection
The amount of Interferon-a (IFNa) in plasma samples was determined using a commercial ELISA kit, product 
number RDI-PB41110, from Research Diagnostics Inc (Fitzgerald Industries International, North Acton, USA). 
The test was performed according to instructions of the manufacturer 
HLA typing
Total NA were isolated using MagNaPure as described above. HLA typing was performed on RNase-treated 
DNA using the lifecodes HLA-SSO typing kit (Tepnel, Manchester, UK) according to manufacturer's instructions 
and EFI/ASHI guidelines for histocompatibility testing.
MDA5 and OAS1 single nucleotide polymorphism (SNP) typing
The MDA5 SNP tested is the A946T polymorphism (rs1990760) that has been described by Smyth et al.24. The 
OAS1 SNP tested is rs10774671, which is an A/G splice-site SNP22, 23, 28. SNPs in MDA5 and OAS1 were assessed 
by amplification of the relevant region, followed by sequencing of the PCR product. From the sequence, 
presence of the SNP and homo- or heterozygosity was determined. Primers are available upon request.
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Results
Detection of enterovirus RNA in PBMC of T1D patients.
Ten recently diagnosed T1D patients were tested by RT-PCR26 and compared with 20 
healthy children of the same age without known risk factors for T1D. PBMC and plasma 
were tested separately. Four of the 10 T1D patients (40%) reacted positive for enterovirus 
in their PBMC, two of them were also positive in plasma (Table 1). The outcome was 
confirmed on separately isolated total NA by real-time PCR27 and by NASBA, an RNA- 
based amplification technique (data not shown). Amplification of part of the 5'UTR
Table 1. Background information and enterovirus RNA detection in T1D patients and controls. 1
Patient Date o f  B irth Gender HLA DRB1 Plasma PBMC Feces Throat IFN-a
1 04-05-1998 M DRB1*04/DRB1*13 + + + <
2 11-05-1989 M DRB1*0301/DRB1*04 - - - - <
3 02-08-1992 M DRB1*01/DRB1*13 - - - - 13
4 30-05-1995 M DRB1*0301/DRB1*04 - + - - <
5 22-03-1996 F DRB1*04/DRB1*15 - - - - <
6 29-11-1995 M DRB1*01/DRB1*0301 - - n.t. - <
7 31-08-1993 F DRB1*04/DRB1*10 - + n.t. - <
8 03-03-1995 F DRB1*01/DRB1*04 - - - - <
9 11-07-1995 F DRB1*04/DRB1*08 - - - - n.t.
10 04-02-1993 F DRB1*04/DRB1*04 + + - - n.t.
Control Date o f  B irth Gender HLA DRB1 Plasma PBMC Feces Throat IFN-a
1 03-07-1998 F DRB1*14/DRB1*15 - n.t. <
2 06-03-1997 M DRB1*0301/DRB1*11 - - n.t. - >500
3 20-05-1989 F DRB1*04/DRB1*11 - - n.t. - <
4 15-08-1988 M DRB1*13/DRB1*14 - - n.t. - <
5 25-05-1992 F DRB1*04/DRB1*13 - - n.t. - <
6 01-02-1989 M DRB1*07/DRB1*07 - - n.t. - <
7 23-05-1995 M DRB1*01/DRB1*04 - - n.t. - <
8 29-09-1989 M DRB1*14/DRB1*14 - - n.t. - <
9 07-02-1996 M DRB1*04/DRB1*15 - - n.t. - <
10 29-01-1993 M DRB1*01/DRB1*13 - - n.t. - <
11 17-02-1997 ? DRB1*01/DRB1*04 - - n.t. - <
12 17-06-1991 F DRB1*04/DRB1*14 - - n.t. - <
13 27-03-1993 F DRB1*07/DRB1*13 - - n.t. - <
14 10-09-1989 M DRB1*04/DRB1*11 - - n.t. - 75
15 30-08-1993 F DRB1*01/DRB1*0301 - - n.t. - <
16 19-04-1989 F DRB1*01/DRB1*04 - - n.t. - <
17 08-01-1987 F DRB1*14/DRB1*15 - - n.t. - <
18 10-09-1988 F DRB1*0302/DRB1*07 - - n.t. - <
19 04-10-1988 M DRB1*04/DRB1*13 - - n.t. - <
20 15-03-1988 F DRB1*01/DRB1*0301 - n.t. <
Abbreviations: M, male; F, female;? gender unknown; + positive reaction; - negative reaction; n.t. = not tested; 
Interferon- a (IFN-a) plasma levels in pg/ml; detection threshold 10 pg/ml; <, less than the detection limit.
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yielded a fragment which showed highest similarities with viruses from the HEV-B 
species. Unfortunately, attempts to amplify the variable region (VP1-2A) using degenerate 
primers failed, thereby making further typing of the enteroviruses impossible. None of 
the 20 children in the control group were positive for enteroviral RNA in either PBMC 
or plasma (Table 1). All controls were sampled in June 2004, whereas T1D patients were 
sampled throughout the year. Although this could have led to a bias, there is no obvious 
cluster of the four positive patients with a particular season, and only one of the four 
was sampled in the "enterovirus season", late summer and early autumn. Virus-positive 
T1D patients were sampled in August, November (2) and February.
Table 2. SNP genotypes 1SAOfo and MDA5
polymorphisms.
Patient Virus MDA5 OAS1
1 + GA AA
2 - GA GA
3 - GG GA
4 + AA AA
5 - AA GG
6 - GA AA
7 + GA GG
8 - GA GA
9 - AA AA
10 + GA AA
Control Virus MDA5 OAS1
1 GG AA
2 - AA GA
3 - GA GA
4 - GA GA
5 - AA GG
6 - AA GA
7 - GG GA
8 - AA AA
9 - GA GA
10 - GA AA
11 - GA GA
12 - GA AA
13 - GA AA
14 - GA GG
15 - GA AA
16 - AA GA
17 - GA AA
18 - GA AA
19 - GG GG
20 - GA AA
Abbreviations: + enterovirus-positive; 
- enterovirus-negative.
Prolonged enterovirus infection in T1D 
patients.
Little is known about the stage of 
enterovirus infection in T1D patients 
that are enterovirus-positive at onset of 
the disease. Therefore, we investigated 
whether virus could be detected in throat 
or stool, which gives some indication 
of the duration of infection. Throat and 
stool samples were collected at the same 
day as blood samples were drawn. The 
samples were tested by RT-PCR (throat) or 
virus isolation and NASBA (fecal samples). 
Throat samples were invariably negative 
as was virus isolation, whereas enterovirus 
was detected by NASBA in only 1 of the 4 
virus positive patients, suggesting that 
the infections were in a late stage or of 
prolonged duration16 (Table 1).
Detection of IFNa
A previous study found that T1D patients 
have elevated levels of IFNa in their blood, 
which correlated with the presence of 
enterovirus7. Using ELISA, we investigated 
whether presence of viral RNA was linked 
with increased IFNa levels in blood, but no 
association was found (Table 1).
Enterovirus and genetic risk factors.
The (prolonged) presence of viral RNA 
in PBMC of T1D patients suggests some 
intrinsic susceptibility to enterovirus 
infection or an inability to clear the 
infection. Some of the genetic risk factors 
that predispose for T1D, play a role in 
antiviral defence and may thus be involved
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in aberrant clearance of enteroviruses. Therefore, we tested whether the presence of 
viral RNA linked with HLA-DR type and(or) with SNPs in either MDA5 or OAS1.
HLA-typing was performed on DNA isolated from PBMC. The T1D predisposing 
HLA-DR4 and to a lesser extent DR3 were more abundant in the T1D population; 9 of 
the 10 (90%) T1D patients had a DR3 and/or DR4 allele versus 13 out of 20 (65%) in the 
control group (Table 1). The "high risk" DR3/DR4 or DR4/DR4 phenotype was found in 3 
of 10 (30%) T1D patients: 2 of 4 (50%) virus-positive, versus 1 of 6 (17%) virus-negative 
patients, but not in any of 20 controls. All virus-positive patients had a DR4 allele.
The MDA5 and OAS1 polymorphisms were assessed by amplification of the 
region containing the SNPs, followed by sequencing of the PCR product. Smyth et al. 
found a higher prevalence of AA and GA in MDA5 in T1D patients (AA + GA 87.4 % in T1D 
patients, 85.5 % in controls)24. We found that the T1D-associated AA and GA genotypes 
in MDA5 are present in 3 and 6 of 10 patients (90%) and in 5 and 12 of 20 controls 
(85%), respectively. Heterozygosity was most prominent in virus-positive patients (3 of 
4, 75%) (Table 2). The remaining virus-positive patient had an AA genotype. Three out 
of 6 virus-negative patients (50%) had a GA genotype, 2 (33%) a GG genotype and 1 
(17%) an AA genotype (Table 2). Thus no major differences were observed in the MDA5 
polymorphism between virus-positive and virus-negative patients.
Field and colleagues reported increased prevalence of GG and GA in OAS1 
in the T1D group (GG + GA 58.7 % in T1D patients, compared to 50.3% in controls)22. 
However, Smyth et al. did not And increased prevalence for GG and GA genotypes in T1D 
patients28. We found that T1D-associated GG and GA genotypes of OAS1 were present 
in 2 and 3 of 10 T1D patients (50%) and in 3 and 8 out of 20 controls (55%), respectively 
(Table 2). Thus, no obvious differences were observed between T1D patients and the 
control group. Remarkably, only 1 of 4 (25%) virus-positive patients had a GG or GA 
genotype compared to 4 out of 6 (67%) virus-negative T1D patients (Table 2). Due to the 
small sample size, future studies in which more T1D patients are included are required 
to shed more light on the association of MDA5 and OAS1 SNPs with T1D, and with the 
presence of viral RNA in PBMCs of T1D patients.
Discussion
In this study we demonstrated the presence of enterovirus RNA in blood of 4 out of 10 
T1D patients early after onset. Viral RNA was mainly detected in PBMC: Throat samples 
were negative and only in 1 case the stool was also positive. An HLA-DR4 allele was 
present in all enterovirus-positive patients, yet no obvious link with polymorphisms in 
MDA5 or OAS1 was found.
Four out of 10 T1D patients were found positive for enterovirus RNA in PBMCs. 
We have used very sensitive methods for virus detection; at least 0.002 to 0.01 TCID50 
is detectable with the PCR and NASBA, depending on the enterovirus strain. All patient 
samples were tested with 2 different PCRs and NASBA, to confirm the outcome. However, 
we can not exclude that the 6 virus-negative T1D patients had RNA levels in their PBMCs 
that were below the detection limit of the PCRs and NASBA.
The finding of viral RNA in blood of T1D patients corresponds with results of 
previous studies6'9, n'13. Most studies have examined presence of enteroviral RNA in 
blood using whole blood, plasma or serum samples. So far, only one study determined 
the presence of enteroviral RNA specifically in PBMCs of T1D patients8. Our study shows
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that the viral RNA is mainly present in the fraction of PBMCs, as only 2 out of 4 PBMC- 
positive patients were also positive in plasma. This indicates that the PBMC-fraction may 
be the most important fraction to consider when screening for enterovirus positivity in 
blood. That viral RNA is mainly detected in PBMCs suggests either infection of cells of the 
immune system or uptake of virus-infected cells or cell-debris, e.g. by dendritic cells as 
we demonstrated in vitro29. Infection of immune cells versus uptake of virus-containing 
material may have different consequences for immune functioning (impairment versus 
immune activation). Whether, and how altered immune homeostasis in the blood may 
affect immune homeostasis in the pancreas, thereby contributing to T1D development, 
requires further investigation.
During the early phase of infection, enterovirus is excreted in throat and 
gastrointestinal tract. In this phase, the virus can sometimes also be detected in blood, 
but this is highly exceptional and occurs mainly during a severe infection30, 31. We found 
no enterovirus RNA in blood of healthy controls, a finding that corresponds with other 
reports, where no or very few controls were found enterovirus RNA-positive in blood6, 7 
n '13. During convalescence, virus is only detected in stool and fecal excretion can last for 
up to 3 months16. Throat- and 3 of 4 stool samples were negative in the 4 T1D patients 
that were positive in PBMCs, arguing against acute infection. Whether this concerns late 
stage of infection or even a prolonged duration remains to be determined.
Occurrence of prolonged enterovirus infection in T1D patients has also been 
suggested by Hyöty and co-workers32 who provided evidence for ongoing enteroviral 
infection in gut mucosa of T1D patients. Detection of enterovirus antigens and RNA in 
pancreatic islets from T1D patients also suggests inadequate clearance3'5.
Assuming that T1D patients or individuals at risk for T1D have delayed clearance 
of enteroviruses, the question raises whether, and which genetic factors predispose to 
it. Thereto we selected genetic risk factors for T1D which play a role in antiviral defence 
and investigated their linkage with viral presence. The most obvious risk factors are 
HLA-DR and molecules of the IFN pathway. It was to be expected that an association 
was found with the well known "high risk" alleles DR3/DR4 and DR4/DR4, but a linkage 
with one of these phenotypes was not found. DR4 was present in all 4 virus-positive 
patients. A previous study reported impaired cellular immune reactivity against CVB4 in 
T1D patients, but this was not associated with either HLA-DR3 or HLA-DR433. Published 
data is inconsistent regarding HLA and virus positivity: Andreoletti et al. found DR3/DR4 
in 2 out of 6 virus-positive T1D patients and 3 carrying a DR3 allele13, whereas Craig et al. 
reported that DR3 is significantly less prevalent in virus-positive T1D patients9. Clearly, 
further studies are required to address the association, but it seems unlikely that a link 
with viral presence will be found.
Among the other genetic risk factors, MDA5 and OAS1 are of ultimate interest, 
because they are involved in the innate response against RNA viruses, e.g. enteroviruses. 
No major differences were found between the T1D and control group, and between 
virus-positive and virus-negative T1D patients in particular. Again, a linkage seems 
unlikely, but the sample size is small.
In conclusion, our data indicate that T1D patients may have delayed enterovirus 
clearance, with virus detected predominantly in PBMC. No obvious linkage was found 
with polymorphisms in MDA5 or OAS1, yet HLA-DR4 was present in all enterovirus- 
positive patients. Further studies are required to elucidate the intriguing relationship
116
Enterovirus in PBMCs of type 1 diabetes patients
between enterovirus infection, genetic determinants of antiviral immunity and risk of 
acquiring T1D.
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Summary
T ype 1 diabetes (T1D) is a chronic endocrine disorder in which the insulin- producing ß-cells in the pancreas are destroyed. It is often accompanied by autoimmunity to ß-cell constituents and is therefore regarded as an autoimmune disease. Both genetic factors and environmental factors play a role in T1D etiology1. 
Enteroviruses, particularly those of the human enterovirus B (HEV-B) species such as 
coxsackie B viruses (CVBs) and echoviruses (EVs), are considered to be an environmental 
factor in the development of T1D2, 3.
HEV-Bs have been associated with T1D etiology by several findings, including (i) 
prospective studies in T1D patients, non-affected siblings and unrelated controls, which 
showed increased numbers of HEV-B infections in T1D patients, (ii) case-control studies 
which showed the presence of HEV-B RNA in blood of T1D patients at onset of disease, 
in the prediabetic stage and in established T1D and (iii) the presence of HEV-B in ß- 
cells of T1D patients at autopsy and their ability to infect and damage pancreatic islets 
in vitro2 3. Several, not mutually exclusive mechanisms have been proposed via which 
these viruses may initiate or accelerate T1D, (i) HEV-Bs can directly infect the pancreatic 
ß-cells and destroy them by their lytic life cycle, (ii) HEV-B induced inflammation results 
in bystander activation of innate immune components resulting in chronic inflammation 
which is harmful for ß-cell function and viability, (iii) autoimmune responses develop in 
the pro-inflammatory microenvironment of the infected pancreatic islets, (iv) molecular 
mimicry, whereby immune responses directed against the virus also recognize self­
antigens and therefore induce autoimmunity4.
Inflammation in pancreatic islets is common in type 1 diabetes patients, and 
immune cells, such as T cells, macrophages and dendritic cells can be detected in the 
islets of type 1 diabetes patients5. The development or acceleration of type 1 diabetes 
might depend on the balance between autoreactive CD4+ and CD8+ effector T cells and 
regulatory T cells (Treg); a balance which is predominantly decided by dendritic cells 
(DCs). DCs are the professional antigen-presenting cells (APCs) of the immune system 
and play a decisive role in initiating immune responses and maintaining self tolerance. 
They do not only participate in innate immunity, but also initiate and control adaptive 
immunity6.
In order to preserve tolerance to self, but fight invading pathogens, DCs need 
to distinguish between Ags in dangerous or steady-state conditions. To this end, DCs 
express a variety of pattern recognition receptors (PRRs), that sense pathogen-associated 
molecular patterns (PAMPs), such as viral double-stranded RNA (dsRNA), or danger- 
associated molecular patterns (DAMPs)7, 8. Upon triggering of these PRRs, the DC will 
start a process called maturation, which includes phenotypical and functional changes. 
Mature DCs are able to generate immune responses via the activation of T cells, whereas 
immature DCs or DCs receiving anti-inflammatory signals in general induce tolerizing 
responses when encountering T cells6, 9.
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Summary of main findings
In this thesis, the interaction between pancreatic islets, enteroviruses and DCs has been 
explored in order to shed light on the putative mechanism of HEV-B-induced T1D.
As stated above, sensing of pathogens or pathogen-associated danger through PRRs is 
crucial for DCs to determine whether immune responses need to be initiated. In light 
of this, chapter 2 gives a concise overview of the expression of different PRRs that are 
involved in viral RNA sensing in DC subsets under pro-inflammatory and steady-state 
conditions. We focussed on viral RNA sensors, such as Toll-like receptor (TLR) 3, 7 and 
8, and RIG-I and Mda5. Furthermore, cross-talk between different DC subsets was 
investigated and a mechanism by which plasmacytoid DCs (pDCs) protect myeloid DCs 
(mDCs) from viral infection via the production of IFNs is described. Chapter 3 deals with 
the susceptibility of DCs to infection with HEV-B species. CVBs were unable to infect 
DCs or influence their function, probably due to lack of the viral entry receptor, CAR 
(coxsackie and adenovirus receptor). EVs, on the contrary, could productively infect 
DCs, resulting in loss-of-function, such as diminished responses upon subsequent TLR- 
triggering and ultimately loss of viability. Chapter 4 reveals that DCs can be protected 
from infection when matured with the double-stranded RNA (dsRNA) analogue poly I:C. 
However, DCs matured with other TLR-ligands were not protected from infection. dsRNA 
is formed in HEV-B-infected cells during virus replication, and we provide evidence that 
CVB-infected cells are efficiently phagocytosed by DCs leading to upregulation of type 
I interferons (IFNs) and IFN-stimulated genes (ISGs) resulting in an antiviral state, that 
also protects DCs from subsequent infection. In chapter 5 the interaction between CVB- 
infected cells and DCs is further explored, with a particular focus on the interaction 
between primary human pancreatic islets and DCs. We report that human pancreatic 
islets are efficiently phagocytosed by DCs, and this also holds true for porcine islets and 
the murine insuloma cell line Min6. Uptake of CVB-, but not mock-infected cells resulted 
in the induction of ISGs and offered DCs protection from subsequent EV-infection. 
This required the presence of viral RNA within CVB-infected islets, and furthermore 
depended on production of IFNs by the DCs. These findings show that antiviral immune 
responses are generated by DCs upon encountering HEV-B-infected islets, and provide 
important new insights in the possible role of DCs in T1D development. In chapter 6 we 
examined the direct responses of pancreatic islets to HEV-B infection. Primary human 
islets that were infected with HEV-B induced antiviral immune responses, as indicated 
by the production of ISGs. Furthermore, mRNA expression of several cytokines and 
chemokines was induced, and importantly, these were also detected in the supernatant 
from infected islets. These data imply that islets, upon infection with HEV-B species, 
start antiviral immune responses and produce a variety of cytokines and chemokines 
that can attract and/or activate components of both the innate as well as the adaptive 
immune system. Although generated in order to control viral infection, these responses 
may under certain circumstances maintain or aggravate inflammation and might even 
trigger development of autoimmune processes against ß-cells.
Imbalance in the immune system may play an important role T1D development, 
and although the pancreatic cells are targeted during T1D, players outside the pancreas 
can be involved as well. Chapter 7 focuses on the presence of enteroviruses in PBMCs 
of T1D patients. We show that enterovirus RNA can be detected in 4 out of 10 T1D
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patients, but not in any of the controls. Merely complete absence of viral RNA in throat 
and stool samples suggests that the presence of RNA in PBMCs may concern prolonged 
enterovirus infection. What the role of prolonged infection in T1D is, remains to be 
determined; however, the continuous immune stimulation that this prolonged infection 
entails, could affect the balance in the immune system.
Putative mechanism of HEV-B-induced type 1 diabetes
Here, a putative model for HEV-B induced T1D is proposed and discussed in relation to 
the data presented in this thesis and existing data. The model will be shortly introduced 
and the separate steps in the putative disease process will be further addressed in a 
step-wise manner. Although I will focus on the role of HEV-B in T1D, this does not exclude 
the existence of other possible triggers in T1D etiology.
Increasing evidence suggests that HEV-B infection and subsequent ß-cell death 
is involved in T1D etiology, and infection of the pancreatic islets may be the initiating 
step in HEV-B induced T1D. Based on this assumption and the results from this thesis we 
propose a putative model for HEV-B induced T1D that originates at infection of islets (Fig. 
1). Infection of islets by HEV-B will result in rapid replication of the virus, and host-cell 
modifications will be induced by the viral proteins leading to cell damage and ultimately 
cell death (Fig 1., step 1). The resulting inflammation causes ß-cell damage, and will 
attract various immune cells. Upon activation, these will also produce cytokines and 
thereby mediate further ß-cell damage and inflammation (Fig 1., step 2, 3). Infection 
and inflammation also facilitate development of autoimmune responses, as DCs will be 
attracted to the islets. They will phagocytose HEV-B infected ß-cells and start maturation 
after sensing PAMPs and DAMPs in the infected ß-cells and in the microenvironment. 
Additional signals, such as pro-inflammatory cytokines from surrounding pancreatic cells 
and immune cells may add to the maturation process (Fig 1., step 4, 5). Matured DCs will 
migrate to the draining lymph nodes where they will activate (autoreactive) T cells in a 
susceptible host. Activated, autoreactive T cells subsequently migrate to the islets where 
they initiate autoimmune processes that facilitate destruction of ß-cells, ultimately 
resulting in clinical T1D (Fig 1., step 6, 7). Below, the several steps of the proposed model 
will be discussed with regard to the data described in this thesis and existing data in 
literature.
Step 1: HEV-B infection of pancreatic ß-cells
The first step in our model is the infection of pancreatic islets with HEV-Bs. We and 
other groups have shown that human pancreatic islets can be infected with CVBs and 
other HEV-Bs in vitro (Chapter 5 and 6 and references10-12). In line with this, expression 
of several HEV-B virus receptors, such as CAR and the integrin a vß3 in pancreatic islets 
has been reported12, 13.
Importantly, evidence exists that HEV-B infections also occur in T1D patients in 
vivo. Viral RNA and viral proteins can be detected in the islets of T1D patients, whereas 
this is not the case for healthy controls13-16(Fig 2). This raises the question how HEV-B can 
spread to the pancreatic islets. HEV-Bs spread via the fecal-oral route and their primary 
replication occurs in the gut. From the gut, a direct connection with the pancreas exists: 
the pancreatic duct, from where pancreatic enzymes are released into the digestive tract
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Figure 1. Putative mechanisms of HEV-B-induced T1D.
Virus infection of pancreatic islets (1) results in the production of cytokines and chemokines that induce 
an antiviral state but may also have damaging effects on ß-cells (2). Various immune cells, including macro­
phages, NK cells and DCs are attracted and activated due to the infection and cytokines produced by these 
cells can have adverse effects on ß-cell function and viability (3). Furthermore, NK cell-mediated killing of 
infected ß-cells may occur (3). DCs phagocytose infected ß-cells and get activated by the signals provided by 
the infected cells (e.g. viral RNA and other PAMPs and DAMPs)(4). Additional influence on DC maturation is 
exerted via surrounding immune cells (macrophages, NK cells), duct cells, and the pro-inflammatory environ­
ment that has arisen (5). Maturing DCs migrate to the draining lymph nodes, where they activate autoreactive 
T cells (6 ). Activated, autoreactive T cells subsequently migrate to the islets where they initiate autoimmune 
processes that facilitate destruction of ß-cells, ultimately resulting in clinical T1D (7).
and via which the virus may reach the pancreas. Interestingly, prolonged HEV-B infection 
in the gut has been suggested to occur in T1D patients, and the gut may thus provide 
a HEV-B reservoir17. Alternatively, virus can spread via the blood stream (viremia), and 
thereby target secondary organs, including the pancreas. During severe infections in 
neonates, virus is known to infect the pancreas, causing pancreatitis. Viremia is common 
during severe infections, and blood may thus be the transport route of the virus. 
Interestingly, in T1D patients, or prediabetic individuals (at risk to develop T1D), HEV-B
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can be detected in blood, and virus may spread to the pancreas via this route.
HEV-B infection of particularly ß-cells within the pancreatic islets, has been 
shown by Dotta and colleagues (Fig. 2), and was also suggested by Richardson et a/.14, 
15. This suggests that ß-cells might be the primary target of HEV-B, and could explain 
why ß-cells are destroyed in stead of a-cells, 5-cells or PP-cells for example. Infection 
of ß-cells may furthermore stimulate autoimmune responses against ß-cells, as more 
ß-cell associated Ags may be released and/or presented in the presence of danger 
signals. Additionally, ß-cells are sensitive for cytokine-induced cell death (discussed in 
the section "Toxic effects o f pro-inflam m atory cytokines and chemokines on ß-cells"), 
and this may also add to specific destruction of ß-cells, but not other islet cells. That ß- 
cell damage and cell death may be the initial step in T1D etiology is further supported 
by studies using the drug streptozotocin (STZ). This drug induces cell death, particularly 
of ß-cells, and administration of multiple low doses of STZ induces immune aggression 
against ß-cells and development of autoimmune T1D18, 19.
Step 2: Production of inflammatory mediators in the pancreas
Interferons: a two-sided sword?
Infection of pancreatic islets will result in rapid virus replication and antiviral responses 
will be induced in the islets, such as the production of type I IFNs. These IFNs are an 
important first defense from the host against viruses. IFNs induce antiviral responses in 
an autocrine and paracrine manner and thereby restrict virus replication in primed cells. 
IFNs can be detected in the islets of T1D patients but not of controls, and this may reflect 
a response to virus infection in T1D15, 20, 21. That the IFNs are critical for host defense 
is shown by Flodström and colleagues who reported that mice with a dysfunctional 
IFN-response in their ß-cells develop rapid and fullblown diabetes upon CVB infection, 
due to complete destruction of ß-cells22, 23. This may represent the type 1B diabetes, in 
which rapid decrease of ß-cell mass is observed, which could be the result of massive, 
unrestricted virus replicaton in ß-cells. Clearly, massive virus replication is inhibited
Fig. 2. Enteroviral infection of pancreatic ß-cells.
Confocal microscopy images from islets of Langerhans from a type 1 diabetes patient demonstrate that ß- 
cells (A-C), but not a-cells (D-F), are positive for VP-1. Cells stained in green are positive for insulin (A and C) 
and glucagon (D and F), those stained in red are positive for VP-1 (B, E, and F), and those stained in yellow are 
double-positive cells for insulin and VP-1 (C). (Scale bars: 18^m.) Reprinted from Dotta et al., PNAS 2007 with 
permission from the authors, © 2007 by The National Academy of Sciences of the USA.
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by IFNs. However, IFNs can work as a two-sided sword; excessive IFN-stimulation can 
stimulate the induction of diabetes. Prolonged administration of IFNs, for example to 
individuals with chronic hepatitis infection, may cause overt diabetes (reviewed by 
Devendra & Eisenbarth24). How IFNs mediate T1D induction is unclear. One possibility 
is direct negative effects of IFNs on ß-cell function by inhibition of insulin production 
and secretion25, 26. In this situation the ß-cells will be continuously stimulated to produce 
more insulin, and this results in cell stress such as ER-stress, which can lead to cell death. 
Indirect effects of IFNs on islet function or viability are the induction of cytokines and 
chemokines that can subsequently affect islets (discussed in the section "Toxic effects 
o f pro-inflam m atory cytokines and chemokines on ß-cells"). Furthermore, IFNs can also 
mediate the chemotaxis of several leukocytes, and stimulate their activation, survival 
and proliferation27-30. Another way how IFNs can promote disease development is 
via stimulation of the adaptive immune system. IFNs differentially affect DC function 
and maturation depending on the time, amount and duration of IFN-stimulation31-34. 
Additionally, IFNs were shown to be crucial for autoimmune transition in mice with 
autoreactive T cells35. Furthermore, IFNs play an important role in systemic lupus 
erythematosus (SLE) development via their actions on DCs36-38. Thus IFNs could take 
part in diabetes development via several ways, yet the exact mechanism remains to be 
elucidated.
Although IFNs are produced in response to viral infection of pancreatic islets 
in all individuals, it is currently unknown why some individuals develop T1D, whereas 
others do not. One of the underlying reasons might be whether prolonged, or chronic 
IFN production occurs, and this may be directly related to the prolonged or chronic 
presence of HEV-B. Both successive as well as prolonged or chronic HEV-B infections 
have been suggested to occur more often in T1D patients than healthy controls (Chapter 
7 and references17, 39). The production of IFNs in the islets prevents rapid virus-induced 
cytolysis and will largely restrict virus replication. But in this situation, the virus may 
persist and replicate at low levels, thereby maintaining continuous IFN production that 
mediates T1D induction. Additionally, DCs that encounter HEV-B infected islets will also 
produce IFNs (Chapter 5), thereby possibly contributing to IFN-mediated ß-cell damage. 
Differences in genetic background of individuals also influence antiviral responses 
(discussed in the section "Predisposition to T1D").
Toxic effects o f pro-inflam m atory cytokines and chemokines on ß-cells 
Virus infection of pancreatic islets results in the production of several pro-inflammatory 
cytokines and chemokines (Chapter 6), and as already noted above, virus-induced IFNs 
can further stimulate the production of several cytokines and chemokines (Chapter 6 and 
references40-44). These cytokines and chemokines serve to start inflammatory processes 
and attract immune cells in order to fight virus infection, yet they can have adverse 
effects on ß-cell function and viability. TNF-a, IL-1ß and IFN-y, for example, are toxic to 
ß-cells either alone or in combination45-48. Thus virus-induced cytokine production may 
contribute to ß-cell death.
Step 3: Chemoattraction and activation of incoming immune cells and progression to 
chronic inflammation
HEV-B induced cytokines which are produced upon infection of islets include several 
chemokines, such as IP-10, RANTES, IL-8, eotaxin and others (Chapter 6). These
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chemokines will mediate the chemoattraction of migratory immune cells via binding of 
the corresponding chemokine receptor. Several different immune cells will be attracted 
by the above-mentioned chemokines, and these include monocytes, macrophages, T 
lymphocytes, NK cells and DCs27, 49.
Immune cells that have migrated towards the inflamed, infected pancreas can 
be activated by cytokines that are produced in the pancreas. For example, IFNs and IL- 
15 are known to stimulate NK cell activity27, IL-8 activates neutrophils49, and IFN-y and 
TNF stimulate macrophage activity and nitric oxide production. Activated immune cells 
produce additional pro-inflammatory cytokines and other inflammatory mediators such 
as nitric oxide, that are toxic to ß-cells, and this process may be aggravated due to the 
pro-inflammatory microenvironment that has arisen. PAMPs, DAMPs and (modified) 
Ags that are released from (infected) dying ß-cells can contribute to excessive activation 
of immune cells leading to a vicious circle of enhanced inflammation, continued ß-cell 
death, and release of more inflammatory mediators. When inflammation is not put to 
a stop, ß-cell mass might further decrease until clinical T1D arises. When on the other 
hand inflammation declines and ß-cell proliferation is stimulated, the homeostasis in the 
islets may slowly return and ß-cell mass might be largely restored, without transition 
to clinical T1D50. What determines whether inflammation is put to a halt is not exactly 
known, but prolonged and/or successive infection may play a role (discussed in the 
section "Interferons: a two-sided sword?'), and furthermore, the genetic background of 
an individual is important, as will be discussed below.
Step 4: Phagocytosis of infected ß-cells by DCs
DCs are critical players in both innate and adaptive immunity and are crucial to maintain 
tolerance to self. In human pancreatic islets DCs are present in low numbers under 
steady-state conditions; however, as ß-cell destruction ensues leading to T1D there is 
an increase in DC-infiltrate5, 51. In chapter 4 and 5 it is shown that DCs can phagocytose 
HEV-B infected cells, and importantly, also pancreatic islets are efficiently phagocytosed. 
We showed that upon engulfment of infected cells, the DCs will start innate responses 
such as IFN production. DCs may also produce other cytokines and chemokines upon 
engulfment of infected islets, although this has not been studied. Induction of innate 
responses depended on the presence of (ds)RNA in the HEV-B infected cells, suggesting 
that dsRNA intermediates formed during virus replication may serve as a PAMP. 
That phagocytosis of infected ß-cells may be an important event in T1D etiology is 
further supported by a mouse study from Horwitz and colleagues. They showed that 
phagocytosis of CVB-infected ß-cells by APCs is crucial for the induction of T1D. Although 
caution should be taken when interpreting mouse data due to the differences that exist 
between mice and humans (see "Future Challenges and Treatment of T1D"), these data 
do support our model.
It is currently unknown what signals on islets/ß-cells facilitate their uptake by 
DCs. Several "eat-me" signals have been described, such as phosphatidyl serines, which 
are expressed on apoptotic and/or necrotic cells52, 53. It is known that under steady-state 
conditions, antigens from ß-cells are phagocytosed by APCs that subsequently migrate 
to the draining lymph nodes54, 55. Presentation of ß-cell peptides under steady-state 
conditions results in deletion of autoreactive T cells and prevents the development of
T1D56-59.
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Step 5: The difficult decision a DC has to make
Whether a DC will induce immune responses or tolerance depends on the maturation 
status of the DC, which is influenced by PRR-stimulation and other signals from the 
microenvironment. Viral RNA, viral proteins, modified host proteins and other virus- 
associated PAMPs and DAMPs may all contribute to maturation induction. Preliminary 
data revealed that DC maturation does not necessarily occur upon in vitro phagocytosis 
of HEV-B-infected cells (Chapter 5). A reason for the observed lack of maturation can be 
the presence of conflicting signals within the infected cells. Although viral PAMPs and 
DAMPs contribute to maturation induction, other signals may inhibit DC maturation. 
For example, apoptotic cells are generally considered to inhibit DC maturation60, 61, 
and apoptotic hallmarks are observed in enterovirus-infected cells62, 63. Additionally, in 
the past years it has become evident that phenotypically mature DCs can also induce 
tolerance and vice versa, thus the picture on DC maturation is not fully complete64, 65. 
In order to understand the interaction between DCs and CVB-infected islets and the 
subsequent (auto)immune responses, further dissection of the players that dictate 
immunogenicity is required. These include viral PAMPs and DAMPs, but also signals 
derived from damaged (infected) ß-cells. Whether a particular (self)Ag will be presented 
by a mature DC may even be determined by how and where the Ag and these different 
signals are sensed inside the DC66.
It should be taken into account that the encounter of infected ß-cells in the 
pancreas occurs in an environment where DCs and HEV-B-infected ß-cells are not the 
only cells present. Signals from the microenvironment greatly influence DC maturation. 
For instance, DAMPs associated with damaged ß-cells, such as high-mobility group box 
1 (HMGB1), can influence the DC. Maturation can furthermore be influenced by pro- 
inflammatory cytokines produced by surrounding immune cells, infected duct cells 
or endothelial cells. Duct cells, for example, produce TNF-a upon CVB-infection (G. 
Vreugdenhil, unpublished observation), and CVB-infected endothelial cells produce IL- 
1ß, IL-6, IFNs and others67. These cytokines may add to the process of DC maturation. 
Furthermore, also cell-cell contact-dependent signaling influences DCs68. Future 
studies aimed at dissecting the requirement for DC maturation upon phagocytosis of 
CVB-infected islets could provide insight in the mechanisms underlying T1D etiology. 
Monitoring DC-responses upon addition of particular cytokines or (virus-stimulated) 
leukocytes to co-cultures of DCs and CVB-infected islets are a good option to investigate 
the human situation. This will provide important insight in the role of DCs in the disease 
process, but may also yield new targets to interfere with autoimmune induction.
Virus infection not only affects ß-cell function and viability, but can also affect 
DCs. EVs, but not CVBs, are able to infect and replicate in DC in vitro, thereby disabling DC 
responses and resulting in cell death (Chapter 3). Further studies revealed that IFNs can 
protect DCs from EV-infection, and also phagocytosis of HEV-B infected cells results in the 
protection of DC from subsequent infection (Chapter 2, 4 and 5). Whether EV infection 
of DCs occurs in the pancreas in vivo and how it could contribute to T1D development is 
currently unknown. However, the production of IFNs by infected islet cells may provide 
some means of protection of DCs that migrate into pancreatic islets. Therefore, it seems 
unlikely that direct EV infection of DCs will play a major role in T1D etiology in humans. 
Moreover, CVBs are unable to infect DCs and are associated with T1D as well.
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Step 6: The induction of autoimmunity
DCs that have phagocytosed damaged (HEV-B infected) ß-cells migrate to the draining 
lymph nodes. Depending on the maturation status of the DC, it will either stimulate 
corresponding T cells, or induce tolerance. Responses against viral Ags will be generated, 
and because (modified) self-Ags are phagocytosed and presented by these DCs, 
autoimmune responses may be provoked. This also depends on the T cell repertoire of 
the host. Whether autoreactive T cells are activated by DCs that have phagocytosed HEV- 
B infected, damaged ß-cells, has not been investigated so far. One of the future challenges 
will be to determine whether this occurs, what the requirements for activation are, and 
if, and how this may be inhibited or prevented in individuals at risk to develop T1D.
Both activated autoreactive CD8+ effector T cells and Tregs can be found in 
the pancreas of T1D patients69. The balance of different T cell subsets, such as CD4+ 
and CD8+ effector T cells and Tregs, in the pancreas is critical in the development of 
autoimmunity70. Therefore, not only the induction of autoreactive T cells on itself, but 
also the presence and number of Tregs determines whether an individual will develop 
autoimmune T1D or not.
Step 7: Full-blown autoimmune responses in the pancreas
Once autoreactive immune cells are activated, they will start proliferating and migrate 
towards the pancreas. Upon arrival in the islets, autoreactive T cells will recognize 
and kill ß-cells that express the particular self-Ag. This dramatically reduces ß-cell 
mass, and will additionally result in the accumulation of apoptotic ß-cells. Self-Ags can 
be modified during the process of apoptosis, and this provides new self-Ags that can 
aggravate the autoimmune process. Furthermore, dying ß-cells may undergo secondary 
necrosis, thereby releasing PAMPs and DAMPs that potentiate the (innate and adaptive) 
inflammatory processes in the islets.
Controversy remains as to whether adaptive immune responses are required 
for T1D development, or are merely an effect of the disease process71. If autoimmunity 
is not required, the strong association of HLA, PTPN22 and CTLA4 with T1D will still have 
to be explained. The involvement of autoimmune processes may speed up the process 
of ß-cell damage and can strengthen the vicious circle of ß-cell death. Thus, adaptive 
immune mediated responses may potentiate inflammation and disease progression.
Presence of enterovirus in blood: a role in T1D etiology?
Local imbalance in immune homeostasis in the pancreatic islets may be a critical factor 
in the development of T1D, and this can be initiated by enterovirus infection of the islets. 
This does not exclude that cells and signals from outside the pancreas can influence 
homeostasis in the pancreas. This is fortified for example by the altered cytokine levels 
of IP-10 and IFN-a in the serum of T1D patients72-74. It is unlikely that events outside 
the pancreas, such as altered immune homeostasis in the blood, are the major events 
in T1D initiation, because they cannot explain why specifically the ß-cells, and not cells 
in the kidney, liver or other organs are destroyed. Thus, even though alterations in the 
remainder of the body could largely contribute to T1D, events in the ß-cells probably 
initiate T1D development. The increased cytokine production in blood of T1D patients 
may prime immune cells that subsequently migrate into the pancreatic islets, which may
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alter the responses of these immune cells once they encounter infected or damaged 
ß-cells. The source of the enhanced serum-cytokines is not well-defined, and could 
originate from tissues which secrete cytokines into the blood stream, but they may also 
be produced by PBMCs in the blood. In this regard, it is interesting that HEV-B RNA can 
be detected in PBMC and serum of T1D patients (discussed in chapter 7). This raises two 
questions, i) whether and how these viruses can infect immune cells and ii) what the 
responses of PBMCs are upon infection.
With regard to the first question, it is known that PBMCs can not be directly 
infected with coxsackieviruses in vitro75'77. However, Fcy-receptor (FcyR)-mediated 
uptake of coxsackievirus-antibody complexes by PBMCs, monocytes and pDCs has 
been reported78, 79 and could be in place during viremia. Alternatively, (prolonged) local 
enteroviral infection, such as described in the intestine of T1D patients17 might serve as 
a virus reservoir, from which several PBMCs (e.g. monocytes, macrophages, DCs) might 
phagocytose virus-containing material. The detection of enterovirus RNA in peripheral 
blood may thus reflect antibody-dependent infection of immune cells or uptake of 
particles/RNA in the absence of active virus replication within PBMCs.
With regard to the second question, FcyR-mediated Ab-dependent activation of 
PBMCs, monocytes and pDCs, results in IFN-a production78, 79. This has been confirmed 
in our laboratory using PBMCs and pooled human serum containing anti-CVB Abs. We 
observed production not only of IFN-a, but many other pro-inflammatory cytokines and 
chemokines, such as IL-6, IL-8, IP-10, MIP-1ß and others upon stimulation of PBMCs with 
CVB in the presence of human serum (unpublished observations). Thus presence of virus 
in the blood provokes inflammatory responses which can influence homeostasis of the 
immune system. Upon phagocytosis of infected cells by blood cells, pro-inflammatory 
cytokines and inflammatory mediators may also be produced. We have described the 
induction of IFNs and ISGs in DCs upon phagocytosis of infected cells (Chapter 4 and 5), 
and also macrophages and monocytes can respond to infected cells with the production 
of cytokines such as IL-1ß, IL6 and TNF-a and inflammatory mediators such as nitric 
oxide. To recap, interactions between enteroviruses and PBMCs may result in immune 
activation in which cytokines such as IFNs are produced. Thus although the local events 
in the islets may be critical in T1D development, inflammatory processes outside the 
pancreas may also influence the disease process.
Predisposition to  T1D
One of the major unanswered questions that remains is: Who develops T1D? In our 
proposed model, T1D will arise/persevere due to flaws in restraining inflammation. 
Some important questions in this context are i) Why is inflammation not restrained? ii) 
Why does autoimmunity develop, in other words, how is peripheral tolerance broken? 
It will be a major challenge to answer these questions, because the answers probably 
depend on both the complex genetic background of people at risk for diabetes and a 
combination of environmental factors such as when and how many encounters with 
HEV-Bs an individual will face. Below some of the genetic factors that are involved in T1D 
etiology will be discussed.
Altered virus clearance could well play a role in T1D development, since prolonged 
or successive HEV-B infections are associated with T1D (chapter 7 and references17, 39).
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As discussed above, this may potentiate prolonged or chronic IFN stimulation, which 
can add to T1D development (section "Interferons: a two-sided sword?'). With regard 
to the putative role of HEV-B in T1D development, it is interesting that single nucleotide 
polymorphisms (SNPs) have been identified in genes which are involved in the innate 
antiviral response. Several SNPs that alter the risk to develop T1D have been found in 
the Mda5 gene80-82. The Mda5 protein is a RIG-I-like helicase (RLH) that is involved in the 
recognition of enterovirus RNA and induces downstream signaling and IFN production 
(S. Hato, unpublished data). Because it is crucial for enterovirus sensing, it may be an 
important gene in HEV-B-induced T1D. Alterations in Mda5 expression levels or function 
may have massive consequences for timing and amount of IFNs that are produced, 
and may therefore influence the antiviral response. A study by Liu et a/. suggests that 
people with increased risk for T1D have higher expression levels of Mda5, and this may 
result in increased IFN production81, 83. This can add to T1D etiology via several ways, as 
described above. On the other hand, diminished Mda5 function can result in suboptimal 
antiviral responses, and may induce prolonged or chronic infections, which can also be 
detrimental. Several polymorphisms in Mda5 have been described, and it is still largely 
unknown if and how they affect the antiviral responses and which SNP (or combination 
of SNPs) may be most critical for T1D predisposition84. New directions for future studies 
include investigating whether the identified SNPs confer increased risk for prolonged or 
successive virus infections, and whether altered IFN responses are found in individuals 
that carry these SNPs upon encountering HEV-Bs.
Another antiviral gene that has been associated with T1D is OAS1, the protein 
that activates RNaseL upon binding of dsRNA and thereby initiates degradation of cellular 
and viral RNAs, although this association was not found in all studies85-87. Particular SNPs 
in OAS1 are known to alter OAS1 splicing and could thereby affect prevalence of OAS 
isoforms, which may influence antiviral responses88. Additionally, OAS1 levels are elevated 
in T1D patients, suggesting that OAS1 plays an important role in disease development89, 
90. Increased OAS1 levels could be the result of (prolonged) HEV-B infection. Thus, SNPs in 
genes that are involved in antiviral defense may affect viral clearance and could thereby 
play a role T1D etiology.
In chapter 7 we studied the prevalence of two SNPs in the above-mentioned 
genes in a small cohort of T1D patients and unrelated controls. We divided T1D patients 
in two groups, those where enteroviral RNA was detected in their PBMCs, and those 
that were negative for enteroviral RNA. We did not find any clear association of either 
SNPs with virus positivity or T1D, but our cohort was small. Large-scale patient-control 
studies in which positivity for viral RNA in PBMCs is determined, as well as an individuals' 
response to HEV-B will shed more light on the role of Mda5 and OAS1 in T1D etiology.
Many other gene-associations have been proposed that confer risk to T1D91, 
92. Among those are loci which are involved in adaptive immunity, such as those that 
shape the T cell repertoire (HLA-locus), and that influence T cells activation (e.g. CTLA4, 
PTPN22)93-96, implying that autoimmunity does play an important role in T1D etiology. 
Furthermore, several SNPs have been identified in cytokines and chemokines, that may 
contribute to enhanced inflammation. For instance, T1D-associated SNPs are found in 
RANTES, where protective alleles correlate with lower levels of RANTES in serum97. This 
implies that people which carry the predisposing alleles have higher RANTES levels, and 
this may contribute to excessive inflammation. A likewise scenario may hold for other 
inflammatory genes in which susceptibility loci are found, such as TNF-a and others98,
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99. Additionally, these cytokines and chemokines are (indirectly) involved in clearance of 
viral infection, and SNPs that alter protein function or expression could thus influence 
viral clearance.
It is clear that multiple different genes and loci are involved in T1D development, 
and that only part of the polymorphisms involved has been discovered. Since there is 
not one specific diabetes gene, "wrong" combinations of several polymorphisms may 
in the end be responsible in determining whether an individual develops T1D or not. 
Besides genetic factors, also age and immune-status of the individual (e.g. lymphopenia) 
may play a role100-102. Future studies that combine several SNPs in their analysis and that 
will determine functional characteristics such as protein expression in parallel may shed 
more light on which genes make up this "wrong" combination.
Future Challenges and Treatment of T1D
The biggest challenge obviously is to find a way to prevent clinical T1D, and in order to 
do so, it will be important to identify the cause(s) of T1D, to know how initiation and 
progression of disease are induced, and to know if and how autoimmunity is involved 
in disease development. Much data is available on (CVB-induced) T1D pathogenesis in 
mice, and this is extrapolated to the human situation. However, inter-species differences 
exist103, 104 and therefore, mouse data cannot blindly be extrapolated to humans. Therefore, 
studies with human material, such as pancreas material from biopsies or autopsies of 
patients with clinical T1D and from "pre-diabetic individuals" is extremely valuable. 
Future studies that further investigate the presence of HEV-B in the pancreas, or the 
composition of mononuclear cells greatly add to our view of human T1D pathogenesis 
even though some contradictions on the observed cell types have been reported5, 15, 69, 105, 
106. A complicating factor is the long pre-clinical phase, which makes it largely impossible 
to investigate composition of infiltrates at the initiating events and early phases of the 
disease. In this regard, another challenge will be to establish methods to identify T1D 
patients, or individuals at risk in an early stage of disease development. (Case-) reports 
of early and/or preclinical T1D may shed light on the events that occur in the pancreas 
before clinical T1D, and on the immune cells that are involved.
Vaccination against HEV-Bs?
HEV-Bs are considered to be triggers that can initiate or accelerate T1D. In that regard, 
some researchers are in search of the HEV-Bs that are "diabetogenic", i.e. those that 
can trigger/accelerate T1D, whereas other HEV-B strains cannot83, 107, 108. Vaccination 
against those diabetogenic viruses early in life may prevent initiation/acceleration of 
T1D. However, several different HEV-Bs were isolated from T1D patients. Additionally, 
various different HEV-Bs have been associated with T1D on the basis viral RNA sequences 
yielded after RT-PCR11, 74, 107, 109, 110. Moreover, most HEV-B species are capable to replicate 
in human islets in vitro, resulting in impaired function and ß-cell death10, 111. Furthermore, 
HEV-Bs can be made more diabetogenic by undergoing several rounds of replication in 
vivo in the pancreas, or in vitro in islets, suggesting that all HEV-Bs have diabetogenic 
potential112. Thus, there may not be one -  or a small group of -  diabetogenic viruses. 
If vaccination studies would be commenced, which viruses should be included? And is 
it feasible to vaccinate against various HEV-Bs, in addition to the currently conducted
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vaccinations against mumps, measles, rubella, polio etc? Who has to be vaccinated? I 
believe vaccination against HEV-Bs may not be the best solution, development of more 
reliable screening methods, and earlier interference in individuals developing T1D may 
be a better option.
How to intervene with T1D?
As already shortly mentioned above, an important unanswered question is whether 
it is possible to stop and/or reverse the ß-cell mass decrease. Restoration of immune 
balance might be realized via the inhibition of inflammatory processes within the islets. 
An additional difficulty is that this should preferably be done in the islets only, without 
systemic inhibition of inflammation in order to maintain immune homeostasis in the 
rest of the body and to prevent opportunistic infections. Furthermore, if autoimmune 
responses have developed, inflammation inhibition in the pancreas may not be sufficient 
to restore homeostasis, because T cell mediated ß-cell killing will reinitiate inflammation 
again. Thus besides restriction of inflammation, also restoration of tolerance to ß-cells 
may be important. The latter might furthermore be important regarding the regeneration 
of ß-cells or transplantation of islets, where continuous autoimmune-mediated attacks 
on ß-cells may reduce ß-cell mass again and thus interfere with insulin production. 
Several studies have already been inititated to halt autoimmunity. Among those are 
studies trying to eliminate autoaggressive T cells113, 114, attempting to regain tolerance to 
particular self-Ags115, 116, and studies that try to regain the balance in the immune system 
via tolerization of DCs in vitro117. In my opinion the best option available so far would be 
the attempt to generate Ag-specific tolerance-inducing DCs. This approach deals with the 
autoimmunity problem at its basis and therefore may have the best chances of success. 
Besides, tolerance to multiple antigens may be achieved, a benefit when compared to 
the "tolerance-to-1-antigen approaches". Furthermore, immune homeostasis may be 
regained due to possible induction of regulatory T cells, making this a preferred method, 
compared to depletion of T cells. Future studies using human pancreatic islets and human 
DCs may give important insights of their role and function in T1D and may provide more 
means that can be used to steer the immune system towards control over inflammation 
and autoimmunity.
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Introductie
Endocrien
uitscheidend in he t bloed. Endocriene  
klieren scheiden  horm onen a f in het 
bloed. Voorbeelden zijn de eilandjes 
van Langerhans (oa insuline productie), 
de hypofyse (oa  g roeihorm oon) en de 
bijnieren (oa  adrenaline).
T ype 1 diabetes (T1D) is een chronische endocriene aandoening, waarbij de insuline-producerende ß-cellen in de alvleesklier kapot gaan. Wanneer de insuline-producerende cellen niet meer voldoende werken blijft de bloedsuikerspiegel in het bloed niet goed op peil; mensen met type 1 diabetes 
moeten insuline inspuiten. Vaak treden bij type 1 diabetes 
auto-immuun reacties op die gericht zijn tegen de ß-cellen. 
Daarom wordt T1D gezien als een auto-immuun ziekte. Zowel 
genetische factoren als omgevingsfactoren spelen een rol bij 
het ontstaan van T1D. Verschillende soorten virussen worden 
gezien als mogelijke omgevingsfactoren die betrokken zijn bij 
het ontstaan van T1D. Onder hen ook de enterovirussen, specifiek degene uit de Humane 
Enterovirus B familie (HEV-B). Hiertoe behoren onder andere coxsackie B virussen (CVB) 
en echovirussen (EV). Deze virussen zijn "broertjes" van het meer bekende poliovirus, 
dat kinderverlamming kan veroorzaken. In het algemeen zijn deze virussen vrij mild. De 
meeste infecties verlopen zonder symptomen, of met een mild ziektebeeld (zomergriep). 
Echter, ernstige infecties komen ook voor, vooral bij jonge kinderen. Verschillende 
complicaties (zoals hersenvliesontsteking of alvleesklierontsteking) kunnen ontstaan en 
dit kan een dodelijke afloop hebben.
De HEV-Bs worden geassocieerd met het ontstaan van T1D op basis van 
verschillende bevindingen, waaronder (i) prospectieve studies 
waarin T1D patiënten worden vergeleken met broers en 
zussen zonder T1D en ongerelateerde controle individuen 
(geen familie). In deze studies vond men dat T1D patiënten 
méér enterovirus infecties krijgen dan controle individuen.
(ii) "Case-control" studies die RNA van enterovirussen (het 
erfelijk materiaal van deze virussen) in het bloed van T1D 
patiënten hebben aangetoond vlak na de diagnose, vóór de 
diagnose, of in bloed van patiënten die al langer T1D hebben. 
In gezonde controles wordt dit RNA vrijwel nooit aangetroffen.
(iii) De aanwezigheid van enterovirus RNA in de ß-cellen van 
T1D patiënten ná overlijden. (iv) Het vermogen van deze 
virussen om in vitro de ß-cellen in eilandjes van Langerhans te 
infecteren en kapot te maken.
Er zijn meerdere theorieën over de manier waarop 
deze virussen T1D zouden kunnen initiëren, dan wel de 
ontwikkeling versnellen: (i) HEV-Bs kunnen de ß-cellen direct 
infecteren en door hun lytische levenscyclus de ß-cellen kapot 
maken. (ii) Ontstekingsreacties (inflammatie) die geïnduceerd 
zijn door de infectie kunnen tot zogenaamde "bystander 
activatie" van allerlei immuun cellen leiden en zo immuun 
reacties tot gevolg hebben. Deze activatie kan op zijn beurt 
leiden tot chronische ontstekingsreacties, en dit is schadelijk 
voor de functie en integriteit van de ß-cellen. (iii) auto-immuun 
reacties kunnen ontwikkelen in de pro-inflammatoire micro- 
omgeving van de virus-geïnfecteerde ß-cellen. (iv) moleculaire
Prospectieve studies
stud ies w a arb ij in een bepaalde groep  
m ensen onderzoek w ord t gedaan  
dat voorafgaat aan een bepaalde  
gebeurten is (het krijgen van T1D in dit 
geva l), m et het doel inzicht te krijgen  
in de ontstaansgesch iedenis.
"Case-control" studies
w a arb ij een groep personen m et 
een bepaalde ziekte (case) en een  
groep personen zonder deze ziekte 
(control) worden onderzocht. M en  
vergelijkt de blootste lling aan een  
m ogelijke risico factor in beide groepen  
(retrospectief).
Enterovirus RNA
het e rfe lijk  m ateriaa l van
enterovirussen  w at codeert voor 
virale eiw itten . N et als ons m enselijke
DNA m oet he t enterovirus RNA
verm enigvuldigd worden voor virus 
replicatie.
¡n vitro
stud ies die in een petrischaaltje  o f 
kw eekfles in het laboratorium  worden  
uitgevoerd.
Lvtisch
lytisch betekent le tterlijk : oplossend. 
De ce l klapt uit e lkaar (en gaa t dus 
kapot) w aardoor n ieuw  gevorm de  
virussen vrijkomen.
Inflammatie
ontsteking. Pro-inflam m atoir: fa ctoren  
die de ontsteking bevorderen . Anti- 
in flam m atoir: fa ctoren  die de 
ontsteking remmen.
138
Nederlandse Samenvatting
mimicry, waar responsen die gericht zijn tegen het virus per 
ongeluk ook delen van het eigen lichaam herkennen en 
aanvallen, en die daardoor leiden tot auto-immuniteit. De ene 
theorie sluit de ander niet uit; het zou zelfs kunnen dat 2 of 
meer theorieën samen een goede weergave zijn van wat er 
tijdens de ontwikkeling van T1D gebeurt.
Ontstekingsreacties in de eilandjes van Langerhans 
van T1D patiënten komt veel voor. Immuuncellen, zoals T 
cellen, macrofagen en dendritische cellen zijn aangetoond in 
de eilandjes van Langerhans van patiënten. De ontwikkeling of 
versnelling van het T1D ziekteproces hangt af van meerdere 
factoren. De balans tussen auto-reactieve effector T cellen 
(die helpen met maken van antistoffen en het aanvallen van 
geïnfecteerde cellen) en zogenaamde regulatoire T cellen (die 
de effector cellen remmen en zo een goede balans bewaren 
tussen immuun reacties en tolerantie) is daarbij erg belangrijk.
Deze balans wordt voornamelijk bepaald door dendritische 
cellen (DCs). De DCs zijn de professionele antigeen- 
presenterende cellen van ons immuun systeem. Ze spelen een 
zeer belangrijke rol bij het initiëren van immuun responsen en 
het bewaren van tolerantie tegen ons eigen lichaam. Zowel bij 
de aangeboren immuun responsen (ofwel "innate respons") als 
de verkregen immuun responsen (ofwel "adaptieve respons") 
zijn de DCs belangrijke spelers. DCs zijn onder andere bekend 
om hun vermogen om allerlei ziekteverwekkers op te eten en 
vervolgens het immuunsysteem aan te schakelen.
Om ervoor te zorgen dat de tolerantie tegen het lichaamseigen gehandhaafd 
wordt, maar er tegelijkertijd wel immuun responsen worden opgewekt tegen invasieve 
pathogenen is het belangrijk dat de DC onderscheid kan maken tussen "eigen" (of 
ongevaarlijk) en vreemd (of gevaarlijk). Hiervoor brengt de DC een aantal specifieke
receptoren tot expressie die bepaalde patronen op oatroon-herkenninas receptoren
pathogenen kunnen herkennen, of die de schade aan het 
lichaam herkennen die een infectie met zich meebrengt. Dit 
zijn de zogenaamde "patroon-herkennings receptoren". Ze 
herkennen pathogeen-geassocieerde moleculaire patronen, 
zoals bijvoorbeeld viraal RNA. Nadat een receptor op een DC 
een indringer heeft herkend, begint de DC een proces dat 
maturatie heet. Dit gaat gepaard met veranderingen in het 
fenotype en de functie van de DC. Gematureerde DCs zijn 
in staat om immuun responsen te starten bijvoorbeeld via 
de activatie van T cellen. Niet-gematureerde DCs, of DCs die 
anti-inflammatoire signalen krijgen, zullen daarentegen juist 
tolerantie induceren wanneer ze een T cel tegenkomen.
Bystander activatie
onbedoelde activatie  van cellen 
(b ijvoorbeeld  doorda t ze in een p ro­
inflam m atoire om geving zijn).
Moleculaire mimicry
overeenkom st tussen  gastheer- 
m oleculen (van het e igen lichaam ) en 
pathogene antigenen (zie beneden). 
Een respons die oorspronkelijk  gericht 
is tegen het pathogeen  kan zich ook  
keren tegen delen van het eigen  
lichaam . Dit kan leiden tot auto- 
im muniteit.
Effector T cellen
de T cellen van het im m uunsysteem  
die betrokken zijn b ij het aanvallen  
van pathogenen . H iertoe behoren de 
T cellen die helpen b ij aanm aak van 
antistoffen gericht tegen pathogenen, 
m aar ook de T cellen die geïnfecteerde  
gastheercellen  aanvallen.
Regulatoire T cellen
de groep T cellen die ervoor zorgt dat 
im m uunresponsen goed  gecontro leerd  
blijven en niet uit de hand lopen. Ze 
kunnen de e ffector T cellen remmen. 
Antiaeen
een m olecuul da t een reactie  van het 
im m uunsysteem kan opw ekken. Dit kan 
een m olecuul zijn van een pathogeen , 
o f  een lichaam seigen m olecuul. Ons 
im m uunsysteem  bouw t tolerantie op 
tegen de lichaam seigen m olecu len, 
terw ijl tegen lichaam svreem de  
antigenen ju is t  w el een reactie  w ordt 
gestart.
receptoren  op cellen die bepaalde  
m oleculaire patronen kunnen 
herkennen. Deze m oleculaire patronen  
komen vaak voor op een pathogeen. 
D aarnaast worden ook  signalen  
herkend die aangeven dat e r schade  
is aan ons eigen lichaam  (b ijvoorbeeld  
als gevolg van een infectie).
oathoaeen-aeassocieerde 
moleculaire patronen
m oleculaire patronen die voorkomen  
op pathogenen en die herkend worden  
door receptoren  op onze immuun 
cellen. Voorbeelden hiervan z ijn : de 
celw and van een bacterie , het RNA 
(genetisch m ateriaal) van een virus.
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Samenvatting van de belangrijkste resultaten
In dit proefschrift is de interactie onderzocht tussen eilandjes van Langerhans, 
enterovirussen en dendritische cellen, met als doel meer inzicht te verkrijgen in de 
mogelijke mechanismen die aan de basis staan van enterovirus-geïnduceerde type 1 
diabetes.
steady state Zoals al eerder genoemd is het herkennen van pathogenen
ongestim uleerd, in balans.
of pathogeen-geassocieerde schade aan het lichaam door 
DCs belangrijk om te bepalen of er een immuun respons moet worden gestart of niet. 
Hoofdstuk 2 geeft een beknopt overzicht van de expressie van verschillende "patroon- 
herkennings receptoren" in DCs in zowel de "steady state" als onder pro-inflammatoire 
omstandigheden (gestimuleerd met een "stukje pathogeen"). Hierbij zijn de receptoren 
geselecteerd die betrokken zijn bij het herkennen van virussen. Verder is ook onderzocht 
hoe verschillende "ondersoorten" van DCs elkaar beïnvloeden. Er is een mechanisme 
gevonden waarvia de plasmacytoïde DCs (pDCs) de myeloïde DCs (mDCs) kunnen 
beschermen tegen virus infecties door de productie van het stofje interferon. Hoofdstuk 
3 houdt zich bezig met de gevoeligheid van DCs voor infectie met verschillende HEV-B 
soorten. We laten zien dat coxsackie B virussen (CVBs) niet in staat zijn de DCs te infecteren, 
waarschijnlijk omdat de receptor die ze nodig hebben om de DC binnen te komen niet 
aanwezig is. Echovirussen daarentegen, zijn wel in staat om DCs te infecteren. Dit heeft 
duhhei-strenas viraai RNA tot gevolg dat de DC zijn functie niet meer goed kan uitoefenen
de vorm van r n a  d ie het virus m aakt (bijvoorbeeld geen respons meer wanneer de "patroon-
om zijn genoom  te verm enigvuldigen.
Tijdens de verm enigvuldiging plakt het herkennings receptoren" gestimuleerd worden) en uiteindelijk 
virus ee n tegengestelde streng r n a  dood gaat. In Hoofdstuk 4 laten we zien dat DCs beschermd
tegen he t RNA aan en m aakt op deze
m anier kopieën van zijn genoom . D it worden tegen echovirussen wanneer ze gestimuleerd worden 
dubbel-strengs r n a  kom t norm aliter met het stofje poly I:C. Dit is een chemisch geproduceerd
niet in een cel voor en is daarom  een
signaa l voor de gastheercel da t e r  molecuul dat erg sterk lijkt op dubbel-strengs viraal RNA.
gevaar d reigt. Echter, wanneer DCs gestimuleerd werden met andere stofjes
interferon die "patroon-herkennings receptoren" stimuleren (zoals
sto fjes geproduceerd  door he t  j .  i ■ i _ i
im m uunsysteem  die in terfereren  m et  stukjes van een bacterie) ontstond er geen bescherming van
(verhinderen van) virus replicatie. de DC tegen infectie. Dubbel-strengs viraal RNA wordt door
Vandaar de naam  interferon. enterovirussen gemaakt om zichzelf voort te planten (het 
virus maakt kopieën van zijn eigen genoom). We laten zien dat CVB-geïnfecteerde cellen 
worden opgegeten door DCs. Dit heeft tot gevolg dat de DCs het beschermende stofje 
interferon gaan maken. Ook worden interferon-gestimuleerde genen aangezet. Dit alles 
brengt de cellen in een zogenaamde "anti-virale" staat, waarbij ze beschermd worden 
tegen infectie. In hoofdstuk 5 hebben we de interactie tussen CVB-geïnfecteerde cellen 
en DCs verder onderzocht. Hierbij hebben we specifiek gekeken naar wat er gebeurt als 
primaire ß-cellen worden geïnfecteerd en worden opgegeten door de DCs. We laten zien 
dat eilandjes van Langerhans van een mens of een varken efficiënt worden opgegeten 
door DCs. Ook een muizen ß-cel lijn, Min6 (cellen die lijken op ß-cellen uit de eilandjes 
van Langerhans en makkelijk in het lab gekweekt kunnen worden), werd efficiënt door 
de DC opgegeten. Opname van niet-geïnfecteerde eilandjes had geen effect op de DCs, 
maar wanneer een DC virus-geïnfecteerde cellen opnam resulteerde dit in het maken 
van interferon en de interferon-gestimuleerde genen. DCs die geïnfecteerde cellen 
hadden opgenomen bleken ook beschermd tegen een opvolgende infectie. Voor al deze
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responsen was het virale RNA in de geïnfecteerde cellen nodig; dat is waarschijnlijk het 
waarschuwingssignaal waar de DC op reageert. Ook het stofje interferon bleek onmisbaar 
in de reactie van de DCs. Samenvattend laten we zien dat een antivirale immuunrespons 
wordt gegenereerd door DCs nadat ze in aanraking komen met geïnfecteerde ß-cellen.
Dit leidt mogelijk tot belangrijke nieuwe inzichten in de rol die DCs spelen tijdens het 
ontstaan van T1D. In hoofdstuk 6 hebben we de reactie van de eilandjes van Langerhans 
op HEV-B-infectie onderzocht. Primaire humane eilandjes van mRNA 
Langerhans die zijn geïnfecteerd met HEV-B startten een anti- m essenger RNA, o fw e l boodschappe
, , « _ ■ , , . .  . . - RNA. H et mRNA w ord t a fgeschreven
virale respons, gekenmerkt door de productie van interferon van ons d n a  (onze genetische  
en de interferon-gestimuleerde genen. Ook mRNA productie in form atie) en codeert voor de
, . « ■ i i -  / • p roductie  van een bepaa ld  eiwit.van andere cytokines en chemokines (signaal stoffen van
het immuun systeem) werd aangeschakeld. We konden niet cytokinesenchemoknes
sto fjes die gem aakt worden door het
alleen het mRNA van cytokines en chemokines aantonen, im m uunsysteem  die w itte bloedcellen  
maar ook de eiwitten die door de cellen gemaakt werden activeren (cy tokine) o f m n u e ^ n
naar de p laats van de infectie
en uitgescheiden werden. Dus, wanneer infectie van de (chem okine). Daarnaast kunnen ze 
eilandjes van Langerhans plaatsvindt starten deze een anti- o° k d e  ontw ikkeling van n ieuwe witte
b loedcellen stim uleren.
virale respons en produceren ze cytokines en chemokines. Die
kunnen op hun beurt andere cellen van het immuunsysteem aantrekken naar de plaats 
van de infectie. Hoewel deze stofjes geproduceerd worden ter bescherming van de ß- 
cellen kunnen ze er ook voor zorgen dat langdurige inflammatie optreedt. Dit kan zelfs 
bijdragen aan het ontstaan van auto-immuun reacties tegen de ß-cellen.
Onbalans in het immuunsysteem speelt waarschijnlijk een belangrijke rol tijdens 
T1D ontwikkeling. Cellen in de alvleesklier worden kapot gemaakt tijdens T1D, maar 
ook invloeden van buiten de pancreas kunnen belangrijk zijn. Hoofdstuk 7 onderzoekt 
de aanwezigheid van enterovirus RNA in de witte bloedcellen van T1D patiënten en 
gezonde controle individuen. In 4 van de 10 T1D patiënten is viraal RNA aangetroffen, 
terwijl geen van de 20 controles positief was. Het nagenoeg afwezig zijn van viraal RNA 
in keel samples en feces samples suggereert dat de aanwezigheid van viraal RNA in de 
witte bloedcellen misschien een langdurige of chronische infectie betreft. Wat de rol van 
deze langdurige infectie is in het ontstaan van T1D moet nog verder uitgezocht worden. 
Echter, duidelijk is dat er hierdoor een continue stimulatie van het immuun systeem kan 
plaatsvinden, die de balans van het hele immuun systeem kan beïnvloeden.
Toekomstperspectief
Bovenstaande bevindingen passen in een model voor het ontstaan van diabetes waarbij 
enterovirussen aan de basis staan. Infectie van eilandjes van Langerhans leidt tot anti-virale 
responsen en inflammatie, onder andere het produceren van cytokines en chemokines.
Dit leidt vervolgens tot het aantrekken en activeren van diverse witte bloedcellen. Die 
kunnen schade veroorzaken aan de ß-cellen, waardoor deze niet goed meer functioneren.
Er wordt "gevaar" gesignaleerd door de witte bloedcellen, terwijl ook de eigen antigenen 
aanwezig zijn. Dit kan tot gevolg hebben dat auto-immuun reacties tegen de ß-cellen 
ontstaan. Dendritische cellen spelen hierbij waarschijnlijk een belangrijke rol; zij zijn 
immers de witte bloedcellen die de balans tussen immuunresponsen en tolerantie in het 
lichaam bewaren. De adaptieve responsen na opname van enterovirus-geïnfecteerde 
cellen dienen nog verder onderzocht te worden.
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De grootste uitdaging is het vinden van een therapie tegen type 1 diabetes. 
Wanneer een goed beeld is gecreëerd van de manier waarop T1D ontstaat kan ook 
het best een passende therapie worden bedacht. Een belangrijk punt is het stoppen of 
terugdraaien van de ß-cel schade. Om dit mogelijk te maken moet de homeostase in de 
alvleesklier hersteld worden. Omdat de dendritische cellen zo'n belangrijke rol spelen 
bij het in balans houden van het immuunsysteem zijn zij wellicht een goed doelwit om 
op in te grijpen. Toekomstige therapieën die dendritische cellen gebruiken die tolerantie 
induceren zijn in dat opzicht veelbelovend, aangezien ze zowel de auto-immuniteit 
aanpakken en tegelijkertijd kunnen helpen om de homeostase te behouden/terug te 
krijgen.
Het is belangrijk dat er verder onderzoek met patiënten gedaan wordt naar het 
ontstaan van T1D. Daarnaast zijn toekomstige in vitro studies die gebruik maken van 
humane eilandjes van Langerhans en humane DCs onmisbaar om goed inzicht te krijgen 
in hun rol tijdens het ontstaan van type 1 diabetes. Bovendien kunnen ze belangrijke 
nieuwe aanknopingspunten bieden om het immuunsysteem zó aan te sturen dat er 
minder inflammatie en auto-immuniteit optreden.
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AF! Nou ja, bijna dan... Er zijn veel mensen die een bijdrage hebben geleverd aan het tot 
stand komen van mijn proefschrift.
Ten eerste wil ik Frank van Kuppeveld bedanken. Beste Frank, jij was degene die mij op 
de stagemarkt jaren geleden enthousiast maakte voor een stage in de virologie. Toen je 
me vroeg of ik een promotietraject binnen de virologie zag zitten heb ik nog wel even 
getwijfeld tussen Utrecht en Nijmegen. Nu ben ik blij dat ik JA heb gezegd! We hebben 
altijd een goed contact gehad en het was fijn dat ik altijd gewoon kon binnenlopen 
naast ons wekelijkse overleguurtje. Ik heb enorm veel geleerd van jouw manier om 
problemen aan te pakken. Je hebt me op allerlei vlakken dingen bijgebracht, van het 
logisch indelen van een manuscript of presentatie tot aan het belang van de controles in 
ieder experiment! Je oneindige enthousiasme is een voorbeeld voor me. Bedankt!
Vervolgens mijn promotor Joep Galama. Beste Joep, bedankt voor je input als klinisch 
viroloog op het basaal wetenschappelijke onderzoek dat ik heb gedaan. Je hebt altijd een 
iets andere kijk op het onderzoek en de manuscripten en daardoor juist commentaar op 
punten waar anderen niet aan hebben gedacht! Fijn dat je iedere dinsdag een uurtje vrij 
probeerde te plannen voor ons overleg.
Mijn tweede promotor Gosse Adema. Beste Gosse, jij gaf de onmisbare immunologie- 
input in ons onderzoek. Als immunoloog heb je altijd een net iets andere kijk gehad op 
allerlei dingen dan virologen (en waren jij en Frank het niet altijd eens), maar dat was des 
te leerzamer voor mij. Na mijn promotietraject ben ik bij jou begonnen als postdoc en ik 
hoop veel van je te leren in de komende jaren!
Mijn twee paranimfen: Kjerstin en Matthijs. Jullie zijn degene die me tijdens de afgelopen 
4% jaar het meest hebben geholpen met praktisch werk, maar waren zeker net zo 
belangrijk voor de gezelligheid! Kjerstin, jij hebt me enorm geholpen met een groot 
aantal experimenten. Daarnaast ben je onmisbaar op het virologie-lab en ben jij degene 
die het lab goed draaiende houdt! Naast de werkzaamheden ben je een heel gezellige 
collega; bedankt voor alle gezelligheid in de pauzes, op het lab en natuurlijk tijdens het 
cellen uitvullen op maandag!
Matthijs, dankzij jou kon ik op een lopende trein springen aan het begin van 
mijn aio-periode. Je hebt me wegwijs gemaakt in de wereld van de DCs! Je bent enorm 
gedreven en ik heb er bewondering voor dat je ook nog geneeskunde (theorie) hebt 
afgerond tijdens je promotie! Onze samenwerking was vanaf het begin af aan erg prettig 
en het was gezellig om tijdens de buffy's lekker te kunnen kletsen! Samen hebben we 
een aantal mooie papers, ik ben er trots op! Ondanks al die jaren trappen lopen heb ik 
nog steeds geen goede conditie .
Alle collega's van de virologie wil ik bedanken voor de gezellige periode op het lab. Fabrizio, 
het was leerzaam, maar vooral gezellig om met jou een Utje te delen. Ook al was GAAP 
voor jou uiteindelijk niet zo'n succes, ik hoop dat je nu op je plek zit! Danny, voor alle 
biochemische vragen kon ik bij jou terecht! Buiten dat was je gezellig en een aantal van 
je uitspraken zijn nog altijd blijven hangen ("ik heb geen slechte dag, ik heb een slecht
144
Dankwoord
millennium"). Jan, jij hebt een enorme hoeveelheid virologie kennis waarvoor mensen 
bij je aankloppen. Het zijn echter de droge, maar gevatte opmerkingen die ik niet snel zal 
vergeten. Stanley en Kelly, als medeaio's weten jullie precies welke ups en downs er zijn 
tijdens je promotie. Kelly, leuk om met jou op congres te gaan naar de kou (ook al was 
het uiteindelijk toch geen -30°C) en daarna Helsinki. Stanley, leuk om jou van een andere 
kant te leren kennen tijdens de salsa-lessen! Lonneke en Hilde, medecellenuitvullers! 
Altijd gezellig op de maandagmiddag! Lonneke, succes met de antivirals en de rest van 
je promotie-onderzoek! Qian, ik doe het gewoon in het Nederlands! Het was gezellig 
samen op de Europic in Barcelona. Succes met de RLHs en veel geluk met Andy!
De RNAi-groep onder leiding van Ronald kwam het virologie-lab versterken. 
Ronald jij bent een goede en kritische wetenschapper. Van jouw kijk op dingen heb ik 
veel geleerd. Joël, Koen en Walter, succes met het ontrafelen van de RNAi pathways 
tijdens virale infectie en het karakteriseren van RNAi-remmers in nieuwe virussen.
Els en Mike, jullie gingen vrij snel weg nadat ik begon als junior onderzoeker. 
Bedankt voor alle leerzame en gezellige dingen, zowel tijdens mijn studenten tijd als mijn 
aio-periode.
De studenten die me geholpen hebben tijdens mijn jaren bij de virologie 
verdienen zeker ook een plekje. Marijke, Neeltje en Katharina: succes met jullie PhDs en 
buitenlandse stages. Het begeleiden van een student is volgens mij net zo leerzaam als 
het doen van een stage zelf!
Ook al zit het research-lab van de virologie een eindje weg van de diagnostiek, toch kon ik 
altijd terecht voor advies. Judith, bedankt dat je tussen al je diagnostiek werkzaamheden 
door tijd maakte om me te helpen met het T1D patiënten project. Willem, bedankt voor 
je interesse en input. Marij, bedankt voor al je hulp bij de celkweek. Marian, jij was 
degene die zorgde dat de afspraken met Joep goed liepen, bedankt daarvoor!
De buren van het parasitologie lab wil ik bedanken voor alle hulp en gezelligheid aan 
de koffietafel. Matthew en Anne, bedankt voor de hulp met opzetten van PBMC- 
experimenten en FACS kleuringen. Ben, Krystelle, Karina, Ivo, Martijn, Will, Rob, Adrian, 
Robbert en alle anderen, bedankt! De gezamenlijke Wii-avonden en bowling competities 
waren een groot succes! Dat er nog veel mogen volgen! Natuurlijk wil ik ook de buren 
van de urologie bedanken!
Een deel van mijn aio-periode bestond uit trappen lopen naar de 5e, en alle mensen 
van het TIL die me hebben geholpen verdienen ook een plekje in dit dankwoord. Liza, 
bedankt voor al je praktische ondersteuning. Al je kleuringen en qPCRs hebben enorm 
geholpen! Maaike L, Maaike vH-K, Dagmar, Bas, Jurjen en Marleen bedankt voor alle 
hulp bij kloneren, qPCRs, statistiek, pDC proeven etc. En natuurlijk alle Tillers bedankt 
voor de gezelligheid en behulpzaamheid.
Huib, bedankt voor je hulp met de confocal.
QM Diagnostics, in de personen van Marleen, Patrick en Ronald, bedankt voor alle hulp 
met de LC480!
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Tijdens de afgelopen 4 jaar zijn er samenwerkingen gestart met verschillende afdelingen. 
Henk-Jan Aanstoot, Mu Bruining, Ciska Westerlaken, Wil Allebes en Kjeld van Houwelingen 
wil ik bedanken voor het patiënten werk en de HLA-typeringen. Mihai, Trees en Liesbeth, 
bedankt voor jullie hulp bij de PBMC-experimenten met RSV en CVB. Dit deel van het 
werk is ongoing, ik hoop dat het nog mooie resultaten oplevert! Richard, Tim en Mark, 
bedankt voor de hulp met al het cytokine-werk! Paul and Paola, thank you for the anti- 
Mda5 antibody! We have used it a lot!
Dear Jon, I would like to thank you for the opportunity to work in your lab for 6 weeks. 
You broadened my view and taught me the mouse-world of diabetes. I really enjoyed all 
the discussions we had in the car on the way to work! Furthermore, I was a guest in your 
family during my stay! Cheryl, Dominic and Jack, thank you for making me part of the 
Piganelli family! Cheryl, you are still the Queen of Margarita's (thanks for sending them 
by fedex!). Jack and Dominic, I really enjoyed having two little brothers for 6 weeks! You 
taught me the guitar hero! Also the people in the Piganelli lab and islet-isolation lab 
should not be forgotten: Jennifer, Hubert, Gina, Martha, Rita and Susan: thanks (for help 
in the lab and for the nice time at the baseball games etc.)! Rita and Massimo, thank you 
for all the help with the primary pancreatic islets. It is very important for my research!
Zonder ontspanning is een promotietraject niet vol te houden! Gelukkig waren een 
aantal mensen om lekker mee te gaan eten, stappen of gewoon lekker bij te kletsen. 
Anouk, Richard, Chris, Marianne, Joost, Sylvie, Karla, Roel, Femke, Kim, Louis, Wouter, 
Janneke, Ralph, Wendela, bedankt voor alle gezelligheid en interesse!
De basis voor dit alles is natuurlijk Thuis! Lieve pap en mam, bedankt voor alles! Jullie 
hebben me altijd in alles gesteund in al mijn keuzes en ik ben enorm blij met jullie! 
Ook al is het denk ik moeilijk om 5 kinderen op te voeden; jullie hebben ons allemaal 
vrij gelaten om te gaan doen wat we zelf kozen. Hester & Jelle, Jolien, Tijmen, Luuk en 
Marriët, het is altijd enorm gezellig als we allemaal thuis zijn. Broeries, leuk dat jullie ook 
in het lab komen te staan!
Hans, Alies, Thijs, Petra en Luuk, mijn tweede familie, bedankt voor al jullie 
interesse en de gezelligheid bij de "Te Riet"familie!
Lieve Joost, bedankt dat je er altijd bent! Jij bent degene die mijn leven in balans houdt! 
Ik hou van je!
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Barbara Maria Schulte werd op 12 juli 1982 geboren te Almelo. In 2000 haalde zij haar 
VWO diploma op het Pius X College te Almelo. Aansluitend volgde zij de studie Biologie 
aan de Katholieke Universiteit Nijmegen (Thans Radboud Universiteit Nijmegen) met de 
afstudeerrichting Medische Biologie. Tijdens deze studie liep ze 9 maanden stage op 
de afdeling Medische Microbiologie onder begeleiding van Ing. Mike de Bruijni en Dr. 
Frank van Kuppeveld. Dit onderzoek richtte zich op de functie van het Leader eiwit van 
het mengovirus, dat antivirale interferon responsen in de gastheer kan onderdrukken. 
Een tweede stage van 9 maanden werd gedaan aan de Universiteit Utrecht in het lab 
Fysiologische Chemie onder leiding van Dr. Karen Lyle en Prof. Dr. Hans Bos. Tijdens deze 
stage werd de kleine GTPase Rhes (Ras homolog enriched in striatum) gekarakteriseerd. 
Gedurende de studie heeft zij vier opeenvolgende jaren geassisteerd bij het vak 
"Functionele Histologie" onder leiding van Dr. Toine Lamers (en later ook Dr. Ineke van der 
Zee). Als nevenactiviteit was ze actief bij de feestcommissie van de Nijmeegse Biologen 
vereniging BeeVee en was ze meerdere malen als mentor betrokken bij de introductie 
van eerstejaars biologie studenten.
Na het behalen van haar doctoraal (Cum Laude) begon ze als junior onderzoeker 
op de afdeling Medische Microbiologie van het UMC St. Radboud. Onder begeleiding 
van Dr. Frank van Kuppeveld en Prof. Dr. Joep Galama werd het promotieonderzoek 
uitgevoerd wat in dit proefschrift beschreven is. Gedurende het promotie traject bracht 
ze een 6 weken durend werkbezoek aan het lab van Dr. Jon Piganelli in het Rangos 
Diabetes Centre van de University of Pittsburgh (Pittsburgh, Pennsylvania, Verenigde 
Staten).
Thans is ze werkzaam als postdoc in het Tumor Immunologie laboratorium van 
het UMC St. Radboud onder begeleiding van Prof. Dr. Gosse Adema. Hier doet zij in een 
Juvenile Diabetes Research Foundation-gefundeerde studie onderzoek naar de interactie 
tussen enterovirussen, primaire humane dendritische cellen en insuline-producerende 
cellen.
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